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Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related 
deaths and is on the rise in incidence worldwide. Treatment of HCC remains abysmal; 
discovery of novel pathways implicated in hepatocarcinogenesis is needed for more 
effective therapeutics. For early stage HCC, curative surgery and liver transplantation 
might be viable options, however, these treatments are often negated by tumor 
recurrence or metastasis. Current treatment algorithm for HCC is based solely on 
clinical features of HCC, the molecular characteristics of tumors are not taken into 
account, despite their potential clinical values. With the advent of high-throughput 
molecular tools like microarray and whole genome sequencing, a few HCC molecular 
classifications have been suggested in recent years. Within the heterogeneous group 
of HCC, those with embryonic stem cell (ESC)/ progenitor cell gene expression 
characteristics have shown to have the worst prognosis. SALL4 is a stem cell factor 
that regulates ESC self-renewal properties. It is also an emerging oncogene. The aim 
of this thesis is to study the potential roles of SALL4 as a molecular biomarker for 
HCC and its roles as an oncogene that promotes hepatocarcinogenesis. 
In this study, we report a novel oncogene in HCC, SALL4, which allows 
identification of a progenitor HCC subset with worse prognosis, and offers a potential 
treatment target. We report for the first time that SALL4 is expressed in human fetal 
liver, silenced in adult liver, but re-expressed in a subgroup of HCC, representing an 
oncofetal protein. We propose genomic amplication of SALL4 as one of the 
mechanisms underlying SALL4 re-activation in HCC. Gene expression analysis 
revealed the enrichment of progenitor-like gene signatures with overexpression of 
proliferative and metastatic genes in SALL4-positive HCCs. Our clinicopathological 
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analysis revealed that SALL4 predicts poor prognosis for HCC patients. Specifically, 
SALL4 predicts poorer overall survival and recurrence for HCC patients. Importantly, 
our multivariate analysis confirmed that SALL4 is an independent prognostic factor 
for HCC. SALL4B transgenic mice and loss-of-function studies mediated by RNA 
interference confirmed that SALL4 is critical for hepatocarcinogenesis. We propose 
that SALL4 promotes hepatocarcinogensis by promoting G1 to S cell cycle 
progression via the regulation of Cyclin D2 expression. Cyclin D2-knockdown HCC 
cells share similar phenotypes with SALL4-knockdown cells, both demonstrated 
decreased cell viability upon gene downregulation. Importantly, we demonstrated that 
a peptide can block the oncogenic function of SALL4 in HCC by modulating the 
PTEN/AKT pathway.  
In conclusion, the findings in this thesis reveal a novel role for SALL4 in HCC 
with important implications for understanding disease mechanisms and development 
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1.1 The Embryonic Stem Cell Factor SALL4 
The human homologue of Drosophila spalt (sal) homeotic gene, SALL4, 
encodes a C2H2 zinc finger transcription factor (De Celis and Barrio, 2009). 
Drosophila spalt was first identified in a mutational study as a novel homeotic gene in 
1988 (Jurgens, 1988). Located on the second chromosome of Drosophila, spalt is 
mapped outside the two major well characterized classes of homeotic selector genes, 
the Antennapedia complex (ANT-C) and the bithorax complex (BX-C) and acts 
independently of the hierarchical order of these gene complexes. spalt acts in both the 
posterior head and the anterior tail regions of Drosophila melanogaster embryo, as 
opposed to the trunk region. Mutations of spalt lead to transformation of the posterior 
head segments to the anterior thoracic region, and the transformation of the anterior 
tail region to the posterior abdominal segments of the embryo (Jurgens, 1988). These 
data are among the first evidence that support an essential role for the spalt family of 
genes during early development. 
spalt gene family is evolutionarily conserved, besides Drosophila, it is also 
found in the C. elegans and various vertebrates, including chicken, mouse, Xenopus 
and human (reviewed by Sweetman and Munsterberg (Sweetman and Munsterberg, 
2006)). SALL (Sal-like) proteins are characterized by the presence of several zinc 
finger domains and a glutamine rich region (polyQ) within the protein (Figure 1.1). 
Zinc finger proteins are one of the most abundant proteins present in eukaryote 
genomes, the first zinc finger transcription factor, transcription factor IIIA, was 
discovered in Xenopus more than two decades ago (Miller et al., 1985). Zinc finger 
motifs vary widely in terms of their structures and functions. Generally, they are small 
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protein structural motifs that require coordination of one or more zinc ions for 
stability of their folding (Laity et al., 2001). Many zinc finger proteins are 
transcription repressors that function by recognizing specific DNA sequences. Of 
various classes of zinc finger proteins, SALL proteins belong to the classical C2H2 
zinc finger protein class. The first zinc finger domain presents near the N terminal 
region of SALL proteins is a C2HC zinc finger, unlike the rest of the C2H2 zinc finger 
domains. In SALL2, the C-terminal double zinc fingers are not homologous to the 
zinc fingers present in other SALL proteins, for instance, it lacks the Sal-box that 
presents in other zinc finger domains (Figure 1.1). As mentioned, besides zinc finger 
domains, SALL proteins have an evolutionarily conserved polyQ domain. The polyQ 
region within SALL proteins might be involved in protein-protein interactions among 
SALL family members as well as with other proteins. From a biochemical co-
immunoprecipitation assay, chick csal1 and csal3 have shown to be dependent on 
polyQ region for their interactions (Sweetman et al., 2003).  
 
Figure 1.1 Schematic representation of main conserved domains in vertebrate 
SALL proteins. There are four members in the vertebrate SALL family, SALL1–4. 
Two main conserved characteristic of SALL transcription factors are the presence of 
several zinc finger domains and a glutamine rich region (PolyQ) in the proteins. Ovals 
represent zinc finger domains and yellow pentagon represents glutamine (Q) rich 
region. Blue ovals represent C2HC zinc fingers, pink ovals represent C2H2 zinc fingers 
and green ovals in SALL2 represent the C terminal zinc fingers that are not 
homologous to those in other SALL proteins (e.g. lacking the Sal-box). Figure 
adapted from (Sweetman and Munsterberg, 2006) and (De Celis and Barrio, 2009). 
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In humans, there are four members in the SALL protein family: SALL1–4. 
Figure 1.1 illustrates the conserved protein domains present in SALL1–4 proteins. 
Phylogenetic studies reveal that SALL4 was produced as a result of duplication of 
SALL2 gene, which was derived from the divergence of ancestral spalt. SALL4 
underwent further duplication to produce  SALL1 and SALL3, which are the most 
closely related SALL members (Sweetman and Munsterberg, 2006). In this thesis, we 
focus on the study of SALL4. Homo sapiens SALL4 show 24% and 75% protein 
sequence identity with Drosophila spalt and mus musculus Sall4, respectively. The 
zinc finger domains are conserved evolutionarily. Interestingly, the N-terminal first 12 
amino acids of SALL4 that is important for its interaction with epigenetic complexes 
are also conserved in mouse and human. Appendix 2 shows the result of SALL4 
Ensembl Orthologue Alignment. 
Two major isoforms of SALL4 exist as a result of alternative splicing – 
SALL4A and SALL4B. SALL4B isoform has a truncated exon 2 and hence has five 
zinc finger domains less compared to the full length SALL4A isoform (Figure 1.2). 
Alternative splicing is an essential mechanism that adds diversity to the gene pool by 
generating variants of genes, it is also one of important mechanisms that regulates the 
self-renewal property of ESCs (Cheong and Lufkin, 2011). Evidence documenting the 
roles or functions of each SALL4 isoform are presently scarce. There are some 
evidence, however, suggest that SALL4A and SALL4B might have different target 
genes and hence function slightly differently. An isoform-specific chromatin 
immunoprecipitation (ChIP) assay identified distinct but overlapping binding sites for 
murine Sall4a and Sall4b in a mouse ESC system, suggesting differential roles for 
both isoforms during development. Furthermore, from a rescue study performed on 
mouse ESCs deprived of Sall4a and Sall4b expression, Sall4b alone was sufficient to 
CHAPTER 1. INTRODUCTION 
5 
 
partially rescue the differentiation phenotypes and gave rise to a mixed pluoripotent 
and differentiated cell population. Sall4a, on the other hand, was not able to rescue the 
phenotypes of loss of both Sall4 isoforms in ESCs (Rao et al., 2010). Furthermore, 
human SALL4B alone has been shown to be able to initiate leukemogenesis in a 
mouse model (Ma et al., 2006). These data suggest that both isoforms of SALL4 play 




Figure 1.2 Alternative splicing generates two major isoforms of SALL4. Two 
major isoforms, SALL4A and SALL4B, of human SALL4 exist as a result of 
alternative splicing. SALL4A is a full length protein with eight zinc fingers whereas 
SALL4B has a truncated exon 2 and hence has only 3 zinc fingers. 
 
Like other Sall family members, vertebrate Sall4 has been shown to play 
important roles during development. Sall4 is implicated in a variety of processes 
during embryonic development, including organogenesis, limb formation and neural 
development. In the mouse, together with Oct4, Nanog, and Sox2, Sall4 forms an 
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extensive interconnected autoregulatory transcriptional regulatory network that is 
crucial for the maintenance of pluripotency and self-renewal of ESCs (Elling et al., 
2006), and depletion of both Sall4 isoforms induces differentiation of ESCs (Rao et 
al., 2010; Yang et al., 2010). Specifically, Sall4 co-expresses with Oct4 from the one-
cell zygotic stage onwards and has been shown to be able to activate Oct4 expression 
and be regulated by Oct4. Sall4 also interacts physically with Nanog. The function of 
Sall4 as a potent stem cell factor is further highlighted by its ability to enhance 
reprogramming of somatic cells to pluripotent cells (Wong et al., 2008). In murine 
liver, Sall4 expression diminishes gradually during development, and is eventually 
silenced in adult hepatocytes, suggesting a role for Sall4 during early to mid-fetal 
liver development. Sall4 is essential in controlling the lineage commitment of murine 
hepatoblasts, by promoting cholangiocytic differentiation while suppressing 
hepatocytic differentiation (Oikawa et al., 2009).  
Given its essential roles during early development, Sall4 null mice are 
embryonic lethal (Sakaki-Yumoto et al., 2006; Tsubooka et al., 2009; Warren et al., 
2007). Sall4 null mice died early at peri-implantation stage between E3.5-8.5 as a 
result of failure of inner cell mass formation. On the other hand, Sall4 heterozygous 
mutants show increased postnatal lethality, the surviving heterozygotes exhibit 
features of Okihiro syndrome, a disease caused by SALL4 truncation mutation, partly 
due to haploinsufficiency of Sall4 gene. Targeting different regions of Sall4 gene 
gives rise to slightly different phenotypes observed in Sall4 heterozygous mutant mice. 
Among the developmental defects observed in Sall4 heterozygous mutants are neural 
tube defect, exencephaly, anorectal malformations, renal agenesis, renal hypoplasia, 
heart defects and deafness, suggesting an important role for Sall4 for the development 
of these organs (Elling et al., 2006; Sakaki-Yumoto et al., 2006; Warren et al., 2007).   
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The roles of SALL4 during early embryonic development might be mediated 
through its function as a zinc finger transcription factor. Intriguingly, SALL4 may 
function as a dual function transcription factor that can either repress or activate gene 
expression. Sall4b or Sall4a/b heterodimers is associated with activating histone 
marks H3K4me3 and H3K36me3, whereas Sall4a alone is associated with repressive 
histone marks H3K27me3 in the mouse ESCs (Rao et al., 2010). The mechanisms 
underlying SALL4 regulatory effects might be dependent on its binding partners. For 
instance, it has been reported that SALL4 represses gene expression via the 
recruitment of the epigenetic NuRD complex or DNA methyltransferases (Lu et al., 
2009; Yang et al., 2012b). The tumor suppressor PTEN is among the genes that are 
repressed by SALL4 via these two mechanisms (Lu et al., 2009). On the other hand, 
SALL4 has been shown to be able to activate various genes, including the Wnt/β-
catenin signaling and the polycomb BMI1 expression (Ma et al., 2006; Yang et al., 
2007). The mechanisms by which SALL4 activates gene expression, however, have 
not been documented previously. 
Being an important transcription factor implicated in early development, 
SALL4 is tightly regulated at different levels to ensure normal development. The 
evolutionarily conserved SALL4 promoter region has been identified and the 
expression of SALL4 can be regulated by LEF/TCF canonical Wnt signaling (Böhm 
et al., 2006), STAT3 (Bard et al., 2009), OCT4 and SALL4 itself (Yang et al., 2010). 
At post-translational level, SALL4B is regulated by sumoylation, and modified by 
phosphorylation and ubiquitination (Yang et al., 2012a). Sumoylation of SALL4B 
modulates its protein stability, localization and transcription activity. SUMO-modified 
SALL4B was more stable and had more active transcription activities in activating 
and suppressing gene expression (Yang et al., 2012a). Furthermore, SALL4 function 
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is greatly modulated via its protein-protein interaction with various partners. Plzf, a 
transcription factor implicated in the maintenance of adult stem cells, has shown to 
antagonize Sall4 function by displacing it from cognate chromatin, and vice versa, in 
differentiating postnatal spermatogonial progenitor cells (Hobbs et al., 2012). Cyclin 
D1, a G1 to S cell cycle modulator, also interacts with SALL4 and acts synergistically 
with SALL4 in repressing gene expression (Böhm et al., 2007). Moreover, the 
localization of Sall4 is affected by its interaction with Sall1. The truncated Sall1, 
causative factor of Townes-Brocks syndrome, acts in a dominant negative manner in 
regulating Sall4 function. C-terminal truncated Sall1 forms a heterodimers with Sall4 
and causes mislocaliaztion of Sall4 from heterochromatin (Sakaki-Yumoto et al., 
2006). Any aberrations in SALL4 regulation or presence of mutations in SALL4 gene 
that affects its functions and regulations are expected to cause various human diseases 
and developmental disorders. 
 
1.2 SALL4 and Human Diseases 
 The link between SALL4 and human diseases was first established in year 
2002 by two independent research groups simultaneously when heterozygous 
mutations of SALL4 were found to cause Okihiro syndrome, an autosomal condition 
characterized by radial malformations and Duane congenital eye retraction syndrome 
(Al-Baradie et al., 2002; Kohlhase et al., 2002). Okihiro syndrome is also known as 
Duane-radial ray syndrome (DRSS). There are no mutation hot spots for SALL4 
detected in the patients with Okihiro syndrome, however, almost all SALL4 mutations 
give rise to truncated proteins with premature stop codon. The truncated protein might 
contribute to the panel of developmental defects observed in Okihiro syndrome 
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patients as a result of haploinsufficiency for SALL4, dominant negative effect or 
disrupted protein-protein interaction.  
In recent years, SALL4 has also emerged as a novel oncogene, first reported in 
leukemia in year 2006. SALL4 was constitutively expressed in human acute myeloid 
leukemia (AML), and SALL4B transgenic mice developed the pre-leukemic 
myelodysplastic syndrome (MDS) and a transplantable AML (Ma et al., 2006). 
Subsequently, SALL4 expression has been implicated in B-cell lymphoblastic 
leukemias/ lymphomas and other solid tumors including lung cancer, gastric cancer, 
ovarian cancer and breast cancer (Cui et al., 2006; Kobayashi et al., 2011). SALL4 
has also been proposed as a diagnostic marker in several cancers, especially in 
metastatic germ cell tumors that are diagnostically difficult to identify (Cao et al., 
2009b; Wang et al., 2009).  
SALL4 is expressed abundantly during early development. However, it is 
silenced in most adult tissues, except in certain germ cells (Kohlhase et al., 2002). The 
mechanisms leading to SALL4 activation in tumor cells are unclear. Mutations of 
SALL4, although cause Okihiro syndrome, do not account for its oncogenic roles. Our 
search of sequencing data from the public databases did not detect SALL4 mutation in 
gastric cancer and hepatocellular carcinoma. A recent paper documented SALL4 
promoter hypomethylation in MDS and a positive correlation between SALL4 
transcript levels and promoter hypomethylation status was established (Lin et al., 
2012). This suggests that SALL4 expression might be activated as a result of promoter 
hypomethylation, leading to the development of MDS and AML. 
Most of the studies pertaining to SALL4 and cancers are concentrating on the 
expression pattern of SALL4 and its roles as a biomarker in various cancers. There 
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are not many existing reports that elucidate the mechanisms of SALL4-induced 
carcinogenesis to date. The study of the role of SALL4 in tumorigenesis is more 
established in the leukemic system. Most of the existing evidence suggests that 
SALL4 drives tumor cells towards their stem/ progenitor cell state. For instance, 
SALL4 activates the polycomb ring finger oncogene BMI1 (Yang et al., 2007). BMI1 
is implicated in stem cell development and carcinogenesis, including in hematopoiesis 
and leukemogenesis (Lessard and Sauvageau, 2003). The side population cells 
isolated from hepatocellular carcinoma cell lines (putative hepatic cancer stem cells) 
also express and require Bmi1 for their maintenance (Chiba et al., 2008). Moreover, 
SALL4 is enriched in the leukemic side population cells and activates ABCA3 and 
ABCG2 genes, contributing to drug resistance in AML (Jeong et al., 2011). SALL4 
also activates the canonical Wnt/β-catenin pathway that plays important roles during 
embryonic development and carcinogenesis (Ma et al., 2006). These data suggest that 
SALL4 activates and represses genes that are important in maintaining cells in a stem/ 
progenitor state and contributes to tumorigenesis by promoting stem-like properties 
and drug resistance in cancer cells. 
 
1.3 Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is the major malignancy of the liver, 
originating from hepatocytes, the liver parenchymal cells. HCC is highly fatal, it is the 
third leading cause of cancer-related deaths globally, with an overall mortality to 
incidence ratio of 0.93 (Figure 1.3) (Ferlay et al., 2010). There are more than half a 
million new cases diagnosed each year worldwide, the estimated new cases and 
deaths from liver cancer in the United States alone in year 2012 are 28,720 and 
20,550 respectively (National Cancer Institute, National Institute of Health). Disease 
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burden of HCC is borne in developing nations, especially in Southeast Asia and sub-
Saharan Africa where hepatitis B virus infection is endemic (Figure 1.3) (El-Serag, 
2011; Ferlay et al., 2010). However, an increase in HCC incidence has been 
evidenced in the western countries, as a result of increase incidence of hepatitis C 
infection and alcoholism. 
 
 
Figure 1.3 Incidence and mortality of HCC worldwide. Liver cancer is the third 
most common cause of cancer related-deaths worldwide, with an overall mortality to 
incidence ratio of 0.93. (Source: Globocan 2008 (Ferlay et al., 2010)) 
 
In Singapore, a Southeast Asian country, liver cancer is the fourth most 
frequently diagnosed cancers and third leading cause of cancer-related mortality in 
males (Table 1.1). Although liver cancer is not one of the top ten most frequently 
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detected cancers in Singapore females (Table 1.1), it is the fifth leading cause of 
cancer-related deaths in females, according to the Singapore Cancer Registry, 




Table 1.1 Ten most frequent cancers in Singapore males and females, years 2006 – 




Site No. % Site No. % 
1 Colo-rectum 4,456 17.8 Breast 7,781 29.3 
2 Lung 4,062 16.2 Colo-rectum 3,750 14.1 
3 Prostate 2,860 11.4 Lung 2,057 7.7 
4 Liver 1,897 7.6 Corpus uteri 1,574 5.9 
5 Lymphoid 
neoplasms 
1,579 6.3 Ovary, etc. 1,455 5.5 
6 Stomach 1,404 5.6 Lymphoid 
neoplasms 
1,136 4.3 
7 Skin, incl. 
melanoma 
1,247 5.0 Skin, incl. 
melanoma 
1,113 4.2 
8 Nasopharynx 1,158 4.6 Stomach 993 3.7 
9 Kidney & 
other urinary 
821 3.3 Cervix uteri 960 3.6 
10 Bladder 759 3.0 Thyroid 808 3.0 
 Others 4,844 19.3 Others 4,943 18.6 
 All sites 25,087 100.0 All sites 26,570 100.0 
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While the major epidemiological risk factors for HCC, including hepatitis B or 
C virus infection, aflatoxin exposures, alcoholic liver disease and non-alcoholic fatty 
liver disease, are well known (Ferlay et al., 2010), the molecular mechanisms 
underlying hepatocarcinogenesis are still not well characterized. Elucidating these 
mechanisms will enable identification of novel candidates for therapeutic targeting. 
While surgery, liver transplantation, or radiological intervention may be a viable 
option for early stage disease, prognosis for advanced stage HCC remain bleak 
(Keating and Santoro, 2009), with more than 90% of patients eventually succumbing 
to the disease within 5 years. For many years, combination chemotherapy has not 
shown to improve overall survival but have nonetheless been in wide usage due to its 
possible role in palliation.  With the advent of molecular targeted therapy, sorafenib, 
an oral multikinase inhibitor, became the first drug to show improved overall survival 
in patients with advanced HCC when compared to palliative care, and quickly became 
standard of care for patients with advanced disease. Nonetheless, despite its promise, 
the absolute overall survival benefit translated into only about 3 months in large scale 
phase III clinical trials (Keating and Santoro, 2009; Yang and Roberts, 2010). The 
race towards improving outcomes for advanced HCC has led to several other 
molecular targeted therapies that are currently in preclinical or early phase clinical 
trials.  In spite of all these efforts, due to its heterogeneity nature, the need to 
understand the molecular pathogenesis of HCC and develop more effective targeted 
therapies to tackle the disease remains urgent, and will be pivotal in conquering HCC. 
Because of the unfavorable prognosis and lack of therapeutic options in HCC, 
we chose to focus our study on this malignancy. 
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1.4 Subgroup of Cancers that Expresses the Embryonic Stem Cell Signatures or 
Share Gene Expression Profile with Progenitor Cells 
Tremendous heterogeneity exists among HCC patients. Unlike other cancers 
where there are established clinically useful genetic profiles (e.g. prognostically 
useful gene expression profiles in acute myeloid leukemia (Marcucci et al., 2011; 
Valk et al., 2004)) or clinically useful molecular drug targets (e.g. Her2 
overexpression in breast cancer (Carlsson et al., 2004; Slamon et al., 1989) and EGFR 
mutations in lung cancer (da Cunha Santos et al., 2011)), there are no clinically useful 
molecular subclasses of HCCs to date. With the generalization of high-throughput 
genomics tools however, various groups have suggested stratification of HCCs 
according to their genetic profiles that might hold clinical benefits (Chiang et al., 
2008; Hoshida et al., 2009; Lee et al., 2006). 
Among the many reported subtypes of HCCs, we are particularly interested in 
the progenitor-like subgroup of HCC, given the physiological function of SALL4 as 
an ESC factor. Within the heterogeneous HCCs, the progenitor-like subgroup of HCC 
has shown to have poor prognosis (Lee et al., 2006). From meta-analysis of a few 
gene expression profiles, including rat hepatoblasts and adult hepatocytes, human 
HCC and HCC mouse models, Lee et al. identified two subtypes of HCC – one that 
shared gene expression profiles with hepatoblasts (HB subtype) and one that clustered 
with hepatocytes (HC subtype) in a hierarchical clustering analysis. From a 
multivariate analysis, the HB subtype of HCC has found to predict poorer survival of 
HCC patients.  
This observation is not tissue-specific, it is not restricted to only human HCCs. 
Within the heterogeneous cancer cell population, there is a group of tumor cells that 
resembles normal stem cells in terms of gene expression, this group of tumor cells 
CHAPTER 1. INTRODUCTION 
15 
 
might either arise from the stem/ progenitor cell population of the tissues or 
dedifferentiate from matured cells. This subgroup of cancers that expresses an ESC-
like gene expression profile is known to have poor prognosis with poorly 
differentiated and more aggressive characteristics (Ben-Porath et al., 2008). The 
enrichment of ESC signature is observed in the histologically poorly differentiated 
subtype of various cancers, including estrogen receptor negative, poorly differentiated, 
basal-like breast cancers, grade 4 glioblastomas, and high grade bladder cancers (Ben-
Porath et al., 2008). 
 
1.5 Hypothesis 
Based on the importance of Sall4 during murine liver development, its 
physiological functions in promoting ESC self-renewal, and its oncogenic role in 
several cancers, we hypothesized that SALL4 would contribute to the development 
and maintenance of HCC when it was expressed in adult hepatocytes. The expression 
of Sall4 specifically in the murine fetal liver, but not the adult liver, led us to 
hypothesize that SALL4 might be an important marker for the progenitor-like subtype 
of HCC which has worse prognosis. Due to the heterogeneity nature of HCC, clinical 
trials that treat HCC as a single common entity have struggled to prove statistical 
significance. The key to making progress in HCC treatment is to be able to identify 
subtypes of HCC, especially the key drivers of those with worse prognosis and be 
able to target these drivers directly. In this study, we report that SALL4 represents a 
novel prognostic marker and promising therapeutic target for a subgroup of HCC 



















MATERIALS AND METHODS 
2.1 Patient Samples and Clinical Outcome Definition 
Permission to perform this study was obtained from NUS Institutional Review 
Boards (NUS IRB 09-261). HCC tissue microarrays (TMAs) were constructed with 
the tissues collected from the National University Hospital (NUH) of Singapore with 
permission from NUS Institutional Review Boards (NUS IRB 10-133). This cohort of 
HCC clinical specimens is identified as SG cohort in this thesis. We also analyzed a 
second batch of primary HCC specimens collected from the Queen Mary Hospital 
Hong Kong, designated as HK cohort in the thesis. HCC stage was analyzed 
according to the conventional TNM and BCLC staging criteria (de Lope et al., 2012). 
Child-Pugh score were computed to document the levels of derangement of liver 
disease of the patients at diagnosis (El-Serag, 2011). Similar HCC treatment 
algorithms based on international treatment guidelines were used in both cohorts. 
Patients were subjected to curative surgery if they were at early BCLC stage. 70-80% 
of HCC patients were positive for Hepatitis B infection and oral nucleoside and 
nucleotide analogs were initiated if HBV DNA was elevated. Oral nucleoside and 
nucleotide analogs e.g. lamivudine work mainly by mimicking nucleosides for DNA 
replication and inhibiting HBV DNA polymerase, thereby decreasing hepatitis viral 
replication (Papatheodoridis et al., 2002). Curative surgery was defined as complete 
resection of the tumor with clear microscopic margin, and no residual tumors detected 
by CT scan or angiography at 1 month after surgery. All post-operative patients were 
subjected to regular surveillance as outpatients with standard protocol including 2-6 
monthly imaging of the liver and measurement of serum alpha-fetoprotein level to 
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monitor for tumor recurrence. Any suspected intrahepatic recurrence was confirmed 
by hepatic angiography, post-lipiodol CT scan, and if necessary, percutaneous fine-
needle aspiration cytology. In our cohorts, 80% of patients were followed up for up to 
2 years.Only patients who died as a result of HCC or its related mortality was 
included in our analysis. 
 
2.2 Hematoxylin & Eosin (H&E) Staining 
Paraffin tissue sections of 4 µm were baked at 60°C for one hour, 
deparaffinized with Histoclear and hydrated in graded ethanols (2× 100% ethanol, 1× 
95% ethanol, and 1× 75% ethanol). The hydrated tissue sections were then immersed 
in Mayer’s Hematoxylin (Dako, Glostrup, Denmark A/S) for 2 minutes and rinsed 
with H2O, followed by immersion in 1% ammonium hydroxide (Sigma, St. Louis, 
MO.) for a few seconds for bluing. Tissue sections were rinsed with H2O again and 
immersed in 95% ethanol. These were followed by an immersion in Eosin Y solution, 
alcoholic (Sigma) for one minute and 95% ethanol briefly. Sections were then 
dehydrated in absolute ethanol twice and air dried for more than 10 minutes at room 
temperature. Tissues sections were mounted with DPX mounting agent (Sigma) after 
serial immersion in Histoclear thrice. 
 Histoclear is a substitute for xylene, a hazardous solvent consisting of 
aromatic hydrocarbon that is used to remove paraffin on tissue sections prior to the 
staining procedure. Xylene is also used after tissue staining, before cover slipping, as 
the mounting agent is xylene-base. Xylene can cause both acute and chronic toxicity; 
the most common health hazard caused by xylene is the depression of the central 
nervous system via the inhalation route.  Common symptoms resulting from 
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inhalation of the clear xylene liquid that has a strong odor include headache, dizziness, 
nausea, and vomiting (Kandyala et al., 2010). To reduce occupational health hazards 
caused by xylene, Histoclear was used to substitute xylene in many laboratories. 
Histoclear is a product of the National Diagnostics; it was distilled from oranges and 
hence brings with it a citrus odor. DPX (Di-n-butyl Phthalate in Xylene) mounting 
agent is a mountant consisting of a mixture of distyrene, a plasticizer, and xylene. It is 
used to preserve histology staining. 
 
2.3 Immunohistochemistry 
Paraffin tissue sections of 4 µm were baked at 60°C for one hour, 
deparaffinized with Histoclear and hydrated in graded ethanols. Antigen retrieval was 
performed by boiling at 120°C in high pH target retrieval solution for 5 minutes in a 
pressure cooker for SALL4 IHC, or heating in citrate buffer at 95°C for 30 minutes 
for Ki-67 IHC. Non-specific signal was blocked by peroxidase block (hydrogen 
peroxide/ 15mM sodium azide/ detergent/ phosphate buffer) for 10 minutes at room 
temperature, followed by protein block (0.25% casein/ stabilizing protein/ 15mM 
sodium azide/ 1X PBS) for 30 minutes at room temperature. Primary antibodies were 
diluted in antibody diluents (0.05 mol/L Tris-HCl/ 0.1% Tween/ 0.015mol/L sodium 
azide/ stabilizing proteins to reduce background) and incubated at room temperature 
for one hour in a humidified chamber, followed by horseradish peroxidise (HRP)-
conjugated secondary antibody incubation for 30 minutes at room temperature. 
Antibody binding was revealed by 3,3-Diaminobenzidine (DAB) and reaction was 
stopped by immersion of tissue sections in distilled water once brown color appeared. 
HRP is an enzyme found in the plant horseradish. In immunohistochemical staining, it 
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oxidizes DAB by using hydrogen peroxide as an oxidizing agent to produce dark 
brown color. Hydrogen peroxide is present in the DAB reagent that is available 
commercially. 
Tissue sections were counterstained by hematoxylin, dehydrated in graded 
ethanols and mounted. The following antibodies were used: SALL4 (Santa Cruz, CA, 
USA #sc-101147) and Ki-67 (Novus Biologicals, Littleton, CO, USA #NB110-
89717). All reagents for immunohistochemistry were from Dako (Dako). Appropriate 
positive and negative controls were included for each run of IHC (Figure 2.1). A 
blocking peptide (Santa Cruz, #sc-46045 P) for SALL4 antibody was used as a 
negative control. Briefly, SALL4 antibody and blocking peptide (1:10 ratio) were 
incubated at room temperature for 2 hrs prior to incubation on the tissues for an hour 
at room temperature. 
 
Figure 2.1 Controls for SALL4 IHC. (A) Human testis tissue was used as positive 
control tissue for SALL4 IHC. Nuclear expression (brown color) of SALL4 was 
observed in the spermatogonia cells (arrows) located on the wall of the seminiferous 
tubules. (B) SALL4 signals on testis tissue were blocked by a blocking peptide as a 
negative control to check for specificity of the antibody used. 
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Only nuclear staining was considered positive for SALL4. For IHC on TMAs, 
SALL4 expression was scored according to the percentage of tumor cells stained 
positive for SALL4, with 0 denotes no tumor cells stained, 1 denotes 1 – 30% of 
tumor cells stained positive, 2 denotes 31 – 50% of tumor cells stained positive, 3 
denotes 51 – 80% of tumor cells stained positive, 4 denotes >80% of tumor cells 
stained positive. SALL4 expression in TMAs was scored by a pathologist and two 
researchers independently. 
 
2.4 Cell Culture 
HCC cell lines were maintained in either Dulbecco’s Modified Eagle Medium 
(DMEM) or RPMI medium supplemented with 10% fetal bovine serum (FBS) at 
37°C in a humidified atmosphere of 5% CO2. Immortalized non-transformed 
hepatocyte cell lines, THLE-2 and THLE-3, were maintained in BEGM basal medium 
(Lonza, Basel, Switzerland. Catalogue #CC-3170) supplemented with hydrocortisone, 
bovine pituitary extract (BPE), transferrin, insulin, rhEGF, triiodothyronine (T3), 
retinoic acid (included in Lonza SingleQuots™ Kit), 5ng/mL EGF (Invitrogen Life 
Technologies, CA, USA #PHG0311L), 70ng/µL phosphoethanolamine (Sigma  
#P0503) and 10% FBS in pre-coated tissue culture flasks at 37°C in a humidified 
atmosphere of 5% CO2 as recommended by ATCC. Tissue culture flasks for culturing 
of THLE-2 and THLE-3 cells were pre-coated with coating medium – 0.01mg/mL 
fibronectin (Invitrogen #PHE0023 or #33016-015), 0.03mg/mL bovine collagen type 
I (Invitrogen #A1064401) and 0.01mg/mL BSA (Invitrogen. AlbuMAX I Catalogue 
#11020021) in BEGM basal medium – overnight at 37°C in 5% CO2 humidified 
atmosphere before use. 
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2.5 Quantitative Real-time RT-PCR 
Total RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen, Valencia, 
CA) and treated with RNase-free DNase (Qiagen) following manufacturer’s 
instructions. Reverse transcription was carried out using High Capacity Reverse 
Transcription Kit with RNase inhibitor (Applied Biosystems, Foster City, CA). 
Nucleic acids quantity and quality were measured by NanoDrop 2000 (Thermo Fisher 
Scientific Inc., Wilmington, DE). Quantitative PCR was performed using GoTaq 
qPCR Master Mix (Promega, Madison, WI). Amplification was done with a Corbett 
Rotor Gene 6000 (Qiagen) using the following parameters: 95°C (10 min), 40 cycles 
of 95°C (15s), 60°C (60s), and 72°C (20s). All measurements were performed in 
duplicate. Primers used in this study are listed in Table 2.1. The position of all SALL4 
primers on SALL4 gene was depicted in Figure 2.2. 
Table 2.1 Primers used in this study 





SALL4 F GCGAGCTTTTACCACCAAAG 194 99.3 
SALL4 R CACAACAGGGTCCACATTCA 
SALL4A F TCCTGGAAACCACATCCTTC 198 109.9 
SALL4A R ATGTGCCAGGAACTTCAACC 
SALL4B F GGTGGATGTCAAACCCAAAG 119 114.1 
SALL4B R ATGTGCCAGGAACTTCAACC 
ACTB F CAGAGCCTCGCCTTTGCCGATC 61 105.7 
ACTB R CATCCATGGTGAGCTGGCGGCG 
 




Figure 2.2 SALL4-related reagents used in this study. Positions of SALL4 primers 
and SALL4-specific shRNAs on SALL4 genomic DNA sequence (NCBI accession: 
NC_000020.10). 
 
To ensure that each qPCR assay was optimal and the efficiency of each 
reaction was comparable, qPCR efficiency of each primer pair was examined. Briefly, 
qPCR reactions were carried out using serial dilutions of SNU-398 cDNAs as 
template for each primer pair. A standard curve was plotted by using log of starting 
quantity of template (or dilution factor for unknown quantities) against CT values of 
each dilution (Figure 2.3). A good qPCR reaction will have a Pearson’s correlation 
coefficient (r) of >0.99 or coefficient of determination (R
2
) of >0.98, this is a measure 
of how well the experimental data fit the regression line. To calculate the percentage 
of efficiency, the following equation was used: 
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Efficiency close to 100% indicates a robust and reproducible assay. To compare the 
expression of two genes in a relative quantitation assay, qPCR efficiency of each 
assay should be comparable.  
 
Figure 2.3 Standard curves of qPCR reactions. qPCR efficiency of each primer 
pair was determined by plotting CT values against log of dilution factor of serial 
dilutions of SNU-398 cDNAs.  
 
2.6 Preparation of Metaphase Spread from Cell Lines 
Cells were cultured in 10cm dishes overnight to achieve a confluency of 70-
85% when they are actively proliferating. A final concentration of 0.01 µg/mL of N-
desacetyl-N-methylocolchicine (Colcemid) was added to the cultures to arrest cells at 
metaphase. To do this, 10 µL of KaryoMAX Colcemid (Invitrogen) was added to the 
cells cultured with 10 mL of medium. Colcemid was incubated with cells for 30 
minutes to 2 hours depending on the proliferation rates of the cells. Cells were 
harvested by trysinization and washed with 10 mL of 1×PBS. 1×PBS was removed 
and cells were resuspended in residual PBS. 10 mL of hypotonic solution (0.075M 
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KCl) was added dropwise and slowly to the cell suspension and incubated in a 37°C 
waterbath for exactly 6 minutes and 1 mL of freshly prepared fixative (3:1 methanol/ 
acetic acid) was then added dropwise. Hypotonic solution was removed after 
centrifugation at 900 RPM for 5 minutes and cells were resuspended in residual 
hypotonic solution. 5 mL of fixative was then added dropwise with mixing by using a 
vortex. Fixative was removed after centrifugation at 900 RPM for 5 minutes and 2 mL 
of fresh fixative was added again followed by centrifugation at 900 RPM for 5 
minutes. Fixative was removed and cells were resuspended in remaining 200–500 µL 
fixative. Metaphase cells can be stored for an extended time at -20°C. To prepare 
metaphase spread, slides were soaked in absolute ethanol and air dry. Metaphase cells 
were dropped from 30–40 cm height onto the slide that has been placed on an ice pack 
(humidified) and air dry. The quality of metaphase spread was investigated under a 
phase contrast microscope and slides were incubated at 37°C overnight prior to probe 
hybridization for FISH. 
 
2.7 Labeling of BAC Probes for Fluorescence in situ Hybridization (FISH) 
Assay 
BAC vectors covering SALL4 gene (RP11-104I12) or centromere 20 (CEP20) 
regions (RP11-108H13) were purchased from BACPAC Resources Centre (BPRC) at 
Children's Hospital Oakland Research Institute. The first set of SALL4 FISH probes 
consist of SALL4 BAC labeled with carboxytetramethylrhodamine (TAMRA) red 
fluorescent dye and CEP20 BAC labeled with CF488 green fluorescent dye (Figure 
2.4A). To generate this probe set, 200-400 ng of BAC DNA was denatured in a final 
volume of 37 µL reaction consisting of 20 µL of 2.5× random priming buffer [125 
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mM Tris-HCl, pH 6.8/ 12.5 mM MgCl2/ 25 mM 2-mercaptoethanol/ 750 µg/ml 
oligodeoxyribonucleotide primers (random octamers)] (2.5× random primers solution, 
Invitrogen) and nuclease-free H2O at 99°C for 5 minutes in a thermocycler. The 
reaction was immediately cooled on ice, and then 5 µL of 10× dNTPs [2 mM each 
d(GAC)TPs/ 0.45 mM dTTP/ 1.7mM Aminoallyl-dUTP (Biotium Inc., Hayward, CA)] 
and 8 µL of 5 U/µL Klenow Fragment, exo- (Fermentas, Thermo Scientific) was 
added on ice. The reaction mix was mixed gently and centrifuged briefly and then 
incubated at 37°C for 2 hours in a thermocycler. After the incubation, the aminoallyl-
labeled BAC DNA was precipitated by adding 50 µL of H2O, 15 µL of 1 µg/µL 
sodium acetate/ glycogen mixture and 250 µL ice cold 100% ethanol and incubated at 
-80°C for 20 minutes. The mixture was then centrifuged at 13,000 RPM for 15 
minutes at 4°C and supernatant removed. The DNA was washed with 200 µL ice cold 
70% ethanol and air dry. The DNA pellets were resuspended in 10 µL nuclease-free 
H2O. To label the DNA with fluorescent dyes, the amine-modified DNA was first 
denatured at 95°C for 5 minutes and then snap cooled on ice. 6 µL of labelling buffer 
(1 M sodium bicarbonate, pH8.5) was then added to the mixture, followed by 4 µL of 
20 µg/µL reactive dye (TAMRA or CF488). The mixture was briefly vortex and then 
incubated for 1 hour at room temperature protected from light. The fluorescent-
labeled DNA was purified by using a PCR purification kit (QIAGEN) and eluted with 
100 µL of warm (55°C) H2O. The purified probes were precipitated following the 
steps mentioned earlier and resuspended with 10-20 µL of hybridization buffer (5.5 
mL formamide/ 1 g dextran sulfate/ 0.5 mL 20× SSC) in the final step. Labeled probe 
can be stored at -20°C. The second set of SALL4 FISH probes consist of SALL4 
BAC labeled with SpectrumGreen fluorescent dye and CEP20 probe labeled with 
SpectrumOrange fluorescent dye (Abbott Vysis Libertyville, IL) (Figure 2.4B). 1 µg 
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of SALL4 BAC was labeled using a Nick Translation Kit (Abbott Vysis) following 
manufacturer’s instructions.  
 
2.8 Fluorescence in situ Hybridization  
Metaphase spread was incubated at 37°C overnight prior to probe 
hybridization. After overnight incubation, slides were immersed in pre-warmed 
denaturing buffer (70% v/v formamide/ 2× SSC, pH7/ 0.1 mM EDTA, pH7) for 45 
seconds and immediately dehydrated for 1 minute each in ethanol series 70%, 80%, 
90%, 100%. Slides were then allowed to air dry. To denature FISH probes, 1:1 
SALL4:CEP20 probes were diluted in hybridization buffer (5.5 mL formamide/ 1 g 
dextran sulfate/ 0.5 mL 20× SSC) and incubated at 75°C for 5 minutes followed by 
37°C for 2 minutes. Denatured probes were added to denatured slide, covered by a 
coverslip and sealed with rubber cement to prevent evaporation. Slides were 
incubated at 37°C in a humidified chamber for 16-18 hours to allow for probe 
hybridization. After overnight hybridization, rubber cement and coverslip were 
removed and slides were washed in 74°C 2× SSC/ 0.1% Tween-20 for 2 minutes 
followed by room temperature 2× SSC/ 0.1% Tween-20. After washing, slides were 
dehydrated for 1 minute each in ethanol series 70%, 80%, 90%, 100% and allowed to 
air dry. Lastly, slides were counterstained with DAPI (Invitrogen) and FISH images 
were acquired with Olympus IX71 fluorescence inverted microscope and Olympus 
DP Controller software. The specificity and quality of each FISH probe were checked 
and confirmed by hybridizing the probes on metaphase spread prepared from 
peripheral blood mononuclear cells (PBMCs) extracted from normal human control 
with normal diploid chromosome number (Figure 2.4). 




Figure 2.4 Hybridization of two SALL4 FISH probe sets on PBMC metaphase 
spread. (A) Chromosome 20 from two metaphase cells of normal individual PBMC 
were labeled with RP11-104I12 BAC tagged with TAMRA red fluorescent dye for 
SALL4 and RP11-108H13 BAC tagged with CF488 green fluorescent dye for 
centromere 20. (B) Metaphase and interphase chromosomes from normal individual 
PBMC were labeled with RP11-104I12 BAC tagged with SpectrumGreen fluorescent 
dye for SALL4 and CEP20 probe tagged with SpectrumOrange dye. Two distinct 
green signals labeling SALL4 on each sister chromatid of chromosome 20 can be seen 
on each of the metaphase chromosome 20. 
 




For profiling HCC samples versus normal controls, datasets from the GEO 
database with the accession numbers of GSE6222, GSE6864, & GSE29721 were used. 
For comparing HCC samples of high and low SALL4 expression with primary 
hepatocytes (Hep) and human fetal liver (HFL) samples, appropriate samples from the 
following GEO datasets (GSE6222, GSE6764, GSE9843, GSE15238, GSE18269, 
GSE23343, GSE29721, & GSE33606) were utilized. For comparison of SNU-398 
samples with primary hepatocytes and human fetal liver samples, Hep and HFL 
samples were taken from GEO datasets, GSE23034 & GSE23413, respectively. SNU-
398 samples with SALL4 knocked down were submitted to GEO database with the 
following accession number: GSE35965. The CNV data were taken from both GEO 
(GSE25097) and the TCGA (TCGA-G3-A25Z) databases. Only HCC samples in 
which SALL4 expression exceeded the threshold of expression intensity of 40 were 
included for the SALL4 copy number and gene expression correlation study to exclude 
samples with background signals. Note: Bioinformatics analyses were performed by 
Dr. Henry Yang from the Cancer Science Institute of Singapore. 
 
2.10 High-throughput Data Analysis 
For Affymetrix data, all CEL files were analyzed together using the Robust 
Multichip Average method to obtain the gene expression intensities (Irizarry et al., 
2003). For Illumina Beadchip data, raw data with background subtraction were used 
for all samples. Normalization was then performed across all samples based on the 
Cross Correlation method (Chua et al., 2006), and normalized data were further log2-
tranformed.  
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The Robust Multichip Average method is an algorithm used to generate an 
expression matrix from Affymetrix data. It is incorporated in the J Express software 
used for microarray data analysis. The MolMine As (developer of the J Express 
software) website has the step-by-step instructions how to run the Robust Multichip 
Average algorithm using J Express: 
http://www.molmine.com/magma/loading/rma.htm. 
As a result of inherent noise and systematic variation, for example, dye bias, 
amount of starting material and surface characteristics of microarray chips, 
normalization of microarray data has to be done  in order to offset the noise and 
accurately determine biological variation or differentially expressed genes between 
samples. Chua et al. proposed the Cross Correlation method in year 2006 that can 
robustly normalize microarray data. The Corss Correlation method normalizes gene 
expression data by using the entire gene set (global normalization) and then uses peak 
matching to minimize the effects of differentially expressed genes (Chua et al., 2006). 
This method is widely accepted and used in many microarray data analyses, including 
ours. Note: Bioinformatics analyses were performed by Dr. Henry Yang from the 
Cancer Science Institute of Singapore. 
 
2.11 Clustering and Heatmaps 
Hierarchical clustering with average linkage was used in all clustering. For 
clustering HCC SALL4 high and low samples with human fetal liver and hepatocyte 
samples, the mean of the four group means (HCC SALL4 high, HCC SALL4 low, 
human fetal liver, and hepatocyte) was subtracted from the log2-transformed 
normalized data prior to clustering. For clustering SNU-398 SALL4 knocked down 
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data, human fetal liver and hepatocyte genes with differential expression between the 
cell line and primary cells were excluded by using only genes with no significant 
changes between any one of SNU-398 SALL4 knocked down (KD) and wild type 
control (WT) and any one of primary cells to remove cell line and primary cell 
expression differences. The cutoff for no significant fold change used is 1.5. The 
mean of the four group means (SNU-398 KD, SNU-398 WT, hepatocyte and human 
fetal liver) was then also subtracted from the log2-transformed normalized data prior 
to clustering. Genes with no significant changes between the four groups of samples 
were not represented in both heatmaps to show clear patterns.  
In hierarchical clustering analysis of gene expression data, each gene is 
assigned to a cluster one after another. To compute the distance between one cluster 
and another cluster, there are several ways, including single linkage, complete linkage 
and average linkage. We employed average linkage clustering in our studies. In 
average linkage clustering, the distance between one cluster and another cluster is 
computed by calculating the average distance from any member of one cluster to any 
member of the other cluster. A simplistic explanation of hierarchical clustering 
written by Stephen P. Borgatti from the University of South Carolina is attached in 
the Appendix of this thesis. Average linkage cluster analysis was chosen in our 
studies because it is an attractive compromise between complete linkage, where the 
maximum dissimilarities between two clusters (maximum distance) were taken into 
account, and simple linkage analysis, where the minimum dissimilarities were chosen 
(minimum distance), which gives rise to more heterogeneous clusters.  
Gene set enrichment analysis (GSEA) was performed by using normalized 
data using GSEA v2.0 tool (http://www.broad.mit.edu/gsea/). For GSEA, we first 
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carried out hierarchical clustering to separate primary HCCs into high and low 
SALL4 groups and obtained four subclusters. Comparing high and low SALL4 HCCs 
from two of the subclusters (a total of 12 high SALL4 primary HCCs and 43 low 
SALL4 HCCs) yielded the data reported in Figure 3.8. Multiple hypothesis testing 
using enrichment score was employed to calculate the significance. Note: 
Bioinformatics analyses were performed by Dr. Henry Yang from the Cancer Science 
Institute of Singapore. 
 
2.12 Statistical Analysis 
All experiments were done in triplicate, unless otherwise stated, standard 
deviation and statistical significance were determined. Statistical analysis was 
performed using SPSS v 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Fisher 
exact test and Chi-square test were used to examine the association between the 
SALL4 expression levels and clinicopathological parameters of SG and HK cohort of 
primary HCCs, respectively. In the HK cohort of primary HCCs, SALL4 expression 
levels were divided into two groups, “high SALL4” group is the group of patients with 
SALL4 gene expression intensity exceeding or equal to the median expression level 
from microarray, while “low SALL4” group indicates the group of patients with 
SALL4 gene expression intensity lower than median expression level from microarray. 
Cumulative univariate overall survival and tumor recurrence were analyzed by the 
Cox proportional hazards regression model and Kaplan-Meier method followed by the 
log-rank test for the SG and HK cohorts of primary HCC, respectively. Factors with 
prognostic significance were included in the subsequent multivariate analyses using 
Cox proportional hazard regression model in both the SG and HK cohorts of HCCs. 
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The correlation significance was analyzed by Spearman and Pearson correlation 
analysis. The chi square test and Student t test were used for comparison between 
groups. A p value ≤ 0.05 was considered statistically significant. Note: 
Clinicopathological analysis of the SG and HK cohorts of primary HCC was 
performed by Mr. Chee Wee Ong and Dr. Kwong-Fai Wong from the Cancer Science 
Institute of Singapore, respectively. 
 
2.13 SALL4 Transgenic Mice and Two-stage Chemical Carcinogenesis 
SALL4B transgenic mice were generated at the background of C57BL/6 as 
previously described (Ma et al., 2006), and were maintained at the mouse facility at 
Children’s Hospital Boston (CHB). All animal work has been approved by and done 
according to the guidelines of the IACUC under protocol 10-10-1832. The SALL4B 
primer sequences for genotyping include the following: forward primer, 5’-AGC 
AGA GCT CGT TTA GTG AAC CG-3’, and reverse primer, 5’-CTG TCA TTC 
ATG ATG AGG ACA GG -3’. For the two-stage chemical carcinogenesis experiment, 
both SALL4B transgenic and wild type C57BL/6 mice received a single 
intraperitoneal (i.p.) injection of 5 mg N-nitrosodiethylamine (DEN)/kg body weight 
(Sigma) in sterile water at 15 days of age. Mice were then administered 0.05% of 
phenobarbital (Sigma) in drinking water from 2 weeks after DEN injection (4 weeks 
of age). Mice were sacrificed 10 and 23 weeks after the start of the PB diet by carbon 
dioxide inhalation and necropsied. Deaths and moribund cases were also necropsied. 
Body weights were recorded and livers removed, weighed and examined for grossly 
visible lesions. Each liver lobe was fixed in 10% neutral buffered formalin, trimmed, 
and embedded in paraffin. For routine histological analysis, two representative 
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sections were prepared from each liver lobe, 4-6 µm sections were prepared from 
paraffin blocks and stained with H&E. Liver lesions were classified according to 
criteria defined previously. The presence of foci of cellular alteration was graded 
based on the percentage of foci area compared to the liver section as follows:   
+: < 15% , ++: 15-40%, +++: 40-75%, ++++: 75-100%. 
The two-stage chemical carcinogenesis protocol is a well-established protocol 
used to induce liver tumor formation in the mice, probably by promoting proliferation 
of the livers. By using this protocol, pre-neoplastic hepatic lesions (foci of cellular 
alteration) can be observed as early as 23 weeks in the wildtype C57BL/6 mice. The 
frequency of liver tumor formation and time-to-tumor formation under this treatment 
regimen are strain- and sex-specific. Two chemicals, N-nitrosodietylsamine (DEN) 
and phenobarbital, are used in this protocol. DEN is a carcinogen; it can induce liver 
tumor formation without phenobarbital, albeit at a much later time point. DEN 
induces liver tumor formation by alkylating DNA. DEN is hydroxylated by 
cytochrome P450 found in the livers to α-hydroxylnitrosamine in the presence of 
oxygen and nicotinamide adenine dinucleotide phosphate (NAPDH). This 
hydroxylation process produces an electrophile, ethyldiazonium ion, which reacts 
with nucleophiles such as DNA bases, leading to DNA damage. Furthermore, the 
cytochrome P450 enzyme-dependent process also causes oxidative stress in the cells 
by generating reactive oxygen species (ROS) such as hydrogen peroxide and 
superoxide anions. The ROS can cause DNA, protein and lipid damage, thereby 
promoting carcinogenesis. Phenobarbital is not genotoxic, it is used in our two-stage 
chemical carcinogenesis protocol to promote liver tumor formation, after the 
induction phase by DEN. Phenobarbital enhances the effect of DEN via several 
CHAPTER 2. MATERIALS AND METHODS 
35 
 
mechanisms. First of all, it increases the activity of cytochrome P450 to 100 fold, 
enhancing the effects of DEN. Phenobarbital also causes increased oxidative stress in 
the cells as a result of increased cytochrome P450 activity. Moreover, there are 
evidences that support a role of phenobarbital in causing epigenetic and genetic 
changes in liver cells (reviewed by (Heindryckx et al., 2009)).  
In our study, DEN and phenobarbital were added to generate pre-neoplastic 
lesions in the livers of SALL4B transgenic mice and the control wildtype C57BL/6 
mice with an objective to determine whether the expression of SALL4B was able to 
accelerate liver tumor formation in the settings of pre-neoplastic liver lesions, thereby 
confirming the role of SALL4B in promoting hepatocarcinogenesis. Note: SALL4B 
transgenic mice were generated by Li Chai et al. from the Brigham and Women’s 
Hospital. These experiments were done with the help from the Li Chai Lab and the 
Pathology core facility in the Brigham and Women’s Hospital. 
 
2.14 Viral Transduction of shRNAs 
Lentiviruses expressing scrambled shRNAs or SALL4-specific shRNAs were 
packaged by transfection of 293T cells with lentiviral vector pLL3.7 or pLKO.1. 24 
hours and 48 hours post-transfection, viruses were harvested and filtered through 0.45 
µm filters. Virus titers were determined by using infected 3T3 cells by the 
conventional ways. Multiplicity of infection (MOI) of 5 to 10 was used depending on 
individual cell lines. MOI is the ratio of infectious agents to infectious targets, in this 
case, ratio of virus particles to cells. For instance, MOI of 5 means the condition of 
having five virus particles infecting one cell. Transduction of HCC cells were carried 
out using spinoculation protocol. Briefly, virus and 8 µg/mL polybrene (Santa Cruz) 
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were added to the trypsinized cells and let settle for an hour at 37°C in a humidified 
atmosphere of 5% CO2, centrifuged at 2,200 RPM at 37°C for 90 minutes and 
incubated overnight at 37°C in a humidified atmosphere of 5% CO2. Transduction 
efficiency was determined by GFP expression by FACS analysis. Table 2.2 
summarizes the sequence of shRNAs used in this study. The position of SALL4-
specific shRNAs on the gene was depicted in Figure 2.2. 
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Table 2.2 Sequence of shRNAs used in this study 
shRNA Sequence 
Scr shRNA 1 GGGTACGGTCAGGCAGCTTCTTTCAAGAGAAGAAGCTGCCTGACCGTACCCTTTTTTC 
Scr shRNA 2 CAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT 
shSALL4 1 GGCCTTGAAACAAGCCAAGCTATTCAAGAGATAGCTTGGCTTGTTTCAAGGCCTTTTTTC 
shSALL4 2 TGCTATTTAGCCAAAGGCAAATTCAAGAGATTTGCCTTTGGCTAAATAGCTTTTTTC 
shCCND2 #3 CCGGCCTTCCGCAGTGCTCCTACTTCTCGAGAAGTAGGAGCACTGCGGAAGGTTTTTG 
shCCND2 #5 CCGGAGGAACTGTGTACGCCATTTACTCGAGTAAATGGCGTACACAGTTCCTTTTTTG 
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2.15 Western Blot 
Total cell lysates were harvested in NP-40 lysis buffer (150mM NaCl, 1% 
Nonidet P-40, 50mM Tris, pH8.0, protease inhibitor cocktail) and protein 
concentrations were determined by BCA protein assay (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). Equal amounts of proteins from each lysate were resolved by 
SDS-PAGE and then transferred to nitrocellulose or PVDF membranes. Membranes 
were blocked with buffer containing 5% skim milk and 0.1% Tween 20 in PBS 
overnight at 4°C or at least one hour at room temperature with gentle shaking. 
Primary antibodies were incubated according to conditions stated in Table 2.3 with 
gentle shaking, followed by secondary antibody incubation at room temperature for 
one hour with gentle shaking. Table 2.3 listed all the antibodies used in this thesis and 
conditions used for western blot.
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mAb: monoclonal antibody; pAb: polyclonal antibody; RT: room temperature; O/N: overnight; FL: full length 
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2.16 Cell Viability Assay 
5000 – 7000 cells were seeded in each well of a microtiter plate in 100 µL of 
medium. Cells from each treatment were seeded in duplicate. Controls using the same 
medium without cells were set up in parallel. At various time points, 317 µg/mL of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (CellTiter96 AQueous One Solution Cell Proliferation Assay, Promega) 
was added to each well. After two to four hours incubation, depending on cell line, of 
the tetrazolium salt, absorbance at 490nm was read by a microplate reader. 
 
2.17 Caspase 3/7 Apoptosis Assay 
Capase 3/7 luminescent-based assay was carried out following manufacturer’s 
instructions (Promega). Equal number of infected HCC cells was seeded in microtiter 
plates compatible for luminescence assay and substrate for Caspase 3/7 was added 
four days post-transduction to detect caspase activity. 
 
2.18 Microarray 
Total RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen) following 
manufacturer’s instructions. RNA quantity was assessed using Nanodrop (Thermo 
Fisher Scientific, Wilmington, DE) and RNA integrity was analyzed using Nano chip 
for Eukaryotes on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA). A RIN of 8.0 and above was considered to indicate a satisfactory sample quality. 
Gene expression array analysis was performed using Affymetrix GeneChip Human 
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Gene 1.0ST Array system (Affymetrix, Santa Clara, CA) according to manufacturer’s 
instructions. Briefly, for each sample, 200 ng of total RNA in a volume of 5 µl was 
amplified using the Applause WT Amp ST, RNA Amplification System (NuGen, San 
Carlos, CA) and labeled with Encore Biotin Module, Post–Amplification System 
(NuGen). A total of 2.5 µg of labeled cDNA, along with GeneChip Hybridization 
Control reagents (Affymetrix), was injected into an Affymetrix GeneChip Human 
Gene 1.0 ST Array. The chips were incubated for 18 hours at 45°C and rotated at 60 
RPM to allow hybridization. The chips were then washed and stained using GeneChip 
Hybridization Wash and Stain Kit (Affymetrix) using the Affymetrix GeneChip 
Fluidics Station 450. Stained arrays were scanned on Affymetrix GeneChip Scanner 
3000 7G. Note: Microarray data was acquired by the Centre for Translational 
Research and Diagnostics (CTRAD), Cancer Science Institute of Singapore. 
 
2.19 In vivo Tumorigenicity Assay 
4- to 8-week-old NOD/SCID mice were used. Animal work was done at CHB 
with approval from IACUC. For loss of function studies, 10 million of SNU-398 or 6 
million of HuH-7 cells infected with viruses expressing scrambled shRNA or SALL4-
specific shRNA (total 300 µL of cell suspension and matrigel in 1:1 ratio) were 
injected subcutaneously into the right flank of NOD/SCID mice. For peptide 
treatment studies, SNU-398 cells were treated in vitro twice, 24 hours apart, with 20 
µM wt peptide and Scr. peptide, respectively.  2 hours post-second dose of treatment, 
cells were counted and 3 million cells were resuspended in 150 µL of PBS.  Cells 
were mixed with matrigel in a 1:1 ratio, then transplanted and injected subcutaneously 
into the right flank of each mouse, with 5 mice in each treatment arm. For TAT-
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peptide treatment studies, 3 million SNU-398 cells were resuspended in 150 µL PBS, 
mixed with matrigel in a 1:1 ratio, and then transplanted subcutaneously into the left 
flank of each mouse. 56 mg/ kg body weight of TAT-Mut. or 60 mg/ kg body weight 
of TAT-wt peptides were administered by intraperitoneal injection for five 
consecutive days starting from the day of subcutaneous HCC cells transplantation. For 
all studies, after injection, mice were examined and tumor volumes were measured at 
various time points. Tumor volume was calculated by using the formula, tumor 
volume = π/6 X larger diameter X (smaller diameter)2. Tumor samples were 
processed for routine histology examination. Mice were sacrificed when tumors were 
too large to be compatible with life and survival analysis was done. Note: Part of 
these experiments was performed by Dr. Chong Gao, Dr. Todor Dimitrov and Dr. 
Joline Lim from the Brigham and Women’s Hospital, Boston, USA. 
 
2.20 BrdU Cell Proliferation Assay 
Analysis of cell proliferation was carried out by measuring 
bromodeoxyuridine (BrdU) incorporation by fluorescence-activated cell sorting 
(FACS) using the FITC BrdU Flow kit following manufacturer’s instructions (BD 
Pharmingen, Franklin Lakes, NJ). Briefly, cells were pulse-labeled with a final 
concentration of 10µM BrdU at varying time period according to different cell lines at 
a humidified atmosphere of 5% CO2 at 37°C. The optimal pulse-labeling time for 
each cell line was empirically determined by a preliminary experiment that labeled 
cells at different time points. We have determined that 30 minutes and 2 hours 
labeling time are good for SNU-387 and SNU-398 cell lines, respectively. Firstly, 
1×10
6
 pulse-labeled cells were collected and resuspended in 50 µL of staining buffer 
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(1X DPBS/ 3% heat-inactivated FBS/ 0.09% sodium azide). Cell suspension was 
fixed and permeabilized with BD Cytofix/Cytoperm buffer (4% paraformaldehyde/ 
reversible permeabilization detergent saponin) for 15 minutes on ice followed by 
washing with 1×BD Perm/Wash buffer (FBS/ saponin) once.  To enhance staining, 
the cells were incubated with BD Cytoperm Permeabilization Buffer Plus (10% 
DMSO/ FBS) that acts as a secondary permeabilization reagent for 10 minutes on ice 
followed by washing with 1×BD Perm/Wash buffer once. Cells were fixed once again 
with BD Cytofix/Cytoperm buffer for 5 minutes on ice and washed once with 1×BD 
Perm/Wash buffer. To expose incorporated BrdU, cells were resuspended in 300 
µg/mL DNase in DPBS and incubated at 37°C for one hour followed by washing with 
1×BD Perm/Wash buffer once. To stain for BrdU, cells were resuspended in 50 µL of 
1:50 diluted FITC-conjugated anti-BrdU monoclonal antibody for 20 minutes at room 
temperature, followed by washing with 1×BD Perm/Wash buffer once. To stain for 
total DNA for cell cycle analysis, cells were resuspended in 20 µL of 7-
Aminoactinomycin D (7-AAD) solution and topped up with 1 mL of staining buffer. 
7-AAD is a fluorescent chemical compound with a strong affinity for DNA, 
especially the GC-rich region. 7-AAD binds DNA in a similar way like 
Aminoactinomycin D (AAD), a non-fluorescent compound. The stained cells were 
then analyzed by FACS using the BD LSRII flow cytometer (BD Biosciences).    
 
2.21 In vitro Peptide Treatment Assay 
SALL4 (wt) and control (Mut. and Scr.) peptides were synthesized 
(Biosynthesis Inc., Lewisville, Texas) using standard solid phase peptide synthesis 
chemistry and purified by the manufacturer to 95% purity. HCC cells were grown in 
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6-well plates to 50-70% confluence 24 hours prior to peptide treatment. For each 
treatment, 100 µL 1×PBS + 1µL diluted peptide was set up. Chariot reagent (Active 
Motif Inc., Carlsbad, CA), used as a peptide carrier, was diluted 1:10 in distilled water. 
Diluted peptide and diluted Chariot reagent were mixed gently and incubated for 30 
minutes at room temperature. Medium was aspirated from the well and cells were 
overlaid with the mixture. 400 µL serum-free medium was then added and cells were 
incubated for one hour at 37°C in a humidified atmosphere of 5% CO2. 500 µL 
complete medium was added one hour later. For determination of cell viability, the 
following doses of peptides were used: 0, 5 and 20 µM of wt, Mut., or Scr. peptides, 
or 0, 50 and 100 nM of trichostatin A (TSA). Cell viability was examined 72 hours 
after peptide treatment. For western blot analysis, 20 µM of wt or Scr. peptide, or 
100nM of TSA was used to treat the cells. Cell lysates were harvested 72 hours 
following peptide treatment. 400 nM of SF1670 PTEN inhibitor was used throughout 


















3.1 SALL4 is Expressed in Human Fetal Liver, Silenced in Adult Liver, and 
Re-expressed in Hepatocellular Carcinoma  
The expression of Sall4 in murine liver at various developmental stages has 
been reported previously (Oikawa et al., 2009), but its expression pattern in human 
liver and HCC has not been well studied. To test our hypothesis that SALL4 is re-
expressed in a subgroup of HCC, we examined the expression of SALL4 in primary 
human HCC specimens at both the mRNA and protein levels. In order to determine if 
there is aberration of SALL4 expression in HCC livers, we first investigated SALL4 
expression in normal human livers at both the fetal and adult stages. By qPCR and 
immunohistochemistry (IHC), we detected SALL4 mRNA and protein expression in 
human fetal but not adult liver (Figure 3.1).  




Figure 3.1 SALL4 is expressed in human fetal livers. (A) Both SALL4A and 
SALL4B were detected in human fetal livers (hFLs) of 14, 18 and 22 weeks gestation 
by quantitative real-time RT-PCR. Gene expression of SALL4 was normalized to 
human ACTB. Three human fetal livers from each gestation period were examined. 
Expression was presented as mean ± standard deviation of two technical replicates. (B) 
Representative images of SALL4 protein expression in human fetal and adult livers. 
SALL4 protein expression was detected in fetal liver but not in adult liver by 
immunohistochemistry. Scale bar = 100 µm. 
  
 Subsequently, we investigated the expression of SALL4 in human HCC. We 
constructed a panel of tissue microarrays (TMAs) consisting of 179 surgically 
resected primary HCCs and their matched non-neoplastic liver tissues from the 
archives of the National University Hospital Department of Pathology, Singapore 
(Singapore cohort). Table 3.1 illustrates the demographic and clinicopathological 
characteristics of the tumors in the Singapore cohort and the association between 
SALL4 expression with these parameters.  
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Table 3.1 Demographic and clinicopathological characteristics of the liver tumors 













 P value 
Age, years  
  
  
< mean (56.2) 38 (48.1) 16 22 1.00 




Female 15 (19) 6 9 1.00 




Chinese 62 (78.5) 28 34 0.58 
Non-Chinese 17 (21.5) 6 11   
Tumor grade  
  
  
I & II 69 (87.3) 48 21 1.00 
III & IV 10 (12.7) 7 3 
 TNM stage  
  
  
I & II 64 (81) 28 36 0.75 
III & IV 15 (19) 6 9   
Child-Pugh class  
  
  
A and B 68 (86.1) 30 38 0.75 




    
     
 












 P value 
BCLC stage  
  
  
A 57 (72.2) 22 35 0.22 
B 22 (27.8) 12 10   
HBsAg (n=76)  
  
  











HCV (n=78)  
  
  
Negative 74 (94.9) 34 40 0.13 
Positive 4 (5.1) 0 4   
Serum AFP, ng/dL (n=70) 
  < 10.0 21 (30) 11 10 0.31 
≥ 10.0 49 (70) 19 30   
Tumor size, cm (n=78)  
  
  
< mean (6.2)  49 (62.8) 18 31 0.24 




No 56 (70.9) 22 34 0.33 
Yes 23 (29.1) 12 11   
Lymphovascular invasion (n=53) 
  No  47 (88.7) 19 28 1.00 
Yes 6 (11.3) 2 4   
    
 
















No  67 (84.8) 27 40 0.34 
Yes 12 (15.2) 7 5   
Portal hypertension  
  
  
No 66 (83.5) 28 38 1.00 
Yes 13 (16.5) 6 7   
Pre-Op Treatment  
  
  
No 55 (69.6) 25 30 0.63 
Yes 24 (30.4) 9 15   
 
 
Recurrence (n=37)  
  
  
Early (<2 years) 9 (24.3) 5 4 0.46 
Late (≥2 years) 28 (75.7) 11 17   
HCC, hepatocellular carcinoma; MMPM, morpho-molecular prognostic model; SD, 
standard deviation; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis 
SALL4
neg
: IHC score 0; SALL4
pos
: IHC score +1 to +4  
a
N=79 (unless otherwise noted in brackets). 
b
Fisher exact test 
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Frequency, n Percentage (%) 
0 76 44.4 
1 75 43.9 
2 12 6.9 
3 4 2.3 
4 4 2.3 
Total 171 100 
a
SALL4 expression was scored according to published scoring criteria used for germ 
cell tumors(Cao et al., 2009a; Mei et al., 2009; Wang et al., 2009), with some 
modifications. We scored SALL4 expression according to the percentage of tumor 
cells stained positive for SALL4, 0: no tumor cells stained positive, 1: 1 – 30% of 
tumor cells stained positive, 2: 31 – 50% of tumor cells stained positive, 3: 51 – 80% 
of tumor cells stained positive, 4: >80% of tumor cells stained positive.  
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By IHC, we observed differential expression of SALL4 in matched primary 
HCC and the non-HCC tissues, with more SALL4-expressing cells in HCC than the 
matched non-neoplastic livers (P<0.001) (Figure 3.2A). Detailed analysis of the IHC 
data revealed SALL4 positivity in 56.6% (98/173) of the HCC tissues analyzed, albeit 
at variable expression levels (Table 3.2). 
 To further confirm that SALL4 is upregulated in a subgroup of HCC, we 
analyzed SALL4 expression by gene expression microarray in various independent 
cohorts of primary HCC samples. In a cohort of 228 matched primary HCC and non-
neoplastic liver samples from Hong Kong (Hong Kong cohort), we detected 
differential SALL4 expression (P<0.0001), similar to what we observed in the 
Singapore cohort, with SALL4 being upregulated in HCCs compared to the non-
tumor tissues (Figure 3.2B). Table 3.3 illustrates the demographic and 
clinicopathological characteristics of the liver tumors in the Hong Kong cohort and 
the association between SALL4 expression with these parameters. In the HK cohort 
of primary HCC, the expression of SALL4 is significantly correlated with age, serum 
AFP level, HBsAg and histological differentiation. As these parameters have certain 
prognostic power in HCC, the significant association between SALL4 expression with 
these parameters suggest that SALL4 expression might be associated with prognosis in 
HCC. More statistical tests have been carried out to further analyze the prognostic 
values of these parameters along with SALL4 expression and the data is presented in 
the following section.   
Furthermore, we pooled various global gene expression data from public 
databases and observed similar differential SALL4 expression in the HCC and non-
tumor liver tissues (P=0.003) (Figure 3.2C). From these independent sizable cohorts 
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of primary HCC and matched non-neoplastic liver tissues, we confirmed that SALL4 
is upregulated in a subgroup of human HCC livers, but remained silenced in their 
matched adult non-neoplastic livers. 
 
 
Figure 3.2 SALL4 is upregulated in a subgroup of primary HCC. (A) 
Representative immunohistochemistry (IHC) images of SALL4 protein expression in 
primary HCC and its matched non-neoplastic liver tissue from the Singapore cohort. 
SALL4 expression was detected in the HCC tissue and localized in the nucleus as 
indicated by the brown staining. Scale bar = 100 µm. (B) Differential SALL4 
expression in 228 matched HCC and non-tumor livers from the Hong Kong cohort of 
primary clinical specimens as determined by microarray. P<0.0001. (C) Microarray 
SALL4 expression of primary HCC and non-tumor livers extracted from public 
databases. P=0.003. Note: Fig. 3.2B was generated by Dr. Kwong-Fai Wong from the 
and Fig. 3.2C was generated by Dr. Henry Yang from the Cancer Science Institute of 
Singapore. 
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Table 3.3 Demographic and clinicopathological characteristics of the liver tumors 








SALL4 mRNA expression 
median  median P values 
Age, years      
  105 (46.1) 44 61 0.02 
  123 (53.9) 70 53   
Gender      
Female 49 (21.5) 19 30  0.08 





Well 37 (19.4) 24 13 0.04 
Moderate/Poor 154 (80.6) 77 77   
TNM stage      
Early (I, II) 103 (45.2) 56 47 0.27 
Late (III, IV) 125 (54.8) 58 67   
BCLC
 
stage (n=94)      
0 & A 67 (71.3) 39 28 0.38 
B & C 27 (28.7) 13 14   
HBsAg      
Negative 31 (13.6) 22 9 0.01 
Positive 197 (86.4) 92 105   
     
     







SALL4 mRNA expression 
median  median P values 
Alcohol
 
(n=217)      
                 No 133 (61.3) 65 68 0.52 
                 Moderate/Heavy 84 (38.7) 45 39  
  
Serum AFP, ng/ml      
  116 (50.9) 78 38 >0.001 
  112 (49.1) 36 76   
Tumor size, cm
 
(n=217)      
  77 (33.8) 37 40 0.67 
  151 (66.2) 77 74   
Venous infiltration
 
(n=227)      
Absent 114 (50.2) 64 50 0.10 
Present 113 (49.8) 49 64   
Early Recurrence
 
(n=139)      
Absent 40 (28.8) 23 17 0.05 
Present 99 (71.2) 39 60   
Late Recurrence
 
(n=89)      
Absent 68 (76.4) 39 29 0.71 
Present 21 (23.6) 13 8   
a
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Analysis of endogenous SALL4 expression across a panel of 10 human HCC 
cell lines by qPCR showed the expression of SALL4 at high, moderate or low levels in 
these HCC cell lines, an expression pattern that recapitulates that of the primary 
human HCC tissues (Figure 3.3). Moreover, SALL4 expression was not detected in the 
two immortalized non-transformed liver cell lines, THLE-2 and THLE-3. This data 
suggests that these cell lines are appropriate models for further testing of our 




Figure 3.3 SALL4 expression in HCC cell lines recapitulates that of the primary 
HCC samples. Quantitative RT-PCR analysis of (A) SALL4A and (B) SALL4B 
expression in 10 human HCC cell lines and two immortalized non-transformed 
hepatocyte cell lines, THLE-2 and THLE-3. All values were normalized to ACTB and 
plotted relative to the expression of THLE-2 cell line. Error bars indicate standard 
error of three replicates. 
 
In summary, the results obtained from a number of different assays and 
cohorts of clinical specimens demonstrated that SALL4 is expressed in human fetal 
livers, silenced in adult livers, and re-expressed in many HCC livers. 
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3.2 SALL4 Copy Number Gain as a Mechanism of SALL4 Re-activation in 
HCC 
After establishing the expression pattern of SALL4 in human livers at various 
stages, including in the diseased state of HCC, we then asked how SALL4 is re-
activated in HCC. The SALL4 gene is located on chromosome 20q13.13-13.2, a locus 
that has been frequently reported to be amplified in HCC (Beroukhim et al., 2010; 
Tabach et al., 2011). Hence, we hypothesized that SALL4 gene amplification is one of 
the mechanisms underlying SALL4 re-activation in HCC. Indeed, Illumina 
genotyping assay confirmed SALL4 copy number gain in 28.9% of the 228 primary 
HCC tissues from the Hong Kong cohort. To investigate whether the genomic status 
of SALL4 is correlated with expression level, we further extracted CNV data 
deposited in the Gene Expression Omnibus (GEO) (accession: GSE25097) and The 
Cancer Genome Atlas (TCGA) (accession: TCGA-G3-A25Z) databases. We observed 
a significant positive correlation between SALL4 copy number and SALL4 expression 
(r=0.7356; P<0.0001; n=97) in these primary HCC tissues (Figure 3.4).  
 
Figure 3.4 SALL4 CNV significantly and positively correlates with SALL4 gene 
expression in primary HCC tissues. Data were extracted from the GEO and the 
TCGA databases and HCC samples with SALL4 expression exceeded the threshold of 
expression intensity of 40 were included in the analysis. n=97, P<0.0001, r=0.7356. 
Note: Fig. 3.4 was generated by Dr. Henry Yang from the Cancer Science Institute of 
Singapore. 




 To verify data obtained from high-throughput SNP arrays, we carried out 
fluorescence in situ hybridization (FISH) assay using a SALL4 BAC probe (RP11-
104I12) and a centromere 20 BAC probe (RP11-108H13) or a reference centromere 
20 (CEP20) probe. Indeed, high level gain of SALL4 gene copy, together with 
centromere 20, was detected in two HCC cell lines tested (Figure 3.5). Importantly, 
most cells from the immortalized non-transformed hepatocyte cell line, THLE-2, 
exhibited two copies of SALL4, with some cells showed gain of SALL4 together with 
centromere 20. Table 3.4 summarizes FISH data for one non-transformed hepatocyte 
cell line and two HCC cell lines. These preliminary FISH data confirmed SALL4 copy 
gained in human HCC cell lines, more cell lines and primary HCC samples should be 
screened. 
Collectively, these data suggest that SALL4 genomic amplification represents 
one of the mechanisms underlying re-expression of SALL4 in HCC.  
 
Table 3.4 SALL4 signal counts from FISH assay 
Cell line Mean SALL4 signal 
(n=15) 




THLE-2 2.7 2.7 1.0 
SNU-398 3.5 3.7 0.9 
SNU-182 8.1 7.0 1.2 
  




Figure 3.5 SALL4 FISH on human hepatocyte and HCC cell lines. Representative 
SALL4 FISH images of (A) metaphase chromosomes of immortalized non-
transformed hepatocyte THLE-2 cell line, (B) SNU-398 HCC cell line, and (C) SNU-
182 HCC cell line. Probe set used for hybridization was indicated in each image. 
Images were acquired by a fluorescence microscope under the oil immersion 
objective (100×). 
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3.3 Patients with SALL4-positive HCC Have Worse Prognosis Compared to 
Patients with SALL4-negative/low HCC  
To analyze the clinical relevance of SALL4 re-activation in HCC, we carried 
out clinicopathological analysis. HCC patients with SALL4 overexpression 
demonstrated worse prognosis compared to SALL4-low HCC, as revealed from the 
clinicopathological analyses of the two cohorts of primary HCC samples from 
Singapore and Hong Kong. Comparing survival status of HCC patients from 
Singapore, absence of SALL4 protein (IHC score 0) confers significant survival 
advantage (P=0.02), from a univariate analysis (Figure 3.6A). Interesting, from this 
batch of primary HCC samples, we also observed a significant positive correlation of 
SALL4 expression with Ki-67, a proliferative marker (r=0.234, P=0.002), suggesting 
a more aggressive phenotype for HCCs with higher SALL4 expression. Similarly, 
SALL4 expression is associated with poor survival outcome in the Hong Kong cohort 
of primary HCC samples (P= 0.002) (Figure 3.6B). Our univariate analysis also 
revealed that SALL4 predicts recurrence for HCC in both cohorts of HCCs (Tables 
3.5 and 3.6).  
 




Figure 3.6 SALL4 expression in HCC predicts poor prognosis. (A) Kaplan-Meier 
curve shows poorer overall survival advantage for SALL4-postive HCCs, as 
compared to SALL4-negative HCCs in primary HCC cases from Singapore. P=0.02. 
(B) Kaplan-Meier curves show poorer overall survival advantage for SALL4-high 
HCCs in the cohort of primary HCC specimens from Hong Kong. P=0.002. Note: 
Fig.3.6A was generated by Mr. Chee Wee Ong and Fig 3.6B was generated by Dr. 
Kwong-Fai Wong from the from the Cancer Science Institute of Singapore. 
 
 
 In addition, our association studies confirmed that there is no significant 
difference between SALL4 expression in the groups of patients with different baseline 
liver functions or tumor stage in both the SG and HK cohorts of HCCs (Tables 3.1 
and 3.3). Moreover, there is no significant difference between SALL4 expression in 
the livers of patients with or without pre-operative treatments. Importantly, in a 
multivariate Cox regression model, SALL4 has shown to be an independent 
prognostic factor for overall survival (P=0.03, HR 2.87, 95% CI 1.09 to 7.52) in the 
SG cohort (Table 3.7) and an independent predictor of both overall survival (P=0.05, 
HR 1.52, 95% CI 1.00 to 2.32) and early recurrence (P=0.014, HR 1.67, 95% CI 1.11 
to 2.51) in the HK cohort of primary HCCs (Table 3.8), after adjusting for other 
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clinicopathological features that have conventionally been accepted to have 
prognostic value in HCC.  
 Recent studies have compared gene expression profiles of various cancers 
with ESC/hepatic progenitor gene expression signatures (Ben-Porath et al., 2008; Lee 
et al., 2006; Woo et al., 2010). Results acquired from these studies suggest that cancer 
patients with ESC/hepatic progenitor cell-like gene expression signatures have a poor 
prognosis. A plausible hypothesis is that tumors evolved either from the stem/ 
progenitor cells or de-differentiated into an early developmental stage are more 
aggressive. To investigate if SALL4-positive HCCs share gene expression pattern 
with fetal hepatoblasts, we extracted global gene expression data of human 
hepatocytes, human fetal livers, and human HCCs from the GEO database and carried 
out hierarchical cluster analysis. From our analysis, high SALL4 HCCs clustered 
tightly with human fetal livers, while low SALL4 HCCs clustered with hepatocytes 
(Figure 3.7), suggesting that HCCs expressing SALL4 share similar gene expression 
pattern with hepatic progenitor cells, hence are poorly differentiated, more aggressive, 
and have poor prognosis. 
 




Figure 3.7 SALL4-expressing HCCs share gene expression profile with human 
fetal livers. Dendrogram and heatmap show the hierarchical cluster analysis of gene 
expression data from primary human hepatocytes, human fetal livers and human HCC 
samples extracted from public databases. Columns represent individual samples and 
rows represent each gene. Each cell in the matrix represents the expression level of a 
gene in an individual sample. Scale bar indicates the expression levels, red and green 
reflect high and low expression levels, respectively. Note: Fig. 3.7 was generated by 
Dr. Henry Yang from the Cancer Science Institute of Singapore. 
 
 
 To correlate the subgroup of SALL4-positive HCC with oncogenic pathways 
in primary HCC samples, we carried out gene set enrichment analysis (GSEA) to 
investigate the enrichment of pathways that have prognostic value in HCC. From our 
analysis, we found that genes that were upregulated in HCC with poor survival, an 
embryonic stem cell signature, genes upregulated in metastasis, hepatoblastoma, and a 
proliferation subclass of HCC (Chiang et al., 2008) were significantly enriched in 
high SALL4 HCC subgroup (Figure 3.8). These data recapitulate our previous 
clinicopathological and hierarchical cluster analyses, and further strengthen the idea 
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of SALL4 being a prognostic marker that is enriched in the more aggressive 
progenitor-like HCC with poor prognosis. 
 Taken together, we conclude that the expression of oncofetal protein SALL4 
can be used as a novel molecular marker to define an aggressive progenitor-like HCC 
subtype and has prognostic value for HCC patients.  




Figure 3.8 Gene signatures associated with poor prognosis are enriched in high 
SALL4 HCC. Enrichment of genes associated with (A) poor survival; (B) embryonic 
stem cells; (C) metastasis; (D) hepatoblastoma; and (E) proliferation subclass of HCC 
(Chiang et al., 2008) in high SALL4 HCC. NES, normalized enrichment score by 
GSEA. Note: Fig. 3.8 was generated by Dr. Henry Yang from the Cancer Science 
Institute of Singapore. 
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Table 3.5 Univariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for clinicopathological features and 
SALL4 expression (SG cohort).
a 
 Overall Survival Early Recurrence Late Recurrence 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Clinicopathological parameters          
Age (<56.2 vs  ≥56.2) 0.6 0.27-1.36 0.22 - - - 0.42 0.11-1.59 0.20 
Gender (female vs male) 0.65 0.3-1.42 0.28 - - - 0.19 0.05-0.67 0.01 
Tumour Grade (I&II vs III&V) 0.87 0.26-2.88 0.82 - - - 1.16 0.34-3.92 0.81 
TNM (I&II vs III&IV) 1.51 0.56-0.41 0.42 - - - 1.22 0.32-4.63 0.77 
BCLC stage (A vs B) 2.08 0.9-4.83 0.09 - - - 1.32 0.38-4.53 0.66 
HBsAG (negative vs positive) 1.27 0.49-3.28 0.62 0.45 0.03-7.37 0.57 0.36 0.09-1.45 0.15 
Serum AFP, ng/dL (<20.0 vs ≥20.0) 2.22 0.89-5.45 0.08 - - - 5.76 0.71-46.47 1.00 
Multinodularity (no vs yes) 1.67 0.73-3.84 0.22 - - - 1.32 0.39-4.53 0.66 
Lymphovascular invasion  (no vs yes) 1.32 0.17-10.46 0.79 - - - - - - 
Protein expression          
 SALL4 (positive vs negative) 2.92 1.15-7.39 0.02 0.39 0.04-3.78 0.42 5.35 1.14-25.06 0.03 
a
Univariate analysis, Cox proportional hazards regression model. Bold values denoted statistical significance at α=0.05; Dashes indicate no 
modelling as coefficients did not converge. SALL4 negative: IHC score 0; SALL4 positive: IHC score +1 to +4. HR, hazard risk ratio; CI, 
confidence interval; TNM, tumor-node-metastasis.
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Table 3.6 Univariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for clinicopathological features and 
SALL4 expression (HK cohort).
a 
  Overall survival Early recurrence Late recurrence 
P value P value P value 
Clinicopathological parameters     
Age (<55 vs  ≥55) 0.53 0.28 0.91 
Gender (female vs male) 0.92 0.47 0.57 
Histological differentiation (well vs moderate/ poor) 0.08 0.22 0.32 
TNM stage (I&II vs III&IV) < 0.001 <0.01 0.06 
BCLC stage (0 & A vs B &C) 0.09 0.41 0.65 
HBsAg (negative vs positive) 0.55 0.31 0.14 
Serum AFP, ng/mL (< 100 vs ≥ 100) 0.01 <0.01 0.06 
No. of tumor nodule (< 3 vs ≥ 3) <0.01 < 0.001 0.83 
Venous infiltration (Y vs N) < 0.001 < 0.001 0.26 
Tumor size, cm (<5 vs ≥5) <0.01 0.10 0.57 
Gene expression     
SALL4 (< median vs ≥ median) <0.01 0.02 0.56 
a
Univariate analysis, Kaplan-Meier analysis.  
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Table 3.7 Multivariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for the clinicopathological features 
and SALL4 expression (SG cohort).
a 
 Overall Survival Early Recurrence Late Recurrence 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Clinicopathological parameters          
Serum AFP
b, ng/dl (<20.0 vs  ≥20.0) 2.08 0.83-5.22 0.12 - - - 3.2 0.25-40.48 0.37 
BCLC stage
c
 (A vs B) 1.84 0.75-4.52 0.18 - - - 0.74 0.16-3.27 0.69 
            
Protein expression          
 SALL4
d
 (positive vs negative) 2.87 1.09-7.52 0.03 0.62 0.05-6.99 0.69 2.7 0.41-18.72 0.29 
a
Multivariate analysis, Cox proportional hazard regression model. Variables were adopted for their prognostic significance (p<0.1) by univariate 
analysis. Dashes indicate no modelling as coefficients did not converge. 
b
N = 70; 
c
N = 79; 
d
N = 79 
SALL4 negative: IHC score 0; SALL4 positive: IHC score +1 to +4. 
HR, hazard ratio; CI, confidence interval.
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Table 3.8 Multivariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for the clinicopathological features 
and SALL4 expression (HK cohort).
a
 
  Overall survival Early recurrence Late recurrence 
  HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Clinicopathological           
Serum AFP
b
, ng/mL (<100 vs ≥ 100) 
 
- - - - - - 0.31 0.11-0.86 0.03 
No. of tumor nodules
c
 (< 3 vs ≥ 3) 
 
- - - 2.33 1.45-3.76 < 0.001 - - - 
Tumor size
d
, cm (<5 vs ≥5) 1.70 1.05-2.76 0.03 - - - - - - 
TNM stage
e
 (I&II vs III&IV) - - - - - - 0.34 0.14-0.83 0.02 
Venous infiltration
f
 (Yes vs No) 0.28 0.17-0.44 < 0.001 0.42 0.27-0.66 < 0.001 - - - 
            
Gene expression           
SALL4
g
 (< median vs ≥ median) 
 
1.52 0.10-2.32 0.05 1.67 1.11-2.51 0.014 - - - 
a
Multivariate analysis, Cox proportional hazard regression model. Dashes indicate no modelling as coefficients did not converge. 
b
N = 228; 
c
N = 228, 
d
N = 217, 
e
N = 228, 
f
N = 227; 
g
N = 228 
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3.4 Induction of Liver Tumors in SALL4 Transgenic Mice  
To investigate if SALL4 has a functional role in hepatocarcinogenesis, we 
analyzed our SALL4 transgenic mice for liver tumor incidence. In adult murine liver, 
both Sall4a and Sall4b, the alternative splice variants of Sall4, are not expressed 
(Oikawa et al., 2009). However, in SALL4B transgenic mice, SALL4 expression, 
driven by the CMV promoter, is maintained in the liver after birth (Ma et al., 2006). 
Remarkably, monitoring of our SALL4B transgenic mice over a period of time has 
revealed increased risk of liver tumor formation in SALL4B transgenic mice from 16 
months onwards. We observed liver tumor formation in 46% (6/13) of SALL4B 
transgenic mice. No evidence of tumor formation was detected in the livers of the 19 
age- and sex-matched wild type (WT) controls (Table 3.9). Unlike WT mouse livers 
in which normal hepatic lobular structure was well preserved (Figures 3.9A and B), 
SALL4B transgenic mice developed moderately to poorly differentiated liver tumors 
(Figures 3.9C and D). 
 






SALL4B 3/13 6/13 








Figure 3.9 SALL4B transgenic mice demonstrated increased risk of liver tumor 
development. (A,C) Gross morphology and (B,D) histology following H&E staining 
of livers of C57BL/6 wild type (A,B) and SALL4B transgenic (C,D) mice. Arrow 
indicates liver tumor. The dashed line in (D) indicates the boundary of normal and 
tumor (right) region. (B,D) 200X, bar = 20 μm. Note: Transgenic mice were 
generated by Dr. Li Chai and her laboratory in the Brigham and Women’s Hospital. 
 
 
To further confirm that expression of SALL4B in adult liver contributes to liver 
tumor development, we employed the two-stage chemical carcinogenesis protocol 
using N-nitrosodiethylamine (DEN) and phenobarbital (PB) to induce pre-neoplastic 
lesions in the transgenic livers. The experimental design is as illustrated in Figure 
3.10. Mice were examined at week 10 and 23 post-treatment. 




Figure 3.10 Scheme of the experimental design of two-stage chemical 
carcinogenesis experiment. N-nitrosodiethylamine (DEN) and phenobarbital (PB) 
were used to induce pre-neoplastic hepatic lesions in the wild type and transgenic 
mice. Livers were harvested at 10- and 23-experimental week. i.p.: intraperitoneal 
injection; wo: week-old; wks: weeks. 
 
Expression of SALL4B in adult liver led to accelerated development of hepatic 
pre-neoplastic lesions and subsequent hepatic tumor formation. At week 10, WT 
littermates demonstrated mild signs of liver damage, while hepatic foci of cellular 
alteration induced by DEN and PB were uniformly observed in all five SALL4B 
transgenic livers (Table 3.10). At week 23, WT control mice started to demonstrate 
pre-neoplastic liver lesions similar to what we have observed in SALL4B mice at week 
10 (Figures 3.11A and B), while SALL4B mice showed advanced stage of foci of 
cellular alteration and adenoma formation (Figures 3.11D and E). Along with 
increased hepatic lesion, SALL4B mice also had increased liver/body weight ratio, an 
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indication of increased liver proliferation following DEN/PB treatment (Table 3.10). 
The observation of increased hepatic proliferation is further confirmed by Ki-67 
staining of the livers (Figures 3.11G-J, Table 3.11); in which SALL4B livers 
demonstrated increased Ki-67 staining compared to the WT livers. Furthermore, 
mitotic cells were only observed in SALL4B transgenic livers, but not in the WT livers 
(Figures 3.11C and F). 
Collectively, our observation of increased HCC development in SALL4B 
transgenic mice and the acceleration of HCC development in SALL4B mice following 
the DEN/PB carcinogenic regimen suggested that SALL4 has a functional role in 
hepatocarcinogenesis.
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Table 3.10 Summary of liver lesions in SALL4B transgenic mice subjected to the DEN initiation and PB promotion regime 




Macroscopic tumor Liver weight (g) Liver/ body weight 
492150-1 WT 10 - - 1.23  
492150-2 WT 10 - - 1.55  
492150-3 WT 10 - - 1.80  
492150-4 WT 10 - - 1.70  
492156-1 WT 10 - - 1.99  
492156-2 WT 10 - - 1.72  
492156-3 WT 10 - - 2.11  
Average     1.73 7.1% 
492152-R SALL4B 10 ++ - 2.31  
492152-L SALL4B 10 ++ - 2.37  
492152-RL SALL4B 10 ++ - 2.32  
492152-RR SALL4B 10 ++ - 2.28  
492152-LL SALL4B 10 ++ - 2.79  
Average     2.41 9.3% 
492146-1 WT 23 + - 2.40  
492146-2 WT 23 + - 2.27  
492146-3 WT 23 + - 2.41  
492146-4 WT 23 + - 2.64  
492146-5 WT 23 + - 2.56  
Average     2.46 6.7% 
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Macroscopic tumor Liver weight (g) Liver/ body weight 
492148-R SALL4B 23 ++ - 2.83  
492148-L SALL4B 23 +++ - 2.28  
492149-RL SALL4B 23 +++ - 2.75  
492149-RR SALL4B 23 +++ - 2.97  
492149-LL SALL4B 23 +++ + 3.79  
492149-NO SALL4B 23 ++ - 2.94  
Average     2.93 9.4% 
a
 Mice were 15 days of age at start of experiment. Mice were given 5mg/kg DEN i.p. at 15 days of age and PB diet was started at 4 weeks of age 
b 
The present of hyper proliferative foci was graded based on the percentage of foci area compared to the liver section:  +: < 15% , ++: 15-40%, 
+++: 40-75%, ++++: 75-100% 
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Table 3.11 Ki-67 expression in DEN/PB-treated mouse livers  
Mouse ID Genotype Experimental week
a
 Strong Ki-67 cells/ 10× field Strong positive foci/ 10× field Mitotic cells/ 10× field 
WT1 Wild type 10 < 5 < 2 0 
WT2 Wild type 10 < 5 < 2 0 
WT3 Wild type 10 < 5 < 2 0 
WT4 Wild type 10 < 5 < 2 0 
WT5 Wild type 10 < 5 < 2 0 
WT6 Wild type 23 5-10 < 2 0 
WT7 Wild type 23 5-10 < 2 0 
WT8 Wild type 23 5-10 < 2 0 
WT9 Wild type 23 5-10 < 2 0 
WT10 Wild type 23 5-10 < 2 0 
S4B1 SALL4B 10 >10 1-5 0 
S4B2 SALL4B 10 >10 1-5 0 
S4B3 SALL4B 10 >10 1-5 0 
S4B4 SALL4B 10 >10 1-5 0 
S4B5 SALL4B 10 >10 1-5 0 
S4B6 SALL4B 23 >50 1-5 1-5 
S4B7 SALL4B 23 >50 1-5 1-5 
S4B8 SALL4B 23 >50 1-5 1-5 
S4B9 SALL4B 23 >50 1-5 1-5 
S4B10 SALL4B 23 >50 1-5 1-5 
a
 Mice were 15 days of age at start of experiment. Mice were given 5mg/kg DEN i.p. at 15 days of age and PB diet was started at 4 weeks of age





Figure 3.11 Expression of SALL4B in adult liver led to increased proliferation, 
accelerated development of hepatic pre-neoplastic lesions and subsequent 
hepatic tumor formation under the DEN/PB treatment regime. (A-C) H&E of 
wild type liver 23 weeks after exposure to DEN/PB. (D-F) H&E of SALL4B 
transgenic liver 23 weeks after exposure to DEN/PB. Arrows in (D) and (E) show foci 
of cellular alteration. Increased mitosis in SALL4B transgenic liver (F) compared to 
wild type control (C) 23 weeks after exposure to DEN/PB. (C) Magnified region 
shows interphase cells. (F) Magnified region and arrows show mitotic cells. (G-J) Ki-
67 IHC staining of livers 23 weeks after exposure to DEN/PB. Brown staining 
indicates Ki-67 expression. SALL4B transgenic mice subjected to DEN/PB treatment 
(H-J) had increased proliferation compared to the control (G). Tg: transgenic. (A,D) 
40×, bar = 100 μm. (B,E) 100×, bar = 40 μm. (C,F) 400×, bar = 1 μm. Note: This 
work is done in collaboration with Li Chai Lab and the Pathology core facility in the 
Brigham and Women’s Hospital. 





3.5 Loss of SALL4 by RNA Interference (RNAi) Leads to Decreased HCC 
Cell Viability in vitro and Impaired HCC Cell Tumorigenicity in vivo 
We next aimed to examine the potential of SALL4 as a molecular target for 
therapeutic intervention in HCC by performing loss-of-function studies. To knock 
down SALL4 expression, we carried out lentiviral-mediated RNAi by introducing 
shRNAs specifically targeting SALL4 into various human HCC cell lines. Two 
SALL4-specific shRNAs, denoted as shSALL4 1 and shSALL4 2, were used to knock 
down both SALL4A and SALL4B in HCC cells. In order to exclude the off-target 
effect of RNAi as well as the effect of virus transduction on HCC cells, scrambled 
shRNAs, denoted Scr shRNA 1 and Scr shRNA 2, were used as negative controls. 
The efficiency of virus transduction was assessed by the percentage of cells 
expressing GFP by flow cytometry. High transduction efficiency was consistently 
obtained (Figure 3.12). By using both shSALL4 1 and shSALL4 2, we managed to 
knock down both SALL4 isoforms to 30% of wild type RNA levels. At the protein 
level, both shSALL4 1 and shSALL4 2 were efficient in knocking down SALL4 
protein to nearly undetectable levels (Figure 3.13). 





Figure 3.12 High transduction efficiency mediated by lentiviruses expressing Scr 
shRNA 1 and shSALL4 1. Representative images show fluorescence-activated cell 
sorting (FACS) analysis of GFP expression of SNU-398 (upper panel), HuH-7 
(middle panel) and SNU-387 (lower panel) cells transduced with lentiviruses 
expressing Scr shRNA 1 or shSALL4 1.  
 
 
Figure 3.13 SALL4-specific shRNAs mediated efficient knockdown of SALL4 
expression at both mRNA and protein levels. (A) qPCR analysis of relative SALL4, 
SALL4A and SALL4B expression in SNU-398 cells four days post-transduction. Error 
bars indicate standard error of three replicates; expression was normalized to ACTB 
and plotted relative to scrambled controls. *** P < 0.001. (B) Western blot analysis of 
SALL4 expression in SNU-398 and HuH-7 cells four days post-transduction. 




 To investigate the phenotypic changes of HCC cells upon SALL4 gene 
knockdown, we knocked down SALL4 in three HCC cell lines with high (SNU-398), 
moderate (HuH-7), and undetectable (SNU-387) endogenous SALL4 expression and 
assessed cell viability by MTS assay. Remarkably, in HCC cell lines that express 
moderate to high endogenous SALL4 expression, cell viability was significantly 
decreased upon SALL4 gene knockdown (Figures 3.14 and 3.15). This implicates that 
SALL4 is essential in maintaining HCC cell viability. In contrast, HCC cell viability 
was not affected by SALL4 RNAi in the SNU-387 cell line that does not express 
SALL4 (Figure 3.14), suggesting that the effects of the shRNAs used in this study 
were specific to SALL4 and not a result of off-target effects. 





Figure 3.14 Knockdown of SALL4 mediated loss of HCC cell viability in HCC 
cell lines that express endogenous SALL4 expression (MTS assay). MTS analysis 
of HCC cell viability upon transduction of scrambled shRNAs (Scr shRNA) or 
SALL4-specific shRNAs (shSALL4) in SNU-398 (upper panel), HuH-7 (middle) and 
SNU-387 (lower) cells at various time points. Error bars indicate standard error of 
three replicates. * P<0.05; *** P<0.0001. 





Figure 3.15 Knockdown of SALL4 mediated loss of HCC cell viability in HCC 
cell lines that express endogenous SALL4 expression.  Representative microscopic 
images show loss of cell viability of SNU-398 (upper panel) and HuH-7 (lower panel) 
HCC cells 11 days post-transduction. Transduction efficiency was examined by GFP 
expression under a fluorescence microscope. Most of the cells expressed GFP, 
confirming high transduction efficiency of the lentiviruses. 
 
 




 To further characterize the effects of loss of SALL4 in HCC cells, we carried 
out more functional assays in SNU-398 cells, which express high SALL4. The 
decrease in cell viability of HCC cells expressing high levels of SALL4 following 
SALL4 knockdown was confirmed by cell counting with trypan blue (Figure 3.16A). 
Furthermore, we observed increased apoptosis in SALL4-knockdown HCC cells by 
assessing caspase activities. We observed increased caspase 3/7 activities upon loss of 
SALL4 in SNU-398 HCC cells (Figure 3.16B), as well as increased cleaved caspase 3 
expression (Figure 3.16C). These data further confirm that SALL4 plays a crucial role 
in maintaining survival of those HCC cells in which it is expressed. 





Figure 3.16 Knockdown of SALL4 in SNU-398 HCC cells by shRNAs led to 
decreased cell growth and increased cell death. (A) Growth curve of SNU-398. 
Error bars indicate standard error of three replicates. ** P < 0.01. (B) Caspase 3/7 
assay shows an increase in apoptosis in SALL4-knockdown SNU-398 cells at day 4 
post-transduction. Error bars indicate standard error of three replicates. ** P < 0.01; 
*** P < 0.0001. (C) Western blot shows the expression of total and cleaved caspase 3 
in SNU-398 cells four days post-transduction. 




 To examine if SALL4 has a role in maintaining tumorigenicity of HCC cells, 
we carried out in vivo xenotransplantation assays. HuH-7 and SNU-398 cells were 
transduced with lentviruses expressing either shSALL4 1 or Scr shRNA 1 and 
transplanted subcutaneously into the flanks of NOD/SCID mice. Knocking down 
SALL4 in these two HCC cell lines greatly reduced the ability of these cells to 
propagate tumors in immunocompromised mice. SALL4 knockdown conferred 
survival advantage to the mice, as seen from the Kaplan-Meier analysis (Figure 3.17). 
Furthermore, SALL4-knocked down HuH-7 cells generated smaller tumors at a later 
onset, as compared to the control cells; only one out of the three mice that received 
SALL4-knocked down HuH-7 had tumor formation, while all the three mice that 
received Scr shRNA 1-treated HuH-7 developed large subcutaneous tumors (Figure 
3.17). These data suggest that SALL4 is required for tumorigenicity of HCC cells. 
 
Figure 3.17 Knockdown of SALL4 gene led to decreased tumorigenicity of HCC 
cells. (Top) Representative images show immunocompromised mice transplanted 
with Scr shRNA 1- or shSALL4 1-treated HuH-7 cells. Arrow shows subcutaneous 
tumor on the right flank of the mouse. (Bottom left) Tumor volumes of the 
subcutaneous tumors. Significance of the last time point could not be determined 
because there was only one mouse left in the Scr group. * P<0.05. (Bottom right) 
Kaplan-Meier plot shows poorer survival advantage for mice harboring SNU-398 or 
HuH-7 cells infected with scrambled control shRNA as compared to mice harboring 
cells infected with shSALL4. n=12; P=0.036. 




 As high SALL4-expressing HCCs share gene expression patterns with fetal 
hepatic cells and have a poorer prognosis, we asked if loss of SALL4 in these cells 
reversed this phenotype. To answer this, we carried out microarray analysis of gene 
expression profiles of Scr shRNA 1- and shSALL4 1-treated SNU-398, and then 
performed hierarchical clustering of these gene expression profiles along with those 
derived from normal human hepatocytes and fetal livers. As expected, SNU-398 cells 
treated with Scr shRNA 1 clustered closely with human fetal livers, as both express 
high levels of SALL4. Interestingly, SALL4-knocked down SNU-398 cells clustered 
with human hepatocytes, suggesting downregulation of SALL4 can render HCC more 
hepatocyte-like and hence less aggressive (Figure 3.18). CCND2, one of our proposed 
targets of SALL4 (discussed in the next section), is one of the significant genes that is 
not expressed in human hepatocytes or SALL4-downregulated SNU-398 cells, while 
overexpressed in human fetal livers and control SNU-398 cells (Figure 3.18). 





Figure 3.18 Knockdown of SALL4 reversed the aggressive phenotypes of HCC 
cells. Dendrogram and heatmap show the hierarchical cluster analysis of gene 
expression data from primary human hepatocytes, human fetal livers and SNU-398 
cells transduced with Scr shRNA 1 or shSALL4 1. Note: Fig. 3.18 was generated by 
Dr. Henry Yang from the Cancer Science Institute of Singapore. 
 
 
 In summary, these loss-of-function studies demonstrate that SALL4 is 
essential in maintaining the viability of HCC cells, and that reduction of SALL4 
diminishes the ability of HCC cells to propagate tumors in xenotransplants, 
emphasizing a functional role for SALL4 in hepatocarcinogenesis. More importantly, 
we propose SALL4 to be an important therapeutic target in HCC, as loss of SALL4 
reversed the aggressive phenotypes of HCCs.  




3.6 SALL4 Induces Hepatocarcinogenesis by Regulating Cyclin D2 
Expression 
 One of the hallmarks of cancer is sustained proliferation signal in cancer cells 
(Hanahan and Weinberg, 2011). We hypothesized that SALL4 induces 
hepatocarcinogenesis by promoting cell proliferation. Indeed, we observed a 
significant positive correlation between SALL4 expression and Ki-67 proliferation 
index in the SG cohort of primary HCC samples (P=0.002). Moreover, we have also 
shown that our SALL4B transgenic livers are more proliferative compared to the wild 
type C57BL/6 livers, as the transgenic livers showed higher Ki-67 staining and have 
more mitotic cells (Figure 3.11). In our cell line model, we performed BrdU staining 
to compare proliferation rate of two HCC cell lines, one with high endogenous 
SALL4 expression (SNU-398) and one with negligible SALL4 expression (SNU-387). 
As expected, SNU-398 has higher proliferation rate, there are more cells cycling in 
the S phase in SNU-398 cells, compared to the low SALL4-expressing SNU-387 cells 
(P<0.001) (Figure 3.19A).  
 From the data gained from our BrdU incorporation assay, we hypothesized 
that SALL4 promotes cell proliferation by promoting G1 to S phase cell cycle 
progression, as there are more cells in S phase in the high SALL4-expressing HCC 
cells, compared to more cells in G1 phase in the low SALL4-expressing SNU-387 cell 
line. To understand how SALL4 regulates cell cycle progression, we analyzed our 
SALL4-knocked down SNU-398 cells microarray data. From the microarray data, we 
found that CCND2, the gene that encodes Cyclin D2 G1-S cell cycle regulator, is 
significantly downregulated upon SALL4 knockdown in SNU-398 cells (P=6.93E-05) 
(Figure 3.19B). We confirmed this by western blot (Figure 3.19C). We also checked 




the endogenous protein expression of Cyclin D2 in SNU-398 and SNU-387 cells. 
Cyclin D2 is much more highly expressed in the high SALL4 SNU-398 cells 
compared to SNU-387, which might account for the more proliferative nature of 
SNU-398 cells (Figure 3.19D).  
 





Figure 3.19 SALL4 promotes G1 to S cell cycle progression by regulating Cyclin 
D2 expression. (A) Representative FACS images show cell proliferation profile of 
SNU-398 and SNU-387 HCC cells as determined by BrdU incorporation. Data are 
presented as mean ± standard deviation of three replicates. (B) Dendrogram and 
heatmap show the hierarchical cluster analysis of gene expression data from SNU-398 
cells transduced with Scr shRNA 1 or shSALL4 1. Arrows show the expression levels 
of CCND2 and SALL4 (upper panel). Bar chart shows the expression level of CCND2 
upon SALL4 gene knockdown. Error bars indicate standard error of three replicates. 
*** P<0.0001 (lower panel). (C) Western blot shows the protein expression of Cyclin 
D2 upon SALL4 knockdown in SNU-398 cells. (D) Western blots show the 








 To investigate if Cyclin D2 is important for HCC cell suvival, we carried out 
loss of function studies by lentiviral-mediated RNA interference. We have identified 
two shRNAs that are efficient in knocking down Cyclin D2 expression but not 
affecting Cyclin D1 and Cyclin D3 expression – shCCND2 #3 that targets CDS 
region of CCND2 and shCCND2 #5 that targets 3’ untranslated region (3’ UTR). We 
analyzed Cyclin D2 expression by western blot four days after lentiviral transduction 
of SNU-398 cells, both shRNAs were able to efficiently knock down Cyclin D2 
expression substantially (Figure 3.20A). Knockdown of Cyclin D2 phenocopy SALL4 
knockdown in SNU-398 cells, we observed a decreased in cell viability upon Cyclin 
D2 knockdown (Figure 3.20B), suggesting the importance of Cyclin D2 in 
maintaining cell viability of HCC cells.  
 
Figure 3.20 CCND2 knockdown phenocopy SALL4 knockdown in SNU-398 HCC 
cells. (A) Western blot shows downregulation of Cyclin D2 protein expression four 
days after transduction of shCCND2 by lentivirus. Expression of Cyclin D1 and 
Cyclin D3 was not affected by shCCND2. (B) MTS assay shows decrease of cell 
viability of SNU-398 cells six, eight and ten days upon shCCND2 transduction. 
 
 




 We next aimed to investigate if Cyclin D2 is a direct target of SALL4. We 
analyzed our ChIP-on-chip data and found that there are indeed SALL4 peaks in 
CCND2 promoter region in H1 human embryonic stem cells (peak score=1.02; 
FDR=0.02) and NB4 leukemic cell line (peak score=1.04; FDR=0.06). These data 
suggest that Cyclin D2 might be a direct target of the transcription factor SALL4 
under both normal physiology condition and pathological condition in malignancy. 
 There are three members in the D class Cyclin family, Cyclin D1, D2 and D3. 
To have an idea which Cyclin D is more important or aberrantly expressed in HCC, 
we checked the expression of these three D class cyclins in both non-neoplastic livers 
and HCC livers from the Oncomine database (Rhodes et al., 2004). Only Cyclin D2 is 
significantly upregulated in primary HCC livers compared to the non-neoplastic livers 
(P=0.05) (Figure 3.21). Lastly, we performed gene ontology (GO) analysis on genes 
that are differentially expressed in high SALL4 HCCs versus low SALL4 HCCs. 
Specifically, we compared genes that are differentially expressed in primary HCCs 
with high and low SALL4 expression levels, Sk-Hep1 high SALL-expressing HCC 
cell line and THLE-3 SALL4 negative non-transformed immortalized liver cell line, 
and Scr shRNA 1-treated and shSALL4 1-treated SNU-398 cells. From GO analysis, 
we found that cell cycle is both an enriched process (P=3.06E-06) and pathway 
(P=0.003) in these cells with differential SALL4 expression. 
 These data support our hypothesis that SALL4 induces the transformation of 
hepatocytes by promoting cell cycle progression and cell proliferation, via direct 
regulation of Cyclin D2. 





Figure 3.21 Cyclin D2, but not Cyclin D1 and D3, is aberrantly expressed in 
HCC. Differential expression of Cyclin D1, D2 and D3 in various tumorous tissues 
and their normal counterparts. Data was extracted from the Oncomine database. Red: 
tumor tissue, green: normal counterpart. Note: Fig. 3.21 was generated by Dr. Henry 
Yang from the Cancer Science Institute of Singapore. 




3.7 Targeting SALL4 by a Novel Peptide Affects HCC Cell Survival   
As SALL4 is potentially a good therapeutic target for HCC, we sought to 
develop targeted therapy to antagonize the oncogenic role of SALL4. It is known that 
SALL4 functions as a transcription repressor by recruiting a HDAC-containing NuRD 
complex, and that the tumor suppressor PTEN is among the target genes repressed by 
SALL4 (Lu et al., 2009). SALL gene family members share a conserved 12-amino 
acid (12-AA) N-terminal domain, which has been implicated in the interaction with 
components of the NuRD complex (Kiefer et al., 2002; Lauberth et al., 2007; 
Lauberth and Rauchman, 2006). We hypothesized that this 12-AA peptide could be 
used as a competitive inhibitor to block the interaction between SALL4 and NuRD 
and as a result block the NuRD mediated SALL4 repression function (Gao et al., 
2013). We also predicted that upon treatment with peptide, PTEN expression would 
be upregulated and that we would observe effects on HCC cell growth and survival 
similar to those observed in SALL4 knockdown studies. 
 Consistent with this hypothesis, when added to cultures, this 12-AA SALL4 
peptide was effective in targeting SALL4 pathways and resulted in a decrease in HCC 
cell viability. When 5 µM or 20 µM of SALL4 peptide (wt) was given to SNU-398 
cells (high SALL4), the number of viable cells was reduced, as compared to SNU-398 
cells treated with control mutant peptide (Mut.) and scrambled peptide (Scr.). 
Trichostatin A (TSA), a general HDAC inhibitor, was used as a positive control drug 
in this assay. Importantly, the PTEN inhibitor SF1670 was shown to be able to rescue 
the phenotype when it was added to the cells treated with SALL4 peptide (wt+Inh.), 
as evidenced by the maintenance of cell viability (Figure 3.22A). These results 




suggest that PTEN plays an important role in the SALL4 peptide-induced loss of 
HCC cell viability. 
 In contrast, SALL4 peptide had no effect on SNU-387 cells that have 
undetectable endogenous SALL4 expression (Figure 3.22B). There was no change in 
the number of viable SNU-387 cells when treated with SALL4 peptide (wt), similar to 
the controls (Mut. or Scr.). However, a similar reduction in the number of viable 
SNU-387 cells was observed in cells treated with TSA at 50 nM and 100 nM doses. 
This suggests that SALL4 peptide is a specific drug for SALL4-overexpressing HCC 
cells with minimal toxicity on SALL4-negative cells, as compared to the HDAC 
inhibitor TSA. 
 
Figure 3.22 SALL4 peptide specifically and effectively targets SALL4 in high 
SALL4-expressing HCC cells leading to decreased cell viability and 
tumorigenicity. MTS cell viability assay shows the effects of SALL4 peptide on (A) 
high endogenous SALL4 SNU-398 cells and (B) SNU-387 cells with undetectable 
SALL4 expression. Cell viability was determined 72 hours after peptide treatments. 
Absorbance at 490 nm is directly correlated to cell viability. Wild type functional 
SALL4 peptide (wt), mutant non-functional SALL4 peptide (Mut.), trichostatin A 
(TSA), scrambled control peptide (Scr.), wild type peptide + PTEN inhibitor SF1670 
(wt + Inh.) were given to the cells at the indicated concentration. PTEN inhibitor 
concentration was 400 nM. 




 To confirm the involvement of the PTEN tumor suppressor in the SALL4 
peptide-induced reduction of HCC cell viability, we analyzed PTEN expression by 
western blot upon drug treatment. SALL4 peptide treatment induced an extensive 
increase in PTEN protein in SNU-398 cells, compared to control untreated cells and 
Scr. peptide-treated cells. Expectedly, TSA also induced PTEN upregulation in SNU-
398 cells (Figure 3.23A). In contrast, SALL4 peptide has negligible effect on PTEN 
expression in SNU-387 cells (Figure 3.23B). We next examined if the increase in 
PTEN expression has an effect in PI3K signaling. PTEN functions as a phosphatase to 
dephosphorylate AKT. Western blot analysis  demonstrated a marked reduction of 
phospho AKT protein levels upon SALL4 peptide treatment in high SALL4 SNU-398 
cells (Figure 3.23A), but not in low SALL4 SNU-387 cells (Figure 3.23B), suggesting 
that the increase in PTEN expression level has a functional role in blocking the PI3K 
survival signaling by dephosphorylating AKT. Furthermore, this effect can be rescued 
by the PTEN inhibitor, consistent with the role of SALL4 regulating this pathway.  
 
Figure 3.23 SALL4 peptide mediated HCC cell death via the modulation of 
PTEN/ AKT pathway. Western blot analyses of the effects of peptides on PTEN, 
AKT, and pAKT expression on (A) SNU-398 and (B) SNU-387 HCC cells 72 hours 
following peptide treatments. 20 µM of wt or Scr. peptide or 100nM of TSA was used. 
PTEN inhibitor concentration was 400 nM. 




To test the therapeutic effect of this peptide in vivo, we subjected SNU-398 
cells to in vitro treatment with 20 µM of wt or Scr. peptide and transplanted the 
peptide-treated cells subcutaneously into the flanks of NOD/SCID mice. Interestingly, 
SALL4 peptide treatment compromised tumorigenicity of the HCC cells, as Scr. 
peptide-treated cells grew into larger subcutaneous tumors when compared to that of 
wt peptide-treatment (Figure 3.24A). Tumor volume in the wt peptide-treated group 
was significantly reduced compared to Scr. peptide treatment (Figure 3.24B).  
Moreover, the tumor burden (weight post-dissection at day 26) further confirmed that 
the tumor load was reduced with wt peptide treatment (Figure 3.24B).   
Direct intracellular delivery of peptides has long been a problem associated 
with peptide- or protein-mediated treatment. To overcome the membrane-mediated 
permeability barriers and enable efficient delivery of the peptides into cells in vivo, 
therapeutic peptides can be conjugated to protein transduction domains, such as the 
HIV-1 TAT motif (Cerchietti et al., 2009). The TAT protein transduction domain is 
able to promote efficient cellular uptake of peptides and acts as a nuclear localization 
signal, which is useful for the delivery of inhibitors of transcription factors (Wadia 
and Dowdy, 2005). We took advantage of this technology to develop a model of in 
vivo treatment of HCC more like that encountered in human patients. We conjugated 
Mut. and wt peptides with TAT and delivered the TAT-Mut. or TAT-wt peptides 
intraperitoneally into NOD/SCID mice transplanted subcutaneously with SNU-398 
cells. Similar to our previous experiments, in which HCC cells were treated in vitro 
with unconjugated peptides prior to transplantation, TAT fusion wild type peptides 
were able to reduce the tumorigenicity of SNU-398 HCC cells (Figure 3.24C). The 
tumor loads (weight post-dissection) at 18 days post-treatment of TAT-wt peptide 




treated mice were significantly smaller than tumors in TAT-Mut. peptide treated mice 
(Figure 3.24D). These experiments confirm that the SALL4 peptide has biological 
activity both in vitro and in vivo in a xenotransplant model. 
Together, our data suggests that the SALL4 peptide can be used as a potential 
targeted therapy for a subgroup of HCC, as it effectively and specifically reduces 
viable SALL4-positive HCC cells by activating the PTEN tumor suppressor and 
inhibiting PI3K/AKT survival signaling in HCC cells. 
 
Figure 3.24 SALL4 peptide caused decreased HCC tumorigenicity in vivo. (A) 
Representative images show NOD/SCID mice transplanted with Scr. peptide- and wt 
peptide-treated SNU-398 cells (left) and the dissected subcutaneous tumors (right). 
Arrow indicates subcutaneous tumor. (B) Growth curves of subcutaneous tumors (left 
panel) and tumor weight of tumors dissected at day 26 post-transplantation (right 
panel). Results are mean ± s.d. n=5; * P<0.05. (C) Representative images show 
NOD/SCID mice transplanted with 3 million SNU-398 cells at the left flank and 
treated intraperitoneally for five consecutive days with 56 mg/ kg body weight TAT-
Mut. peptide or 60 mg/ kg body weight wt peptide (top panel) and the dissected 
subcutaneous tumors (bottom). (D) Tumor weight of tumors dissected at day 18 post-
transplantation and post-treatment of mice treated intraperitoneally with TAT fusion 
peptides as described in (C). Results are mean ± s.d. n=5; * P<0.05. Note: This work 
















HCC is one of the deadliest cancers, with a mortality to incidence ratio of 
almost one (Ferlay et al., 2010). Although previously considered a dominant disease 
mostly in developing countries, in which hepatitis B is endemic, there has been an 
increasing trend of HCC incidence in developed nations like Europe and United states, 
with increasing prevalence of hepatitis C and alcoholism. While surgical intervention 
is curative, most patients are not good candidates due to late stage of presentation 
and/or poor liver function owing to underlying liver cirrhosis. In the United States, 
less than 5% of patients are candidates for hepatic resection (El-Serag, 2011). To date, 
even the most effective chemotherapy drug for advanced HCC, sorafenib, has limited 
efficacy (Keating and Santoro, 2009; Yang and Roberts, 2010), possibly due to the 
disease complexity and heterogeneity in hepatocarcinogenesis. Therefore, there is an 
urgent need for better understanding of the underlying mechanism in 
hepatocarcinogenesis, and more effective therapies for HCC.  
SALL4 is one of the important transcription factors implicated in the 
transcriptional regulatory network essential for the maintenance of embryonic stem 
cell characteristics (Elling et al., 2006; Yang et al., 2010). It is important in murine 
liver development, as Sall4 regulates differentiation of hepatoblasts to the 
cholangiocytic lineages (Oikawa et al., 2009). Genes involved in liver development 
and regeneration are likely to be implicated in the development of HCC. In this report, 
we established the unique expression pattern of SALL4 in human livers at various 
developmental stages – activated in fetal liver, silenced in adult livers, and re-
expressed in HCC as an oncofetal protein (Figure 4.1).  




Figure 4.1 SALL4 is a novel oncofetal protein in HCC. In healthy humans, SALL4 
is expressed in fetal liver but silenced in mature adult liver. In a subgroup of HCC 
livers, SALL4 is re-activated and plays a functional role in hepatocarcinogenesis by 
silencing the tumor suppressor PTEN through the recruitment of the NuRD complex. 
A therapeutic peptide can be used to block the interaction between SALL4 and the 
NuRD complex, thereby activating PTEN transcription. Upregulation of PTEN 
expression leads to downregulation of pAKT level and silencing of the PI3K/AKT 
survival signaling, resulting in decreased HCC cell viability and tumorigenicity. We 
propose SALL4 to be a novel oncofetal protein that can be specifically targeted for 
treatment of a subgroup of aggressive HCCs with SALL4 expression. 
 
The role of SALL 4 in HCC has been inconclusive to date. Two earlier reports, 
however, documented negative SALL4 expression in HCC by IHC staining (Cao et al., 
2009b; Ushiku et al., 2010). The discrepancy in SALL4 staining can possibly be 
attributed to the difference in antibodies used. Also, we analyzed a larger cohort of 
primary HCC tissues, compared to a total of seven and 60 cases analyzed by Cao et al. 
and Ushiku et al., respectively (Cao et al., 2009b; Ushiku et al., 2010). Despite the 
difference, we believe our result is reliable because we have rigorously tested the 
specificity the antibody used in our study, and our IHC data is supported by gene 
expression microarray data in a number of primary HCC cohorts. 
Many mechanisms can account for re-activation of oncogenes in malignancies. 
Chromosome 20q13 is frequently amplified and implicated in cancer initiation 
(Tabach et al., 2011). The frequent gain of chromosomal locus 20q13.13-20q13.2 
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(Beroukhim et al., 2010; Tabach et al., 2011), where SALL4 is located, led us to 
hypothesize that genomic amplification of SALL4 is a mechanism leading to SALL4 
reactivation in HCC. From our analysis of high throughput genomics data from 
various cohorts of primary human HCC, we confirmed copy number gain of SALL4 in 
HCC. This data not only confirms the mechanism underlying SALL4 re-activation, it 
also identifies a novel oncogene located in this frequently amplified chromosomal 
region in cancers. Our FISH data confirmed gain of SALL4 in HCC cell lines, it would 
be more informative if FISH can be carried out on primary HCC tissues. Besides 
genomic amplification, we also hypothesized that SALL4 promoter hypomethylation 
is another mechanism that lead to SALL4 overexpression in HCC. Indeed, 21.7% of 
the pre-leukemic myelodysplastic syndrome (MDS) demonstrated hypomethylation of 
the CpG island of SALL4 promoter region, and a positive correlation was established 
between SALL4 transcript level and hypomethylation in MDS (Lin et al., 2012). It is 
generally believed that DNA is hypomethylated in the repetitive, CpG-sparse regions 
of the cancer genome, as opposed to hypermethylation of the CpG islands (Hatada et 
al., 2006). In HCC, however, it has been shown that hypomethylation does not only 
enrich in CpG-sparse regions, it is also detected in the CpG islands of coding gene 
promoter regions. Intriguingly, hypomethylated promoters are enriched in 
chromosome 20, one of the seven chromosomes that demonstrated enrichment of 
hypomethylated promoters in HCC (Stefanska et al., 2011). Hypomethylation of 
SALL4 promoter that locates on chromosome 20 might be responsible for elevated 
SALL4 expression in HCC. Future studies should investigate the complex interplay of 
genomic status and promoter methylation status in regulating SALL4 expression level.  
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Identification of robust biomarkers that can be used to predict patient outcome 
ensures more effective clinical management, and we propose that SALL4 be utilized 
as such in HCC. The re-expression of SALL4 in HCC is clinically significant, as HCC 
patients overexpressing SALL4 have enriched hepatic progenitor-like gene signatures 
and tend to have poorer prognosis. Our study also established that examination of 
either protein or mRNA level of SALL4 is useful in this regard. Given the strong 
prognostic value of SALL4 established in our retrospective study, we propose that the 
prognostic value of SALL4 should be further verified in prospective clinical trials. If 
SALL4 is found to be useful in prognosticating HCC patients from these trials, the 
expression of SALL4 should be tested routinely in the clinics and adjuvant therapy to 
be added in the treatment regimen for HCC patients with elevated SALL4 expression 
to prevent relapse after surgery. Our preliminary studies suggest that SALL4 
expression only increases in HCC samples, and not in cirrhotic livers, or benign 
tumors. If more extensive prospective studies confirm these findings, then SALL4 
expression could be used as a novel diagnostic marker for HCC progression. 
Immunohistochemistry and other in situ hybridization (ISH) assays can also be 
developed and standardized to identify HCC patients that have elevated SALL4 
expression and/or genomic amplification in the clinical settings. 
Ectopic expression of SALL4 can enhance the efficiency of reprogramming of 
adult cells to become induced pluoripotent stem (iPS) cells (Wong et al., 2008). 
During the process of carcinogenesis, the activation of SALL4, together with other 
stem cell regulators and oncogenes, might drive the cancer cells to form a cancer with 
early progenitor characteristics, and give rise to more aggressive phenotypes.  
CHAPTER 4. DISCUSSION 
104 
 
Overexpression of a particular gene in tumor tissues can play a role as a driver 
in the cancer development or a bystander expressed only as a result of carcinogenesis. 
Our loss-of-function studies substantiate that SALL4 has a functional role in human 
HCC and is not merely a bystander. Knocking down of SALL4 leads to decreased 
HCC cell viability, slower growth, increased apoptosis, and impaired tumorigenicity, 
suggesting that SALL4 is required and essential for maintaining the malignant state. 
Furthermore, loss of SALL4 did not affect HCC cells that do not express SALL4, 
further highlighting SALL4 as a good candidate for therapeutic targeting. 
In addition to our loss-of-function studies, we have also conducted gain-of-
function studies to investigate the contributory roles of SALL4 in HCC development. 
We have observed spontaneous liver tumor formation in SALL4B transgenic mice, 
which suggests a functional role for SALL4 in HCC. We went on to confirm the 
contributory role of SALL4 in liver tumor formation by employing a two-stage 
chemical carcinogenesis protocol to induce pre-neoplastic lesions in the livers. Using 
the two well-characterized hepatotoxins, alkylating agent N-nitrosodiethylamine as an 
initiator and phenobarbital as a promoter, we demonstrated accelerated liver adenoma 
and carcinoma development in SALL4B livers subjected to this treatment regime. 
Oncofetal antigens are surface proteins that are expressed only in defined fetal 
organs during normal development, but are re-expressed in cancers that originated 
from these specific organs. Given their unique expression pattern, they can be used 
for diagnosis of certain cancers. For example, positive alpha-fetoprotein expression in 
a tumor can help the clinician to diagnose HCC and to follow up for disease relapse. 
Some are targets for vaccination against cancers. However, most of these proteins do 
not have functional roles in the induction or promotion of carcinogenesis. We propose 
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SALL4 to represent a new class of oncofetal proteins with great prognostic and 
therapeutic values. Unlike alpha-fetoprotein, SALL4, besides being a prognostic 
marker for HCC, can be a direct drug target owing to its functional roles in 
hepatocarcinogenesis. 
Reviews of the pathways involved in pathogenesis of HCC have revealed that 
the Ras/Raf/MAPK, PI3K/AKT/mTOR, and Wnt/-catenin pathways are critical 
pathways for hepatocarcinogenesis (Farazi and DePinho, 2006; Llovet and Bruix, 
2008). While the Ras/Raf/MAPK pathway is currently being clinically targeted by 
sorafenib, molecular targeted therapies against the others are still in preclinical or 
early phase clinical trials. Of these, some have shown promising results, including the 
mTOR inhibitor AZD8055 and HDAC inhibitor vorinostat. Our study has emphasized 
that SALL4 is clinically important in HCC, and targeting SALL4 with our novel 
peptide is a promising intervention for HCC, especially for the more advanced stage 
HCCs. The SALL4 peptide works by blocking the recruitment of a HDAC-containing 
complex, NuRD, at the N-terminal of SALL4, and hence antagonizing the 
transcriptional repression function of SALL4. This activates PTEN transcription and 
represses the PI3K/AKT survival signaling. Our studies suggest that the SALL4 
peptide exerts its therapeutic effect through both the HDAC and PI3K/AKT/mTOR 
signaling pathways; it works as a gene-specific or cell-type specific HDAC inhibitor 
that can affect the PTEN/PI3K/AKT/mTOR pathway.  
The discovery of a role for SALL4 in HCC, its association with prognosis, and 
a novel peptide blocker has potential therapeutic significance in HCC. Testing for the 
presence of SALL4 at diagnosis may be helpful not only in prognosis, but also allows 
specific selection of patients who are likely to be responsive to treatment. In addition, 
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given the mechanism of action of the peptide, patients with SALL4 may be responsive 
to therapies which include HDAC and/or PI3 kinase inhibitors. Further studies can be 
done to establish SALL4 as a predictive marker for these therapies. Furthermore, the 
SALL4-expressing HCC patients would likely benefit from treatment with SALL4 
peptide. Given the specific expression of SALL4 in HCC cells but not in normal adult 
hepatocytes, treatment with SALL4 peptide will likely carry less tissue toxicity, 
which is especially beneficial in patients with underlying cirrhosis whose baseline 
liver function is already compromised.  Future studies will determine whether this 
peptide has synergistic potential with other molecular therapies, such as sorafenib, 
which act on parallel non-overlapped pathways.  
It is also noteworthy that SALL4 is known to be enriched in "side population 
cells", a putative stem cell population, and its expression is associated with drug 
resistance in leukemia and other solid tumors such as breast cancer (Jeong et al., 
2011). SALL4 also upregulates Bmi1 (Yang et al., 2007), a gene that is important for 
the maintenance of the HCC side population (Chiba et al., 2008). Future work will 
determine whether this peptide can inhibit SALL4 in hepatic cancer stem cells and 
prevent drug resistance in HCC.  
Transcription factors, unlike kinases or enzymes, have traditionally been 
perceived as “undruggable” targets. Here we propose an innovative approach to target 
SALL4 by interrupting the interaction between SALL4 (transcription factor) and the 
NuRD complex (epigenetic complex). The first generation of epigenetic modifiers, 
that are currently in clinical use (for example, HDAC inhibitors) mediate global 
changes and have non-specific effects. New classes of epigenetic drugs aim to target 
specific epigenetic regulators, transcription factors or protein-protein interactions to 
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achieve specificity. The idea of targeting the interplay between transcription factor 
and its epigenetic co-factors is not without precedent. Two existing examples of 
pharmacologic intervention of the interplay between transcription factors and 
epigenetic complexes include the BCL6 peptide inhibitor that targets the BCL6-
SMRT complex and the MI-2 small molecule that specifically blocks MLL-menin 
interaction (Grembecka et al., 2012; Polo et al., 2004). Current preclinical or in vitro 
studies have shown that these drugs are promising for the treatment of hematopoietic 
malignancies. Given that we have identified the interaction between SALL4 and the 
NuRD complex (Lu et al., 2009), and that the crystal structure of SALL4 binding 
domain on the binding partner within NuRD has been solved (Lejon et al., 2011), we 
are currently initiating studies to develop small molecules that can disrupt this 








The number of new drugs approved for cancer treatments by FDA has 
plummeted, owing, at least in part, to the fact that most oncogenic proteins are being 
perceived as undruggable. Hence, more innovative approach of cancer treatments 
needs to be developed, in order to surmount the challenges posted by undruggable 
therapeutic targets. Current efforts have focused on developing small molecule 
inhibitors that target kinases, the decline in new therapies also suggests that new drug 
targets need to be identified for the development of effective treatments. We have 
identified a new therapeutic target for HCC treatment and proposed an innovative 
approach for the treatment of HCC in this thesis work – by targeting the protein-
protein interaction of an oncofetal protein (which is also a transcription factor) and its 
epigenetic complex.  
In summary, our study reveals a novel role of the oncofetal protein SALL4 in 
the extensive network of heterogeneous cellular pathways underlying 
hepatocarcinogesis.  A 12-amino acid peptide has been shown for the first time to be 
able to block the oncogenic role of SALL4, and hence has therapeutic potential in 
SALL4-positive HCCs. Our study proposes SALL4 to be a prognostic marker and 
therapeutic target in HCC, laying a foundation for a more vigorous development of 






The findings from this thesis work provide the first evidence to support a role 
for SALL4 in promoting hepatocarcinogenesis and acting as a prognostic marker and 
therapeutic target for HCC. The mechanisms of SALL4-induced haptocarcinogenesis, 
however, are not well studied. We proposed two mechanisms in this thesis – 
transcription repression of tumor suppressor PTEN via the interaction with the 
epigenetic NuRD complex and activation of CCND2 expression. The mechanism of 
transcription repression of PTEN by SALL4 is well established, at least in other 
models/ systems (Lu et al., 2009). However, the mechanism underlying activation of 
Cyclin D2 by SALL4 is poorly understood. Although we provide indirect evidence to 
support SALL4 binding on the CCND2 promoter regions in H1 human embryonic 
stem cells and NB4 leukemic cells, it will be interesting to carry out a chromatin 
immunoprecipitation (ChIP) assay to confirm direct binding of SALL4 on CCND2 
promoter in HCC cells. Furthermore, it has been proposed that SALL4 induces 
transcription repression through the recruitment of histone deacetylases (HDACs)-
containing NuRD complex (Lu et al., 2009) and DNA methyltransferases (Yang et al., 
2012b). The mechanisms by which SALL4 activates transcription are not reported 
previously. Besides Cyclin D2 that we proposed in this thesis, it has also been 
documented that SALL4 activates Wnt signaling. It will be interesting to investigate 
how SALL4 promotes transcription activation and what are its binding partners 
associated with this function. 
Another interesting perspective that is worth pursuing is the establishment of 
combination therapy to target SALL4 and an additional pathway for the treatment of 





efficient in treating this malignancy. This has actually been demonstrated by the lack 
of effective targeted therapeutics for the treatment of HCC to date. Crosstalk between 
signaling pathways and the feedback circuits arise as a result of targeting a single 
pathway suggest that a therapeutic regimen that combines two agents that target 
different but overlapping pathways is our better bet for the treatment of HCC. We 
have identified an aggressive progenitor-like subgroup of HCC that expresses SALL4 
in this thesis work. We shall next aim to focus on the study of combination therapy 
for HCC, by investigating the combinatory effects of drugs that target SALL4 and 
other oncogenic pathways in HCC. Furthermore, by performing drug combination 
study, we might be able to salvage drugs that have dropped out from HCC clinical 
trials as a result of severe adverse effects experienced by the patients, this is because 
by combining two agents that work synergistically, we will be able to decrease the 
dosage of the drugs, thereby minimizing the adverse effects. In addition, by carrying 
out drug treatment experiments, we will also be able to obtain some insights into the 
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Ensembl Orthologue Alignment 
Gene: SALL4 ENSG00000101115 
Description 
sal-like 4 (Drosophila) [Source:HGNC Symbol;Acc:15924] 
 
Location 






This gene has 5 transcripts (splice variants)  
Orthologue alignment 
1. SALL4 and spalt-related 
Species Gene ID Peptide ID Peptide length % identity Genomic location 
Homo sapiens ENSG00000101115 ENSP00000217086 1053 aa 24 % 20:50400581-50419059 
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ENSP00000217086/1-1053 IHLRSHTGERPFVCSVCGHRFTTKGNLKVHFHRH----PQVKANPQLFAEFQDKVAAGN- 
FBpp0297936/1-1267     IHLRSHTGERPFVCNVCGSKFTTKGNLKVHYQRHTQIFPPMLLPPGVAP----NVGHSGQ 
                       **************.*** :**********::**    * :   * : .    :*. ..  
 
ENSP00000217086/1-1053 ----GIPYALSVPDP-IDEPS--------LSLDSKP--VLV--TTSV--GLPQNLSSGTN 
FBpp0297936/1-1267     GQVQGEQYPIRLPFAPPVAPVGQEQHQNQVE---EPEEIRQEIPVPQAEDLS-------- 






FBpp0297936/1-1267     -------KPMVKEKEKSHSPVERVKTPKEVKTDAALPSSEKPEKEISKPVVTSSRRNGSV 
                               .:  : :           *.  :::..  .   *                   
 
ENSP00000217086/1-1053 ----------PNYN--------------------SPRAG-------GFQGSG-------- 
FBpp0297936/1-1267     RKRQTSAVSPPQEDRERDLVEHLHIAKLVRRSSASRESQPAEYSLAQMERIIDKSWEDLI 
                                 *: :                    * .:         ::            
 
ENSP00000217086/1-1053 TPEPGSETLKLQQLVENIDKATTDPNECLICHRVLSCQSSLKMHYRTHTGERPFQCKICG 
FBpp0297936/1-1267     EIDKTSETSKLQQLVDNIENKLTDPNQCIFCQKVMSCRSSLQMHIRTHTGERPFRCKICG 
                         :  *** ******:**::  ****:*::*::*:**:***:** *********:***** 
 
ENSP00000217086/1-1053 RAFSTKGNLKTHLGVHRTNTSIKTQHSCPICQKKFTNAVMLQQHIRMHMG-------GQI 
FBpp0297936/1-1267     RAFATKGNLKAHMSIHKIKPPMRSQFKCPVCHQKFSNGIILQQHIRIHTMDDGSGGQGAP 
                       ***:******:*:.:*: :..:::*..**:*::**:*.::******:*         *   
 
ENSP00000217086/1-1053 PNTPL-PENP--CDFTG-SEPMTVGENG-STGAI----------------------CHDD 
FBpp0297936/1-1267     AANPGEAERLGIEDQNSNKSLGTSDTLDFSTTISDHSGQRSESSQGGDFDEFMTMDSTDD 
                       . .*  .*.    * .. ..  * .  . **                         . ** 
 
ENSP00000217086/1-1053 VIESIDV---------------------------EEVSSQE-APSSSSKVPTPLPSIHSA 
FBpp0297936/1-1267     SRDNSSAATATPHPLERERDREKERERRIPNDCSDERSHSNPDLTGGRSESGEMPAMDLS 
                         :. ..                           :* * .:   :.. . .  :*::. : 
 
ENSP00000217086/1-1053 --SPTLGFAMMASLDA-PGK------V---GPAPFNLQRQG----SRENGSV----ES-- 
FBpp0297936/1-1267     SPSSNSGRIFATGLANGAAGGGSGNGGLPMLGMPMPPNLLLMAAAREEMHALGHAHAKFP 






FBpp0297936/1-1267     LLPFGPLGFMGLHPPPNVCNLCFKMLPSLAALESHLQSEHAKEPATGHAQRPQCSDAGSP 
                                                  .*:   *   *  ..:     :: *:  :: :. 
 
ENSP00000217086/1-1053 F---------QA-LSPANSQAESIKSKS-----PD---------AGSKAESSEN-----S 
FBpp0297936/1-1267     YGAKLTLNPNLFAKKPPSSSSSSSGEKLPESSNPPFPAENPPATP-IKEDPDQEQLMVEE 
                       :             .*..*.:.*  .*      *          .  * :..::     . 
 
ENSP00000217086/1-1053 RTEM---E--G-RSSLP-STFIRAPP-TYVKVE----------------VPGTFVGPSTL 
FBpp0297936/1-1267     GASAGEGSGTGA--TSNYPQEAGDAEQSLMKMQLHAHRFPASPLDFQQA---------LM 
                        :.    .  *   :   .     .  : :*::                          : 
 
ENSP00000217086/1-1053 SPG-MTPLLAAQ-PRRQAKQHGCTRCGKNFSSASALQIHERTHTGEKPFVCNICGRAFTT 
FBpp0297936/1-1267     SAGPPTSSL---DPP-VNNKHFCHVCRRNFSSSSALQIHMRTHTGDKPFQCNVCQKAFTT 
                       *.*  *. *    *    ::* *  * :****:****** *****:*** **:* :**** 
 
ENSP00000217086/1-1053 KGNLKVHYMTHGANNNSARRGRKLAIENTMAL--LGTDGKR---VSEIF--PKEILAPSV 
FBpp0297936/1-1267     KGNLKVHMGTHMWTNPTSRRGRRMSLELPMRPGPNSGQGHPGSSAEQEFMQRR------- 
                       *******  **  .* ::****::::* .*     . :*:    ..: *   :        
 
ENSP00000217086/1-1053 NVDP-VVWNQYTSMLNGGLAVKTNEIS----------VIQSGG--V-PTLPVSLGATSVV 
FBpp0297936/1-1267     ---PELFF-PYLPPFFNGLPPKPGELSPGAFPNIPPPPFANGGKYPYPPGLLGFPGFLAQ 
                          * :.:  * . : .**. *..*:*           : .**    *.  :.: .  .  
 
ENSP00000217086/1-1053 ----NN-ATVSKMDGSQSG--------IS---------------------ADVEK---PS 
FBpp0297936/1-1267     HPYILERRSSSKSPTPEPAQSPALREEEGSGNIWHPLSRIKVENNQNESMGGFNEQEDHA 






FBpp0297936/1-1267     ETDATGGDNDESESRDAEK---- 
                        **    .:: ..  : :*     
 
 
2. SALL4 and spalt major 
Species Gene ID Peptide ID Peptide length % identity Genomic location 
Homo sapiens ENSG00000101115 ENSP00000217086 1053 aa 24 % 20:50400581-50419059 
Drosophila melanogaster FBgn0261648  FBpp0088852  1365 aa 18 % 2L:11434311-11445603  
 
CLUSTAL W(1.81) multiple sequence alignment 
 
ENSP00000217086/1-1053 MSRRKQAKPQHINSEEDQGEQQPQQQTPEFADAAPAAPAAGELGAPVNHPGNDEVASEDE 
FBpp0088852/1-1365     ------------------------------------------------------------ 
                                                                                    
 
ENSP00000217086/1-1053 ATVKRLRREETHVCEKCCAEFFSISEFLEHKKNCTKNPPV------LI--MNDSEGPVPS 
FBpp0088852/1-1365     --------MKNHLSNVLCAMRSDFKD--NHQETINKMIQFGTVKYGIVKQLKDRARSADK 
                                :.*:.:  **   .:.:  :*::. .*   .      ::  ::*   .. . 
 
ENSP00000217086/1-1053 ------------------------------------------EDFSGAV-------LSHQ 
FBpp0088852/1-1365     DIGSDQEENGGCSPLTTATTTASPSRSPEPEEEQPEEQSTSEQSIPEQSTPDHQLENDIK 
                                                                 :.:.           . : 
 
ENSP00000217086/1-1053 PTSPGSKD-CHREN--GGSS-EDM--------------------KEKPDAES-------- 
FBpp0088852/1-1365     SEAKSEIEPVEDNNNRVAMTKPSSEEREPNASGSMPSSPVAEASAEEAATERTPEKEKEK 






FBpp0088852/1-1365     DVEVDVEK----------------PDEAPSSAVPSTEVTLPGGAGAPVTLEAIQNMQMAI 
                                                .  ... *.          .: ***:*::. ::*: 
 
ENSP00000217086/1-1053 NQRSADALPAPVP-------GANSIPWVLEQILCLQQQQLQQIQLTEQIRIQVNMWASHA 
FBpp0088852/1-1365     AQFA-AKTIANGSNGADNEAAMKQLAFLQQTLFNLQQQQLFQIQLIQQLQSQLALNQAKQ 
                        * :     *  .       . :.:.:: : :: ****** **** :*:: *: :  ::  
 
ENSP00000217086/1-1053 L---------------------------------H-SSGAG--ADTLKTLGSHMSQQVSA 
FBpp0088852/1-1365     EEDTEEDADQEQDQEQETDTYEEEERIADMELRQKAEARMAEAK---------ARQHLIN 
                                                         : .:  .              *::   
 
ENSP00000217086/1-1053 AVALLSQKAGSQGLSLDALKQ---------------------AKLPHANIP-SATSSLSP 
FBpp0088852/1-1365     AGVPLRESSGSPAESLKRRREHDHESQPNRRPSLDNTHKADTAQDALAKLKE-------- 
                       * . * :.:** . **.  ::                     *: . *::           
 
ENSP00000217086/1-1053 GL---APFTLKPDGTRVLPNVMSRLPSALLPQAP------GSVLFQSPF-----STVALD 
FBpp0088852/1-1365     --MENTPLPFGSDLASSIITNHDDLP---EPNSLDLLQKRAQEVLDSASQGILANSMA-D 
                            :*:.: .* :  : .  . **    *::       .. :::*.      .::* * 
 
ENSP00000217086/1-1053 T----SKKGKGKPPNISAVDVKPKDEAALYKHKCKYCSKVFGTDSSLQIHLRSHTGERPF 
FBpp0088852/1-1365     DFAFGEKSGEGKGRN-----------EPFFKHRCRYCGKVFGSDSALQIHIRSHTGERPF 
                            .*.*:**  *            .::**:*:**.****:**:****:********* 
 
ENSP00000217086/1-1053 VCSVCGHRFTTKGNLKVHFHRH----PQVKANPQLFAEFQDKV---------AAGNGIPY 
FBpp0088852/1-1365     KCNVCGSRFTTKGNLKVHFQRHAQKFPHVPMNATPIPEHMDKFHPPLLDQMSPTDS-SPN 






FBpp0088852/1-1365     HSPAPPPLGSAPASFPPAFPGLQNLYRPPMEILKSLGAAAPHQYFPQELPTDLRKPSPQL 
                         ..* *  . *:        *. *   *  :*    ::     :**:*.:.  :*.  * 
 
ENSP00000217086/1-1053 T-----------------------GG---------------------------------- 
FBpp0088852/1-1365     DEDEPQVKNEPVEEKDQREEHEQEMAECSEPEPEPLPLEVRIKEERVEEQEQVKQEDHRI 
                                                .                                   
 
ENSP00000217086/1-1053 -------SLPGDLQ---------PGPS---P-ESEGG--P-TLPGV-------------- 
FBpp0088852/1-1365     EPRRTPSPSSEHRSPHHHRHSHMGYPPVVQPIQPAALMHPQSSPGSQSHLDHLPTPGQLP 
                              . . . .           *.   * :. .   * : **                
 
ENSP00000217086/1-1053 -----------------------------------------------------------G 
FBpp0088852/1-1365     PREDFFAERFPLNFTTAKMLSPEHHSPVRSPAGGALPPGVPPPPHHHPHHMARSPFFNP- 
                                                                                   
 
ENSP00000217086/1-1053 PNYNSPRAG----GFQGSG--------TPEPGSETLKLQQLVENIDKATTDPNECLICHR 
FBpp0088852/1-1365     ----IKHEMAALLPRPHSNDNSWENFIEVSNTCETMKLKELMKN--KKISDPNQCVVCDR 
                             :          *.          .  .**:**::*::*  *  :***:*::*.* 
 
ENSP00000217086/1-1053 VLSCQSSLKMHYRTHTGERPFQCKICGRAFSTKGNLKTHLGVHRTNTSIKTQHSCPICQK 
FBpp0088852/1-1365     VLSCKSALQMHYRTHTGERPFKCRICGRAFTTKGNLKTHMAVHKIRPPMRNFHQCPVCHK 
                       ****:*:*:************:*:******:********:.**: ...::. *.**:*:* 
 
ENSP00000217086/1-1053 KFTNAVMLQQHIRMHMG--------------------------------------GQIPN 
FBpp0088852/1-1365     KYSNALVLQQHIRLHTGEPTDLTPEQIQAAEIRDPPPSMMPGHFMNPFAAAAFHFGALPG 






FBpp0088852/1-1365     GPGGPP--GPNHGAHNGALGSESSQGDMDDNMDCGEDYDDDVSSEHLSNSNLEQEGDRSR 
                        *  *       *  :    .*.. .            .*** ..           :.   
 
ENSP00000217086/1-1053 SQE-APSSSSKVPTPLPSIHSA--SPTLGFAMMASLDA-PGK------V---GPAPFNLQ 
FBpp0088852/1-1365     SGDDFKSLLFEQKLRIDATGVVNTNPVRPRSSASSHGHSVGSTSAPTSPSVHASSQVIKR 
                       * :   *   :    : :   .  .*.   :  :* .   *.          ..: .  : 
 
ENSP00000217086/1-1053 RQG----SRENGSV----ES--DGLTNDSS--SLMGDQEYQ--SRSPDILET-TSF---- 
FBpp0088852/1-1365     SSSPARSEASQGALDLTPRAAP------TSSSSSRSPLPKEKPVSPPSLPRSPSGSSHAS 
                        ..    . .:*::    .:        :*  *  .    :    .*.: .: :.      
 
ENSP00000217086/1-1053 -QA-LSPANS------------------QAESIKSKS-----PD---------AG----- 
FBpp0088852/1-1365     ANILTSPLPPTVGIDCLPPGLQHHLQQQHQHLMQQQAAVAAAAAAQHHHHQQMAALHQHQ 
                        :   **  .                  : . ::.::     .          *.      
 
ENSP00000217086/1-1053 --SKAESSENSRTEMEG-----------------------------------RSSLP-ST 
FBpp0088852/1-1365     EQLRREAAEA-------QQKAAAAAAAAAAAAAAQRQTPPQARDQRQEGGPGAGPPPNPL 
                          : *::*                                            .. * .  
 
ENSP00000217086/1-1053 FIRAPP-TYVKVE------VPGTFVGPSTLS---------------PG-MTPLLAAQPRR 
FBpp0088852/1-1365     MGARPPFGM----FPNLPLFPPA-----TTQNMCNAMNQIAQSVMPAAPFNPLA------ 
                       :   **             .* :     * .               .. :.**        
 
ENSP00000217086/1-1053 QAKQHGCTRCG---KNFSSASALQIHERTHTGEKPFVCNICGRAFTTKGNLKVHYMTHGA 
FBpp0088852/1-1365     LSGVRGSTTCGICYKTFPCHSALEIHYRSHTKERPFKCSICDRGFTTKGNLKQHMLTHKI 






FBpp0088852/1-1365     RDMEQETFRNRAVK-----------------------------YMSEWN----------- 
                       .: . .  *: *::                                 **            
 
ENSP00000217086/1-1053 VKTNEISVIQSGGVPTLPVSLGATSVVNNATVSKMDGSQSGISADVEKPSATDGVPKHQF 
FBpp0088852/1-1365     ------------------------------------------------------------ 
                                                                                    
 
ENSP00000217086/1-1053 PHFLEENKIAVS 
FBpp0088852/1-1365     ----EDRE---- 
                           *:.:     
 
 
3. SALL4 and Sall4 
Species Gene ID Peptide ID Peptide length % identity Genomic location 
Homo sapiens ENSG00000101115 ENSP00000217086 1053 aa 75 % 20:50400581-50419059 
Mus musculus ENSMUSG00000027547  ENSMUSP00000029061  1067 aa 74 % 2:168748332-168767943  
 
CLUSTAL W(1.81) multiple sequence alignment 
ENSP00000217086/1-1053    MSRRKQAKPQHINSEEDQGEQQPQQQTPEFADAAPAAPAAGELGAPVNHPGNDEVASEDE 
ENSMUSP00000029061/1-1067 MSRRKQAKPQHINWEEGQGEQPQQLPSPDLAE----ALAAEEPGAPVNSPGNCDEASED- 
                          ************* **.****  *  :*::*:    * ** * ***** *** : ****  
 
ENSP00000217086/1-1053    AT--VKRLRREETHVCEKCCAEFFSISEFLEHKKNCTKNPPVLIMNDSEGPVPSEDFSGA 
ENSMUSP00000029061/1-1067 -SIPVKRPRREDTHICNKCCAEFFSLSEFMEHKKSCTKTPPVLIMNDSEGPVPSEDFSRA 
                           :  *** ***:**:*:********:***:****.***.******************* * 
 
ENSP00000217086/1-1053    VLSHQPTSPGSKDCHRENGGSS-EDMKEKPDAESVVYLKTETALPPTPQDISYLAKGKVA 
ENSMUSP00000029061/1-1067 ALSHQLGSPSNKDSLQEN-GSSSGDLKK-LGTDSILYLKTEATQPSTPQDISYLPKGKVA 
                          .****  **..**. :** ***  *:*:  .::*::*****:: *.********.***** 





                          *******************.*:*  **:*.*:.**************************: 
 
ENSP00000217086/1-1053    QVNMWASHALHSSGAGADTLKTLGSH------MSQQVSAAVALLSQKAGSQGLSLDALKQ 
ENSMUSP00000029061/1-1067 QVNMWAAHALHSGVAGADTLKALSSHVSQQVSVSQQVSAAVALLSQKASNPALSLDALKQ 
                          ******:*****. *******:*.**      :***************.. .******** 
 
ENSP00000217086/1-1053    AKLPHANIPSATSSLSPGLAPFTLKPDGTRVLPNVMSRLPSALLPQAPGSVLFQSPFSTV 
ENSMUSP00000029061/1-1067 AKLPHASVPSAASPLSSGLTSFTLKPDGTRVLPNFVSRLPSALLPQTPGSVLLQSPFSAV 
                          ******.:***:*.**.**:.*************.:**********:*****:*****:* 
 
ENSP00000217086/1-1053    ALDTSKKGKGKPPNI----SAVDVKPKDEAALYKHKCKYCSKVFGTDSSLQIHLRSHTGE 
ENSMUSP00000029061/1-1067 TLDQSKKGKGKPQNLSASASVLDVKAKDEVVLGKHKCRYCPKVFGTDSSLQIHLRSHTGE 
                          :** ******** *:    *.:***.***..* ****:**.******************* 
 
ENSP00000217086/1-1053    RPFVCSVCGHRFTTKGNLKVHFHRHPQVKANPQLFAEFQDKVAAGNGIPYALSVPDPIDE 
ENSMUSP00000029061/1-1067 RPYVCPICGHRFTTKGNLKVHLQRHPEVKANPQLLAEFQDKGAVSAASHYALPVPVPADE 
                          **:**.:**************::***:*******:****** *.. .  ***.** * ** 
 
ENSP00000217086/1-1053    PSLSLDSKPVLV--TTSVGLPQNLSSGTNPKDLTGGSLPGDLQPGPSPESEGGPTLPGVG 
ENSMUSP00000029061/1-1067 SSLSVDAEPVPVTGTPSLGLPQKLTSGPNSRDLMGGSLPNDMQPGPSPESEAGLPLLGVG 
                          .***:*::** *  *.*:****:*:**.*.:** *****.*:*********.* .* *** 
 
ENSP00000217086/1-1053    PNYNSPRAGGFQGSGTPEPGSETLKLQQLVENIDKATTDPNECLICHRVLSCQSSLKMHY 
ENSMUSP00000029061/1-1067 MIHNPPKAGGFQGTGAPESGSETLKLQQLVENIDKATTDPNECLICHRVLSCQSSLKMHY 
                            :*.*:******:*:**.***************************************** 
 
ENSP00000217086/1-1053    RTHTGERPFQCKICGRAFSTKGNLKTHLGVHRTNTSIKTQHSCPICQKKFTNAVMLQQHI 
ENSMUSP00000029061/1-1067 RTHTGERPFQCKICGRAFSTKGNLKTHLGVHRTNTTVKTQHSCPICQKKFTNAVMLQQHI 
                          ***********************************::*********************** 
ENSP00000217086/1-1053    RMHMGGQIPNTPLPENPCDFTGSEPMTVGENGSTGAICHDDVIESIDVEEVSSQEAPSSS 
ENSMUSP00000029061/1-1067 RMHMGGQIPNTPLPESPCDFTAPEPVAVSENGSASGVCQDDAAEGMEAEEVCSQDVPSGP 





ENSP00000217086/1-1053    SKVPTPLPSIHSASPTLGFAMMASLDAPGKVGPAPFNLQRQGSRENGSVES--DGLTNDS 
ENSMUSP00000029061/1-1067 STVSLPVPSAHLASPSLGFSVLASLDTQGKGALPALALQRQSSRENSSLEGGDTGPANDS 
                          *.*. *:** * ***:***:::****: ** . ..: ****.****.*:*.   * :*** 
 
ENSP00000217086/1-1053    SSLMGDQEYQSRSPDILETTSFQALSPANSQAESIKSKSPDAGSKAESSENSRTEMEGRS 
ENSMUSP00000029061/1-1067 SLLVGDQECQSRSPDATETMCYQAVSPANSQAGSVKSRSPE-GHKAEGVESCRVDTEGRT 
                          * *:**** ******  ** .:**:******* *:**:**: * ***. *..*.: ***: 
 
ENSP00000217086/1-1053    SLPSTFIRAPPTYVKVEVPGTFVGPSTLSPGMTPLLAAQ--PRRQAKQHGCTRCGKNFSS 
ENSMUSP00000029061/1-1067 SLPPTFIRAQPTFVKVEVPGTFVGPPSMPSGMPPLLASQPQPRRQAKQHCCTRCGKNFSS 
                          ***.***** **:************.::..**.****:*  ******** ********** 
 
ENSP00000217086/1-1053    ASALQIHERTHTGEKPFVCNICGRAFTTKGNLKVHYMTHGANNNSARRGRKLAIENTMAL 
ENSMUSP00000029061/1-1067 ASALQIHERTHTGEKPFVCNICGRAFTTKGNLKVHYMTHGANNNSARRGRKLAIENPMAA 
                          ********************************************************.**  
 
ENSP00000217086/1-1053    LGTDGKRVSEIFPKEILAPSVNVDPVVWNQYTSMLNGGLAVKTNEISVIQSGGVPTLPVS 
ENSMUSP00000029061/1-1067 LSAEGKRAPEVFSKELLSPAVSVDPASWNQYTSVLNGGLAMKTNEISVIQSGGIPTLPVS 
                          *.::***..*:*.**:*:*:*.***. ******:******:************:****** 
 
ENSP00000217086/1-1053    LGATSVVNNATVSKMDGSQSG----ISADVEKPSATDGVPKHQFPHFLEENKIAVS 
ENSMUSP00000029061/1-1067 LGASSVVSNGTISKLDGSQTGVSMPMSGNGEKLAVPDGMAKHQFPHFLEENKIAVS 
                          ***:***.*.*:**:****:*    :*.: ** :..**:.**************** 
 
Legend: 
             Zinc finger domains 
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How to Explain Hierarchical Clustering 
Stephen P. Borgatti  
University of South Carolina 
  
Given a set of N items to be clustered, and an NxN distance (or similarity) matrix, the 
basic process of Johnson's (1967) hierarchical clustering is this: 
1. Start by assigning each item to its own cluster, so that if you have N items, 
you now have N clusters, each containing just one item. Let the distances 
(similarities) between the clusters equal the distances (similarities) between 
the items they contain. 
2. Find the closest (most similar) pair of clusters and merge them into a single 
cluster, so that now you have one less cluster. 
3. Compute distances (similarities) between the new cluster and each of the old 
clusters. 
4. Repeat steps 2 and 3 until all items are clustered into a single cluster of size N. 
Step 3 can be done in different ways, which is what distinguishes single-
link from complete-link and average-link clustering. In single-link clustering (also 
called the connectedness or minimum method), we consider the distance between one 
cluster and another cluster to be equal to the shortest distance from any member of 
one cluster to any member of the other cluster. If the data consist of similarities, we 
consider the similarity between one cluster and another cluster to be equal to 
the greatest similarity from any member of one cluster to any member of the other 
cluster. In complete-link clustering (also called the diameter or maximum method), we 
consider the distance between one cluster and another cluster to be equal to 
the longest distance from any member of one cluster to any member of the other 
cluster. In average-link clustering, we consider the distance between one cluster and 
another cluster to be equal to the average distance from any member of one cluster to 
any member of the other cluster. A variation on average-link clustering is the UCLUS 
method of D'Andrade (1978) which uses the median distance. 
Example. The following pages trace a hierarchical clustering of distances in miles 






Input distance matrix: 
  BOS NY DC MIA CHI SEA SF LA DEN 
BOS 0 206 429 1504 963 2976 3095 2979 1949 
NY 206 0 233 1308 802 2815 2934 2786 1771 
DC 429 233 0 1075 671 2684 2799 2631 1616 
MIA 1504 1308 1075 0 1329 3273 3053 2687 2037 
CHI 963 802 671 1329 0 2013 2142 2054 996 
SEA 2976 2815 2684 3273 2013 0 808 1131 1307 
SF 3095 2934 2799 3053 2142 808 0 379 1235 
LA 2979 2786 2631 2687 2054 1131 379 0 1059 
DEN 1949 1771 1616 2037 996 1307 1235 1059 0 
 
The nearest pair of cities is BOS and NY, at distance 206. These are merged into a 
single cluster called "BOS/NY". 
Then we compute the distance from this new compound object to all other objects. In 
single link clustering the rule is that the distance from the compound object to another 
object is equal to the shortest distance from any member of the cluster to the outside 
object. So the distance from "BOS/NY" to DC is chosen to be 233, which is the 












After merging BOS with NY: 
  BOS/NY DC MIA CHI SEA SF LA DEN 
BOS/NY 0 223 1308 802 2815 2934 2786 1771 
DC 223 0 1075 671 2684 2799 2631 1616 
MIA 1308 1075 0 1329 3273 3053 2687 2037 
CHI 802 671 1329 0 2013 2142 2054 996 
SEA 2815 2684 3273 2013 0 808 1131 1307 
SF 2934 2799 3053 2142 808 0 379 1235 
LA 2786 2631 2687 2054 1131 379 0 1059 
DEN 1771 1616 2037 996 1307 1235 1059 0 
  
The nearest pair of objects is BOS/NY and DC, at distance 223. These are merged 
into a single cluster called "BOS/NY/DC". Then we compute the distance from this 
new cluster to all other clusters, to get a new distance matrix: 
After merging DC with BOS-NY: 
  BOS/NY/DC MIA CHI SEA SF LA DEN 
BOS/NY/DC 0 1075 671 2684 2799 2631 1616 
MIA 1075 0 1329 3273 3053 2687 2037 
CHI 671 1329 0 2013 2142 2054 996 
SEA 2684 3273 2013 0 808 1131 1307 
SF 2799 3053 2142 808 0 379 1235 
LA 2631 2687 2054 1131 379 0 1059 





Now, the nearest pair of objects is SF and LA, at distance 379. These are merged into 
a single cluster called "SF/LA". Then we compute the distance from this new cluster 
to all other objects, to get a new distance matrix: 
 
After merging SF with LA: 
  BOS/NY/DC MIA CHI SEA SF/LA DEN 
BOS/NY/DC 0 1075 671 2684 2631 1616 
MIA 1075 0 1329 3273 2687 2037 
CHI 671 1329 0 2013 2054 996 
SEA 2684 3273 2013 0 808 1307 
SF/LA 2631 2687 2054 808 0 1059 
DEN 1616 2037 996 1307 1059 0 
 
Now, the nearest pair of objects is CHI and BOS/NY/DC, at distance 671. These are 
merged into a single cluster called "BOS/NY/DC/CHI". Then we compute the 
distance from this new cluster to all other clusters, to get a new distance matrix: 
After merging CHI with BOS/NY/DC: 
  BOS/NY/DC/CHI MIA SEA SF/LA DEN 
BOS/NY/DC/CHI 0 1075 2013 2054 996 
MIA 1075 0 3273 2687 2037 
SEA 2013 3273 0 808 1307 
SF/LA 2054 2687 808 0 1059 





Now, the nearest pair of objects is SEA and SF/LA, at distance 808. These are merged 
into a single cluster called "SF/LA/SEA". Then we compute the distance from this 
new cluster to all other clusters, to get a new distance matrix: 
 
After merging SEA with SF/LA: 
  BOS/NY/DC/CHI MIA SF/LA/SEA DEN 
BOS/NY/DC/CHI 0 1075 2013 996 
MIA 1075 0 2687 2037 
SF/LA/SEA 2054 2687 0 1059 
DEN 996 2037 1059 0 
 
Now, the nearest pair of objects is DEN and BOS/NY/DC/CHI, at distance 996. These 
are merged into a single cluster called "BOS/NY/DC/CHI/DEN". Then we compute 
the distance from this new cluster to all other clusters, to get a new distance matrix: 
After merging DEN with BOS/NY/DC/CHI: 
  BOS/NY/DC/CHI/DEN MIA SF/LA/SEA 
BOS/NY/DC/CHI/DEN 0 1075 1059 
MIA 1075 0 2687 









Now, the nearest pair of objects is BOS/NY/DC/CHI/DEN and SF/LA/SEA, at 
distance 1059. These are merged into a single cluster called 
"BOS/NY/DC/CHI/DEN/SF/LA/SEA". Then we compute the distance from this new 
compound object to all other objects, to get a new distance matrix: 
After merging SF/LA/SEA with BOS/NY/DC/CHI/DEN: 
  BOS/NY/DC/CHI/DEN/SF/LA/SEA MIA 
BOS/NY/DC/CHI/DEN/SF/LA/SEA 0 1075 
MIA 1075 0 
  
Finally, we merge the last two clusters at level 1075. This process is summarized by 
the clustering diagram printed by many software packages: 
 
In the diagram, the columns are associated with the items and the rows are associated 
with levels (stages) of clustering. An 'X' is placed between two columns in a given 




D'andrade,R. 1978, "U-Statistic Hierarchical Clustering" Psychometrika, 4:58-67. 







Part of this thesis work has been summarized in a manuscript and accepted for 
publication by the New England Journal of Medicine. The manuscript proof is 
attached in this thesis as appendix. 
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ABSTRACT
Background
Hepatocellular carcinoma is the third leading cause of cancer-related deaths world-
wide. In the heterogeneous group of hepatocellular carcinomas, those with charac-
teristics of embryonic stem-cell and progenitor-cell gene expression are associated 
with the worst prognosis. The oncofetal gene SALL4, a marker of a subtype of hepa-
tocellular carcinoma with progenitor-like features, is associated with a poor prog-
nosis and is a potential target for treatment.
Methods
We screened specimens obtained from patients with primary hepatocellular carci-
noma for the expression of SALL4 and carried out a clinicopathological analysis. 
Loss-of-function studies were then performed to evaluate the role of SALL4 in hepa-
tocarcinogenesis and its potential as a molecular target for therapy. To assess the 
therapeutic effects of a peptide that targets SALL4, we used in vitro functional and 
in vivo xenograft assays.
Results
SALL4 is an oncofetal protein that is expressed in the human fetal liver and silenced 
in the adult liver, but it is reexpressed in a subgroup of patients who have hepatocel-
lular carcinoma and an unfavorable prognosis. Gene-expression analysis showed 
the enrichment of progenitor-like gene signatures with overexpression of prolifera-
tive and metastatic genes in SALL4-positive hepatocellular carcinomas. Loss-of-
function studies confirmed the critical role of SALL4 in cell survival and tumorige-
nicity. Blocking SALL4–corepressor interactions released suppression of PTEN (the 
phosphatase and tensin homologue protein) and inhibited tumor formation in xe-
nograft models in vivo.
Conclusions
SALL4 is a marker for a progenitor subclass of hepatocellular carcinoma with an 
aggressive phenotype. The absence of SALL4 expression in the healthy adult liver 
enhances the potential of SALL4 as a treatment target for hepatocellular carcinoma. 
(Funded by the Singapore National Medical Research Council and others.)
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Hepatocellular carcinoma is the third leading cause of cancer-related deaths globally. Although the epidemio-
logic risk factors for hepatocellular carcinoma 
are well known,1 the molecular mechanisms un-
derlying hepatocarcinogenesis are not well char-
acterized. Elucidation of these mechanisms may 
allow identification of new candidates for thera-
peutic targeting. Although surgery, liver transplan-
tation, and radiologic intervention may be viable 
options for patients with early-stage disease, the 
prognosis associated with advanced-stage hepa-
tocellular carcinoma remains bleak.2 Combination 
chemotherapy has not improved overall survival but 
has nonetheless been in wide use for many years 
because of its possible role in palliation. The need 
to understand the molecular pathogenesis of he-
patocellular carcinoma and develop more effec-
tive targeted therapies remains urgent.
The human homologue of the Drosophila spalt 
homeotic gene, SALL4, encodes a C2H2 zinc-finger 
transcription factor.3 It is one of the key factors 
for maintenance of pluripotency and self-renew-
al of embryonic stem cells.4-6 In the murine liver, 
Sall4 expression diminishes gradually during de-
velopment and is silenced by adulthood; this sug-
gests a role for Sall4 during early-to-middle de-
velopment of the fetal liver.7 SALL4 is an oncogene 
that was first described in leukemia. SALL4 was 
found to be constitutively expressed in human 
acute myeloid leukemia, and acute myeloid leu-
kemia developed in SALL4B-transgenic mice.8 Sub-
sequently, SALL4 expression has been reported in 
various types of cancers9,10 and is proposed to have 
diagnostic value in several of them.11-13
The progenitor-like subtype of hepatocellular 
carcinoma is known to be associated with a poor 
prognosis.14 The expression of Sall4 in murine fetal 
liver but not in adult liver led us to hypothesize 
that SALL4 might be an important marker for the 
progenitor-like subtype of hepatocellular carcino-
ma. We also hypothesized that SALL4 would con-
tribute to the development and persistence of 
hepatocellular carcinoma when it was expressed 
in hepatocytes in adults.
Methods
Patients and Samples
We obtained specimens of hepatocellular carci-
noma from patients at the National University 
Hospital in Singapore (hereafter referred to as 
the Singapore specimens) to construct hepatocellu-
lar-carcinoma tissue microarrays. We also analyzed 
a second batch of specimens obtained from pa-
tients at the Queen Mary Hospital in Hong Kong 
(hereafter referred to as the Hong Kong specimens). 
The patients received various treatments and were 
not participants in any clinical trials evaluating 
treatment approaches. The institutional review 
board of the National University of Singapore ap-
proved the study, and patients provided written 
informed consent for the use of all surgically re-
moved tissue specimens used in this study.
Study Conduct
The study had no commercial sponsors. The au-
thors vouch for the accuracy and completeness of 
the data and analysis. No one who is not listed as 
an author contributed to the manuscript.
Statistical Analysis
All experiments were performed in triplicate un-
less otherwise stated. Statistical analyses were 
performed with the use of SPSS software, ver-
sions 15.0 and 16.0 (SPSS). To examine the as-
sociation between levels of SALL4 expression 
and clinicopathological characteristics, Fisher’s 
exact test was used for analysis of the Singapore 
Figure 1 (facing page). SALL4 Expressed in Human 
Fetal Liver, Silenced in Adult Liver, and Reactivated  
in a Subtype of Hepatocellular Carcinoma.
Panel A shows immunohistochemical staining of for-
malin-fixed, paraffin-embedded human fetal liver and 
human adult liver. SALL4 expression is indicated by 
brown staining. Scale bars indicate 100 μm. Panel B 
shows immunohistochemical staining of a hepatocel-
lular carcinoma specimen and the matched non-neo-
plastic liver specimen on tissue microarray analysis. 
SALL4 expression was detected in the hepatocellular 
carcinoma tissue and localized in the nucleus, as indi-
cated by the brown staining. Scale bars indicate 100 
μm. Panel C shows differential SALL4 expression in 
228 matched specimens of primary hepatocellular car-
cinoma and non-neoplastic liver tissue from the Hong 
Kong cohort, as determined by means of microarray 
analysis. Panel D shows microarray SALL4 expression 
in primary hepatocellular carcinoma and non-neoplas-
tic liver tissue on the basis of pooled data from public 
databases. Panel E shows the results of quantitative 
reverse-transcriptase–polymerase-chain-reaction anal-
ysis of SALL4A (left) and SALL4B (right) expression in 
10 human hepatocellular-carcinoma cell lines and two 
immortalized nontransformed hepatocyte cell lines, 
THLE-2 and THLE-3. All values were normalized to 
ACTB and plotted relative to the expression of the 
THLE-2 cell line.
SALL4 in Aggressive Hepatocellular Carcinoma
n engl j med 368;24 nejm.org june 13, 2013 2267
specimens of primary hepatocellular carcinomas 
and the chi-square test was used for analysis of 
the Hong Kong specimens. In the Hong Kong 
specimens, levels of SALL4 expression were di-
vided into two groups. The group with a high 
level of SALL4 expression (high-SALL4 group) had 
SALL4 expression intensity that was equal to or 
exceeded the median level of expression detected 
on microarray analysis, whereas the group with a 
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had SALL4 expression intensity that was lower 
than the median level of expression. Univariate 
analyses of cumulative overall survival and tu-
mor recurrence were performed with the use of a 
Cox proportional-hazards regression model in the 
Singapore cohort and with the use of the Ka-
plan–Meier method followed by the log-rank test 
in the Hong Kong cohort. Factors with prognos-
tic significance were included in the subsequent 
multivariate analyses with the use of the Cox 
proportional-hazards regression model in both 
cohorts. For statistical analysis of the Singapore 
specimens of primary hepatocellular carcinomas, 
79 of the 179 specimens for which full clinico-
pathological data were available were analyzed. 
The correlation significance was determined by 
means of Spearman and Pearson correlation anal-
yses. The chi-square test and Student’s t-test were 
used for comparisons between the high-SALL4 
and low-SALL4 groups. A P value of 0.05 or less 
was considered to indicate statistical significance.
Results
SALL4 Expression in Hepatocellular Carcinoma
To test our hypothesis that SALL4 is reexpressed 
in a subtype of hepatocellular carcinoma, we exam-
ined the expression of SALL4 in liver specimens 
from patients with and those without hepatocel-
lular carcinomas. With the use of immunohisto-
chemical analysis, we detected SALL4 expression 
in fetal liver specimens but not in adult liver 
specimens (Fig. 1A).
We then investigated the level of expression 
of SALL4 in patients with hepatocellular carci-
noma. We constructed a panel of tissue microar-
rays consisting of 179 surgically resected speci-
mens of primary hepatocellular carcinomas and 
matched, archived, non-neoplastic liver specimens 
obtained from the National University Hospital 
in Singapore. The patients in the Singapore co-
hort were approximately 56 years of age, 81% 
were men, and 87.3% had grade I or II tumors. 
Detailed demographic and clinicopathological 
characteristics of these patients are described in 
Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
With the use of immunohistochemical analysis, 
we observed differential expression of SALL4 in 
matched tissue specimens, with more SALL4-
expressing cells in the specimens with hepato-
cellular carcinoma than in the matched non-neo-
plastic specimens (P<0.001) (Fig. 1B). Data from 
the immunohistochemical analysis showed SALL4 
positivity in 55.6% (95 of 171) of the hepatocel-
lular carcinoma specimens analyzed, albeit at vari-
ous levels of expression (Table S2 in the Supple-
mentary Appendix).
We further confirmed SALL4 up-regulation by 
means of gene-expression microarray analysis in 
various independent groups of specimens of pri-
mary hepatocellular carcinoma. In a group of 
228 matched neoplastic and non-neoplastic liver 
specimens obtained from patients in Hong Kong, 
we detected differential SALL4 expression (P<0.001) 
(Fig. 1C), which was similar to the pattern of ex-
pression observed in the Singapore specimens. 
Table S3 in the Supplementary Appendix lists the 
demographic and clinicopathological character-
istics of the patients with hepatocellular carcino-
ma in the Hong Kong cohort. Furthermore, we 
pooled various global gene-expression data from 
public databases and observed differential SALL4 
expression in the hepatocellular-carcinoma and 
non-neoplastic liver-tissue specimens (P = 0.003) 
(Fig. 1D). From these sizable independent groups 
of adult liver specimens, we confirmed that SALL4 
was up-regulated in the subgroup of specimens 
with hepatocellular carcinoma but remained si-
lenced in the matched non-neoplastic specimens.
Analysis of endogenous SALL4 expression 
across a panel of 10 human hepatocellular carci-
noma cell lines by means of a quantitative 
polymerase-chain-reaction assay showed the ex-
pression of SALL4 at various levels, reflecting the 
expression pattern observed in the hepatocellu-
lar carcinoma tissue specimens described above 
(Fig. 1E). Moreover, SALL4 expression was not 
detected in the two immortalized, nontransformed 
liver-cell lines, THLE-2 and THLE-3. These data 
suggest that these cell lines are appropriate mod-
els for further testing of our hypothesis and 
confirm our finding that SALL4 is reexpressed in 
a subgroup of hepatocellular carcinomas.
In summary, the results obtained from a 
number of different assays and groups of clini-
cal specimens showed that SALL4 was ex-
pressed in fetal liver tissue, silenced in normal 
adult liver tissue, and reexpressed in many of 
the tissue specimens from adults with hepato-
cellular carcinoma (Fig. S2 in the Supplemen-
tary Appendix).
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Figure 2. Poor Prognosis Predicted by SALL4 Expression in Hepatocellular Carcinoma.
In Panel A, Kaplan–Meier curves show a lower rate of overall survival with SALL4-postive hepatocellular carcinomas 
than with SALL4-negative hepatocellular carcinomas in the Singapore cohort. In Panel B, Kaplan–Meier curves show 
a lower probability of overall survival with high-SALL4 hepatocellular carcinomas in the Hong Kong cohort. In Panel 
C, the dendrogram and heat map show the hierarchical cluster analysis of gene-expression data from human speci-
mens of primary hepatocytes, fetal liver tissue, and hepatocellular carcinoma; gene-expression profiles were ob-
tained from public databases. Columns represent individual samples, and rows represent individual genes. Each cell 
in the matrix represents the expression level of a gene in an individual sample. The scale bar indicates the level of 
expression; red indicates a high level of expression, and green a low level of expression. In Panel D,  the dendrogram 
and heat map show the hierarchical cluster analysis of gene-expression data from human specimens of primary he-
patocytes, fetal liver tissue, and SNU-398 cells transduced with scrambled short hairpin RNA 1 or SALL4-specific 
shRNA (shSALL4 1).
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SALL4 as a Prognostic Factor for 
Hepatocellular Carcinoma
To analyze the clinical relevance of SALL4 reacti-
vation in hepatocellular carcinoma, we carried 
out a clinicopathological analysis of the Singa-
pore and Hong Kong specimens of primary hepa-
tocellular carcinoma. This analysis showed that 
patients with a high level of SALL4 expression 
had a worse prognosis than patients with a low 
level of SALL4 expression. A univariate analysis of 
survival among patients in the Singapore cohort 
showed that the absence of SALL4 protein (an im-
munohistochem-ical score of 0 on a scale of 0 to 4, 
with higher scores indicating a greater propor-
tion of positive cells [see the Supplementary 
Methods section in the Supplementary Appen-
dix]), conferred a significant survival advantage 
(P = 0.02) (Fig. 2A). Similarly, SALL4 expression 
was associated with poor survival among the pa-
tients in the Hong Kong cohort (P = 0.002) (Fig. 2B). 
Our univariate analysis also showed that SALL4 
predicted disease recurrence in both the Singa-
pore cohort (Table S4 in the Supplementary Ap-
pendix) and the Hong Kong cohort (Table S5 in 
the Supplementary Appendix).
In addition, our association studies confirmed 
that SALL4 expression status was not associated 
with baseline liver function or the tumor–node–
metastasis and Barcelona Clinic Liver Cancer stag-
es in either the Singapore cohort (Table S1 in the 
Supplementary Appendix) or the Hong Kong 
cohort (Table S3 in the Supplementary Appendix). 
Moreover, SALL4 expression status in the Singa-
pore cohort did not differ significantly accord-
ing to whether the patients received or did not 
receive preoperative treatment. In a multivariate 
Cox regression model, SALL4 was an independent 
prognostic factor for overall survival (hazard ratio 
for death, 2.87; 95% confidence interval [CI], 
1.09 to 7.52; P = 0.03) in the Singapore cohort 
(Table S6 in the Supplementary Appendix) and 
an independent predictor of both overall survival 
(hazard ratio for death, 1.52; 95% CI, 1.00 to 2.32; 
P = 0.05) and early recurrence (hazard ratio, 1.67; 
95% CI, 1.11 to 2.51; P = 0.01) in the Hong Kong 
cohort (Table S7 in the Supplementary Appendix), 
after adjustment for other clinicopathological 
features that have conventionally been accepted 
as having prognostic value in hepatocellular car-
cinoma.
Gene-profiling studies suggest that patients 
with cancers that have embryonic stem-cell or he-
patic progenitor cell–like gene-expression signa-
tures have a poor prognosis.14-16 To investigate 
whether SALL4-positive hepatocellular carcino-
mas share a gene-expression pattern with fetal 
hepatoblasts, we extracted global gene-expression 
data on hepatocytes, fetal liver tissue, and hepa-
tocellular carcinomas (all from humans) from 
the Gene Expression Omnibus database for hier-
archical cluster analysis. Our analysis showed 
that high-SALL4 hepatocellular carcinomas clus-
tered tightly with fetal livers, whereas the low-
SALL4 hepatocellular carcinomas clustered with 
normal hepatocytes (Fig. 2C). These findings sug-
gest that hepatocellular carcinomas that express 
SALL4 have a gene-expression pattern that is simi-
lar to the pattern in hepatic progenitor cells and 
thus are poorly differentiated, aggressive, and 
associated with a poor prognosis.
We next examined the importance of SALL4 in 
hepatocellular carcinoma by performing loss-of-
function studies. Knocking down SALL4 by means 
of short hairpin RNA (shRNA) caused a decrease 
in cell viability, an increase in apoptosis, and a 
decrease in tumorigenicity of hepatocellular car-
cinoma cells (Fig. S1 in the Supplementary Ap-
pendix). To investigate whether loss of SALL4 in 
hepatocellular carcinoma cells reverses the ag-
gressive progenitor-like phenotype, we carried 
out microarray analysis of gene-expression pro-
files of SNU-398 cells treated with control scram-
bled shRNA (Scr shRNA 1) or SALL4-specific 
shRNA (shSALL4 1) and then performed hierar-
chical clustering of these profiles along with those 
derived from normal human hepatocytes and fe-
tal liver tissues. As expected, SNU-398 cells treated 
with scrambled shRNA 1 clustered closely with 
human fetal liver tissue, since both express high 
Figure 3 (facing page). Enriched Gene Signatures Asso-
ciated with a Poor Prognosis in High-SALL4 Hepatocel-
lular Carcinoma.
Enrichment of genes associated with poor survival 
(Panel A), embryonic stem cells (Panel B), metastasis 
(Panel C), hepatoblastoma (Panel D), and a prolifera-
tion subclass of hepatocellular carcinoma was de-
scribed by Chiang et al.17 (Panel E) in high-SALL4 hepa-
tocellular carcinoma. Red indicates a high level of 
expression, and green a low level of expression. NES 
denotes normalized enrichment score in gene-set en-
richment analysis. An NES score of more than 1 indi-
cates enrichment of the gene set in high-SALL4 hepa-
tocellular carcinoma.
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levels of SALL4. SALL4–knocked down SNU-398 
cells clustered with human hepatocytes; this sug-
gested that down-regulation of SALL4 can render 
hepatocellular carcinoma more hepatocyte-like 
with respect to gene expression (Fig. 2D).
To correlate the subgroup of SALL4-positive 
hepatocellular carcinomas with oncogenic path-
ways in primary hepatocellular carcinoma speci-
mens, we carried out gene-set enrichment analysis 
to investigate the enrichment of pathways that 
have prognostic value in SALL4-high and SALL4-
low hepatocellular carcinomas. We found that 
genes that were up-regulated in hepatocellular 
carcinoma associated with poor survival, genes 
in an embryonic stem-cell signature, and genes 
that were up-regulated in metastasis, hepatoblas-
toma, and a proliferation subclass of hepatocel-
lular carcinoma17 were significantly enriched in 
the high-SALL4 hepatocellular-carcinoma subgroup 
(Fig. 3A through 3E). Taken together, these data 
suggest that the expression of oncofetal protein 
SALL4 can be used as a molecular marker to 
identify an aggressive progenitor cell–like sub-
type of hepatocellular carcinoma and that SALL4 
expression has prognostic value for patients with 
hepatocellular carcinoma.
Targeting SALL4 by a Novel Peptide 
Our loss-of-function studies suggested that SALL4 
is a potential therapeutic target for hepatocellu-
lar carcinoma and that down-regulation of SALL4 
might reverse the aggressive phenotype of hepa-
tocellular carcinomas. We next sought to develop 
targeted therapy to antagonize the oncogenic 
role of SALL4. It is known that SALL4 functions as 
a transcription repressor by recruiting a histone 
deacetylase (HDAC)–containing nucleosome re-
modeling and HDAC (NuRD) complex, and that 
the tumor suppressor PTEN (phosphatase and 
tensin homologue) is among the target genes re-
pressed by SALL4.18 Our SALL4 loss-of-function 
microarray data provided direct evidence that in 
hepatocellular carcinoma, the PTEN–AKT path-
way is involved in SALL4-induced hepatocarcino-
genesis, since the class I phosphatidylinositol 
3–kinase (PI3K) signaling events mediated by 
AKT were significantly affected by SALL4 down-
regulation (P = 0.02).
We recently described a SALL4 12-AA peptide 
as a competitive inhibitor that blocks the inter-
action between SALL4 and NuRD and as a result 
blocks the NuRD-mediated SALL4-repression func-
tion.19 We tested whether this 12-AA SALL4 pep-
tide was effective in targeting the SALL4–PTEN–
AKT pathway and resulted in decreased viability 
of hepatocellular carcinoma cells. When 5 μM 
or 20 μM of nonmutant SALL4 peptide was added 
to SNU-398 cells, the number of viable cells was 
reduced, as compared with SNU-398 cells treated 
with control mutant peptide and scrambled pep-
tide. Tricho-statin A, a general HDAC inhibitor, 
was used as a positive control drug.20,21 When 
the PTEN inhibitor SF1670 was added to the 
cells treated with SALL4 peptide, it rescued the 
phenotype, as evidenced by the maintenance of 
cell viability (Fig. 4A). These results suggest that 
PTEN plays an important role in the SALL4 pep-
tide–induced loss of tumor-cell viability in hepa-
tocellular carcinoma. In contrast, SALL4 peptide 
had no effect on SNU-387 cells with undetect-
able endogenous SALL4 expression (Fig. 4B). This 
finding suggests that SALL4 peptide is a specific 
drug for SALL4-overexpressing hepatocellular car-
cinoma cells, with minimal toxic effects on 
SALL4-negative cells, as compared with the HDAC 
inhibitor trichostatin A.
To confirm the involvement of the tumor sup-
pressor PTEN in the SALL4 peptide–induced re-
duction of hepatocellular carcinoma cell viability, 
we analyzed PTEN expression by means of West-
ern blotting. SALL4 peptide treatment induced an 
extensive increase in levels of PTEN protein in 
SNU-398 cells (Fig. 4C). In contrast, SALL4 pep-
tide had a negligible effect on PTEN expression 
in SNU-387 cells (Fig. 4D). We next examined 
whether the increase in PTEN expression had an 
effect on PI3K signaling. PTEN functions as a 
phosphatase to dephosphorylate AKT. Western 
blot analysis showed a marked reduction of 
phosphorylated AKT protein levels with SALL4 
peptide treatment in SNU-398 cells (Fig. 4C), but 
not in low-SALL4 SNU-387 cells (Fig. 4D); this 
suggests that the increase in the level of PTEN 
expression had a functional role in blocking the 
PI3K survival signaling by dephosphorylating AKT. 
Furthermore, this effect could be rescued by the 
PTEN inhibitor, which is consistent with the role 
of SALL4 in regulating this pathway.
To further test the therapeutic effect of this 
peptide for in vivo treatment, we conjugated mu-
tant and nonmutant peptides with the transacti-
vator of transcription (TAT) protein transduction 
domain and administered the peptides intraperi-
toneally in nonobese diabetic mice with severe 
SALL4 in Aggressive Hepatocellular Carcinoma
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Figure 4. Specific Targeting of SALL4 by SALL4 Peptide in Hepatocellular Carcinoma Cells with High SALL4 Expression.
A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium cell-viability assay shows the ef-
fects of SALL4 peptide on SNU-398 cells with high endogenous SALL4 expression (Panel A) and SNU-387 cells with unde-
tectable SALL4 expression (Panel B). Cell viability was determined 72 hours after peptide treatments. Absorbance at 490 nm 
was directly correlated with cell viability. Nonmutant functional SALL4 peptide, mutant nonfunctional peptide, trichostatin A 
(TSA), scrambled control peptide, and nonmutant peptide plus PTEN (phosphatase and tensin homologue) inhibitor were 
added to the cells at the indicated concentration. The PTEN inhibitor concentration was 400 nM (Panels A through D). In 
Panels A and B, treatment 1 was treatment of cells with 0 μM of peptides or TSA, treatment 2 was treatment of cells with 5 
μM of peptides or 50 nM of TSA, and treatment 3 was treatment of cells with 20 μM of peptides or 100 nM of TSA. West-
ern blot analyses show the effects of peptides on PTEN, AKT, and phosphorylated AKT (pAKT) expression on SNU-398 cells 
(Panel C) and SNU-387 cells (Panel D) 72 hours after peptide treatments; α-tubulin was analyzed as a loading control. 
Twenty μM of nonmutant or scrambled peptide or 100 nM of TSA was used. The PTEN inhibitor concentration was 400 
nM. Panel E shows nonobese diabetic mice with severe combined immunodeficiency that underwent transplantation with 3 
million SNU-398 cells at the left flank and were treated intraperitoneally for 5 consecutive days with 56 mg of TAT-mutant 
peptide per kilogram of body weight or 60 mg of nonmutant peptide per kilogram (top panel). The dissected subcutaneous 
tumors are shown below. Panel F shows the mean weight of tumors dissected at day 18 after transplantation and treatment 
in five mice that received TAT fusion peptides intraperitoneally. T bars indicate standard deviations.
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combined immunodeficiency, in which SNU-398 
cells had been transplanted subcutaneously. TAT 
fusion nonmutant peptides reduced the tumori-
genicity of SNU-398 hepatocellular carcinoma cells 
(Fig. 4E). The tumor loads at 18 days after treat-
ment in mice that received TAT-nonmutant pep-
tides were significantly smaller than tumors in 
mice that received TAT–mutant peptides (Fig. 4F). 
These experiments confirm that the SALL4 pep-
tide had biologic activity both in vitro and in vivo 
in a xenotransplant model.
Our in vitro and murine data suggest that the 
SALL4 peptide is a potential targeted therapy for 
a subgroup of hepatocellular carcinomas, since it 
effectively and specifically reduced viable SALL4-
positive hepatocellular carcinoma cells.
Discussion
Hepatocellular carcinoma is one of the deadliest 
cancers, with a ratio of mortality to incidence of 
almost 1.1 Our study shows the unique expres-
sion pattern of the stem-cell factor SALL4 in hu-
man livers at various stages — activated in fetal 
liver tissue, silenced in adult liver tissue, and re-
expressed as an oncofetal protein in hepatocel-
lular carcinoma.
Identification of reliable biomarkers that can 
be used to predict patient outcomes ensures more 
effective clinical management, and we propose 
that SALL4 is such a biomarker in hepatocellular 
carcinoma. The reexpression of SALL4 in hepato-
cellular carcinoma is clinically significant, since 
patients with the subtype that overexpresses SALL4 
have enriched hepatic progenitor cell–like gene 
signatures and tend to have a poor prognosis. 
Given the strong prognostic value of SALL4 es-
tablished in our retrospective study, we propose 
that the prognostic value of SALL4 should be fur-
ther verified in prospective clinical trials. If SALL4 
is found to be useful in predicting the prognosis 
in patients with hepatocellular carcinoma in these 
trials, the expression of SALL4 should be tested 
routinely in clinics and adjuvant therapy should 
be added to the treatment regimen in patients 
with hepatocellular carcinoma and elevated SALL4 
expression to prevent relapse after surgery.
The discovery of a role for SALL4 in hepatocel-
lular carcinoma, its association with prognosis, 
and the antitumor effects of a newly identified 
peptide blocker targeting it have potential thera-
peutic significance. Testing for the presence of 
SALL4 at diagnosis may be helpful not only for 
determining the prognosis but also for identify-
ing patients who are likely to have a response to 
treatment. Given the expression of SALL4 in he-
patocellular carcinoma cells but not in normal 
adult hepatocytes, treatment with SALL4 peptide 
may have less tissue toxicity, which is especially 
beneficial in patients with underlying cirrhosis 
whose baseline liver function is already compro-
mised. Future studies will determine whether 
this peptide has synergistic potential with other 
molecular therapies, such as sorafenib, which 
act on parallel nonoverlapping pathways.
In conclusion, our study shows that the on-
cofetal protein SALL4 plays an important role in 
the extensive network of heterogeneous cellular 
pathways underlying hepatocarcinogenesis. A 
12–amino acid peptide can block the oncogenic 
role of SALL4 and hence has therapeutic poten-
tial in SALL4-positive hepatocellular carcinoma. 
We propose that SALL4 is a prognostic marker 
and therapeutic target in hepatocellular carcino-
ma, and our study lays a foundation for the de-
velopment of SALL4-specific targeted therapy to 
treat aggressive hepatocellular carcinomas.
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DEFINITION OF CLINICAL OUTCOME 
Preoperative diagnosis of HCC was based on imaging criteria on CT or MRI scan, and if 
necessary, by percutaneous biopsy. Diagnosis of HCC was confirmed by histology. HCC stage 
was analyzed according to the conventional TNM and BCLC staging criteria.1 Child-Pugh score 
were computed to document the levels of derangement of liver disease of the patients at 
diagnosis.2 Similar HCC treatment algorithms based on international and Asian treatment 
guidelines were used in both cohorts.1,3,4 Generally, patients were subjected to curative surgery if 
they were at BCLC stage 0, A or B, resection was however also offered to selected good risk 
patients with BCLC stage C tumors, such as those with portal vein branch invasion. In our patient 
cohorts, 70-80% of HCC patients were positive for Hepatitis B infection, and oral nucleoside and 
nucleotide analogs were initiated if HBV DNA was elevated. Curative surgery was defined as 
complete resection of the tumor with clear microscopic margin, and no residual tumors detected by 
CT scan or angiography at 1 month after surgery. All post-operative patients were subjected to 
regular surveillance as outpatients with standard protocol including 2-6 monthly CT scan imaging 
of the liver and measurement of serum alpha-fetoprotein level to monitor for tumor recurrence. Any 
suspected intrahepatic recurrence was confirmed by hepatic angiography, post-lipiodol CT scan, 
and if necessary, percutaneous fine-needle aspiration cytology. Recurrent tumors were treated 
with re-resection, ablation, transarterial chemoembolization or systemic therapy as appropriate. In 
our cohorts, 80% of patients were followed for up to 2 years. Only patients who died as a result of 








Paraffin tissue sections of 4 µm were deparaffinized with Histoclear and hydrated in graded 
ethanols. Antigen retrieval was performed by boiling at 120°C in high pH target retrieval solution for 
5 minutes in a pressure cooker for SALL4 IHC, or heating in citrate buffer at 95°C for 30 minutes 
for Ki-67 IHC. Non-specific signal was blocked by peroxidase block for 10 minutes at room 
temperature, followed by protein block for 30 minutes at room temperature. Primary antibodies 
were incubated at room temperature for one hour in a humidified chamber, followed by HRP-
conjugated secondary antibody incubation for 30 minutes at room temperature. Antibody binding 
was revealed by DAB and reaction was stopped by immersion of tissue sections in distilled water 
once brown color appeared. Tissue sections were counterstained by hematoxylin, dehydrated in 
graded ethanols and mounted. The following antibodies were used: SALL4 (Santa Cruz, CA, USA 
#sc-101147) and Ki-67 (Novus Biologicals, Littleton, CO, USA #NB110-89717). All reagents for 
immunohistochemistry were from Dako (Dako, Glostrup, Denmark A/S). Appropriate positive and 
negative controls were included for each run of IHC. Only nuclear staining was considered positive 
for SALL4. For IHC on tissue microarrays, SALL4 expression was scored according to the 
percentage of tumor cells stained positive for SALL4, with 0 denotes less than 5% of tumor cells 
stained positive, 1 denotes 5 – 30% of tumor cells stained positive, 2 denotes 31 – 50% of tumor 
cells stained positive, 3 denotes 51 – 80% of tumor cells stained positive, 4 denotes >80% of tumor 
cells stained positive. SALL4 expression in tissue microarrays was scored by a pathologist and two 
researchers independently. 
 
CELL CULTURE  
HCC cell lines were maintained in either Dulbecco’s Modified Eagle Medium (DMEM) or RPMI 
medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 
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5% CO2. Immortalized hepatocyte cell lines, THLE-2 and THLE-3, were maintained in BEGM 
medium supplemented with growth factors (Lonza, Basel, Switzerland) in pre-coated tissue culture 
flasks at 37°C in a humidified atmosphere of 5% CO2 as recommended by ATCC. 
 
MICROARRAY DATASETS  
For profiling HCC samples versus normal controls, datasets from the GEO database with the 
accession numbers of GSE6222, GSE6864, & GSE29721 were used. For comparing HCC 
samples of high and low SALL4 expression with primary hepatocytes (Hep) and human fetal liver 
(HFL) samples, appropriate samples from the following GEO datasets (GSE6222, GSE6764, 
GSE9843, GSE15238, GSE18269, GSE23343, GSE29721, & GSE33606) were utilized. For 
comparison of SNU-398 samples with primary hepatocytes and human fetal liver samples, Hep 
and HFL samples were taken from GEO datasets, GSE23034 & GSE23413, respectively. 
Microarray data for the Hong Kong cohort of primary HCCs was deposited in GEO database with 
the accession number GSE25097, and the software/ methods used for molecular profiling and 
computation were previously described.5 SNU-398 samples with SALL4 knocked down were 
submitted to GEO database with the following accession number: GSE35965.  
 
MICROARRAY DATA NORMALIZATION 
For Affymetrix data, all CEL files were analyzed together using the Robust Multichip Average 
method to obtain the gene expression intensities.6 For Illumina Beadchip data, raw data with 
background subtraction were used for all samples. Normalization was then performed across all 
samples based on the Cross Correlation method7 using R script, and normalized data were further 
log2-tranformed.  
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CLUSTERING, HEATMAPS AND GENE SET ENRICHMENT ANALYSIS (GSEA) 
Hierarchical clustering with average linkage was used in all clustering. For clustering HCC SALL4 
high and low samples with human fetal liver and hepatocyte samples, the mean of the four group 
means (HCC SALL4 high, HCC SALL4 low, human fetal liver, and hepatocyte) was subtracted 
from the log2-transformed normalized data prior to clustering. For clustering SNU-398 SALL4 
knocked down data, human fetal liver and hepatocyte genes with differential expression between 
the cell line and primary cells were excluded by using only genes with no significant changes 
between any one of SUN-398 SALL4 knocked down (KD) and wildtype control (WT) and any one 
of primary cells to remove cell line and primary cell expression differences. The cutoff for no 
significant fold change used is 1.5. The mean of the four group means (SNU-398 KD, SNU-398 
WT, hepatocyte and human fetal liver) was then also subtracted from the log2-transformed 
normalized data prior to clustering. Genes with no significant changes between the four groups of 
samples were not represented in both heatmaps to show clear patterns. Gene set enrichment 
analysis (GSEA) was performed by using normalized data using GSEA v2.0 tool 
(http://www.broad.mit.edu/gsea/). For GSEA, we first carried out hierarchical clustering to separate 
primary HCCs into high and low SALL4 groups and obtained four subclusters. Comparing high and 
low SALL4 HCCs from two of the subclusters (a total of 12 high SALL4 primary HCCs and 43 low 
SALL4 HCCs) yielded the data reported in Figure 3. P values were obtained by applying 
Kolmogorov-Smirnov test across different gene sets. 
 
QUANTITATIVE REAL-TIME RT-PCR 
Total RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA) and treated with 
RNase-free DNase (Qiagen) following manufacturer’s instructions. Reverse transcription was 
carried out using High Capacity Reverse Transcription Kit with RNase inhibitor (Applied 
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Biosystems, Foster City, CA). Quantitative PCR was performed using GoTaq qPCR Master Mix 
(Promega, Madison, WI). Amplification was done with a Corbett Rotor Gene 6000 (Qiagen) using 
the following parameters: 95°C (10 min), 40 cycles of 95°C (15s), 60°C (60s), and 72°C (20s). All 
measurements were performed in duplicate. The following primers were used:  
SALL4 F: 5’-GCGAGCTTTTACCACCAAAG-3’ 
SALL4 R: 5’-CACAACAGGGTCCACATTCA-3’ 
SALL4AF: 5’-TCCTGGAAACCACATCCTTC-3’ 
SALL4A R: 5’-ATGTGCCAGGAACTTCAACC-3’ 
SALL4B F: 5’-GGTGGATGTCAAACCCAAAG-3’ 
SALL4B R: 5’-ATGTGCCAGGAACTTCAACC-3’ 
ACTB F: 5’-CAGAGCCTCGCCTTTGCCGATC-3’ 
ACTB R: 5’-CATCCATGGTGAGCTGGCGGCG-3’ 
 
VIRAL TRANSDUCTION OF SHRNAS 
Lentiviruses expressing scrambled shRNAs or SALL4-specific shRNAs were packaged by 
transfection of 293T cells with lentiviral vector pLL3.7 or pLKO.1. 24 hours and 48 hours post-
transfection, viruses were harvested and filtered through 0.45 µm filters. Virus titers were 
determined by using infected 3T3 cells by the conventional ways. MOI 5 to 10 was used depending 
on individual cell lines. Transduction of HCC cells were carried out using spinoculation protocol. 
Briefly, virus and 8 µg/mL polybrene (Santa Cruz) were added to the trypsinized cells and let settle 
for an hour at 37°C in a humidified atmosphere of 5% CO2, centrifuged at 2,200 RPM at 37°C for 
90 minutes and incubated overnight at 37°C in a humidified atmosphere of 5% CO2. Transduction 
efficiency was determined by GFP expression by FACS analysis. The following shRNAs were 
used:  
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Scr shRNA 1: 
GGGTACGGTCAGGCAGCTTCTTTCAAGAGAAGAAGCTGCCTGACCGTACCCTTTTTTC;  








Total cell lysates were harvested in NP-40 lysis buffer (150mM NaCl, 1% Nonidet P-40, 50mM 
Tris, pH8.0, protease inhibitor cocktail) and protein concentrations were determined by BCA 
protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal amounts of proteins from 
each lysate were resolved by SDS-PAGE and then transferred to nitrocellulose or PVDF 
membranes. Membranes were blocked with buffer containing 5% skim milk and 0.1% Tween 20 in 
PBS overnight at 4°C or 1 hour at room temperature with gentle shaking. Primary antibodies were 
incubated for one hour (α-tubulin and β-actin) or two hours (SALL4) at room temperature or 
overnight at 4°C (PTEN, AKT, pAKT, caspase-3, and cleaved caspase-3) with gentle shaking, 
followed by secondary antibody incubation at room temperature for one hour with gentle shaking. 
The following antibodies were used: SALL4 (Santa Cruz #sc-101147), β-actin (Santa Cruz #sc-
47778), α-tubulin (Sigma #T6074), PTEN (Cell Signaling #9559), total AKT (Cell Signaling #2966), 
pAKT (Cell Signaling #9271), caspase-3 (Cell Signaling #9668), and cleaved caspase-3 (Cell 
Signaling #9664). 
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CELL VIABILITY ASSAY 
5000 – 7000 cells were seeded in each well of a microtiter plate in 100 µL of medium. Cells from 
each treatment were seeded in duplicate. Controls using the same medium without cells were set 
up in parallel. At various time points, 317 µg/mL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (CellTiter96 AQueous One Solution Cell 
Proliferation Assay, Promega) was added to each well. After two to four hours incubation, 
depending on cell line, of the tetrazolium salt, absorbance at 490nm was read by a microplate 
reader. 
 
CASPASE 3/7 ASSAY 
Capase 3/7 luminescent-based assay was carried out following manufacturer’s instructions 
(Promega). Equal number of infected HCC cells was seeded in microtiter plates compatible for 
luminescence assay and substrate for Caspase 3/7 was added four days post-transduction to 
detect caspase activity. 
 
MICROARRAY 
Total RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen) following manufacturer’s 
instructions. RNA quantity was assessed using Nanodrop (Thermo Fisher Scientific, Wilmington, 
DE) and RNA integrity was analyzed using Nano chip for Eukaryotes on the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). A RIN of 8.0 and above was considered to 
indicate a satisfactory sample quality. Gene expression array analysis was performed using 
Affymetrix GeneChip Human Gene 1.0ST Array system (Affymetrix, Santa Clara, CA) according to 
manufacturer’s instructions. Briefly, for each sample, 200 ng of total RNA in a volume of 5 µl was 
amplified using the Applause WT Amp ST, RNA Amplification System (NuGen, San Carlos, CA) 
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and labeled with Encore Biotin Module, Post–Amplification System (NuGen). A total of 2.5 µg of 
labeled cDNA, along with GeneChip Hybridization Control reagents (Affymetrix), was injected into 
an Affymetrix GeneChip Human Gene 1.0 ST Array. The chips were incubated for 18 hours at 
45°C and rotated at 60 RPM to allow hybridization. The chips were then washed and stained using 
GeneChip Hybridization Wash and Stain Kit (Affymetrix) using the Affymetrix GeneChip Fluidics 
Station 450. Stained arrays were scanned on Affymetrix GeneChip Scanner 3000 7G. 
 
IN VITRO PEPTIDE TREATMENT ASSAY 
SALL4 (nonmutant) and control (mutant and scrambled) peptides were synthesized (Biosynthesis 
Inc., Lewisville, Texas) using standard solid phase peptide synthesis chemistry and purified by the 
manufacturer to 95% purity. HCC cells were grown in 6-well plates to 50-70% confluence 24 hours 
prior to peptide treatment. For each treatment, 100 µL 1×PBS + 1µL diluted peptide was set up. 
Chariot reagent (Active Motif Inc., Carlsbad, CA), used as a peptide carrier, was diluted 1:10 in 
distilled water. Diluted peptide and diluted Chariot reagent were mixed gently and incubated for 30 
minutes at room temperature. Medium was aspirated from the well and cells were overlaid with the 
mixture. 400 µL serum-free medium was then added and cells were incubated for one hour at 37°C 
in a humidified atmosphere of 5% CO2. 500 µL complete medium was added one hour later. For 
determination of cell viability, the following doses of peptides were used: 0, 5 and 20 µM of 
nonmutant, mutant, or scrambled peptides, or 0, 50 and 100 nM of trichostatin A (TSA). Cell 
viability was examined 72 hours after peptide treatment. For western blot analysis, 20 µM of 
nonmutant or scrambled peptide, or 100nM of TSA was used to treat the cells. Cell lysates were 
harvested 72 hours following peptide treatment. 400 nM of SF1670 PTEN inhibitor was used 
throughout all experiments.  
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IN VIVO TUMORIGENICITY ASSAY 
4- to 8-week-old NOD/SCID mice were used. Animal work was done at CHB with approval from 
IACUC. For loss of function studies, 10 million of SNU-398 or 6 million of HuH-7 cells infected with 
viruses expressing scrambled shRNA or SALL4-specific shRNA (total 300 µL of cell suspension 
and matrigel in 1:1 ratio) were injected subcutaneously into the right flank of NOD/SCID mice. For 
TAT-peptide treatment studies, 3 million SNU-398 cells were resuspended in 150 µL PBS, mixed 
with matrigel in a 1:1 ratio, and then transplanted subcutaneously into the left flank of each mouse. 
56 mg/ kg body weight of TAT-mutant or 60 mg/ kg body weight of TAT-nonmutant peptides were 
administered by intraperitoneal injection for five consecutive days starting from the day of 
subcutaneous HCC cells transplantation. For all studies, after injection, mice were examined and 
tumor volumes were measured at various time points. Tumor volume was calculated by using the 
formula, tumor volume = π/6 X larger diameter X (smaller diameter)2. Tumor samples were 
processed for routine histology examination. Mice were sacrificed when tumors were too large to 
be compatible with life and survival analysis was done.  
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Figure S1. Loss of SALL4 leads to decreased HCC cell viability and tumorigenicity. (A) Left 
panel: qPCR analysis of relative SALL4, SALL4A and SALL4B expression in SNU-398 cells four 
days post-transduction. Error bars indicate standard error of three replicates; expression was 
normalized to ACTB and plotted relative to scrambled controls. *** P < 0.001. Right panels: 
Western blot analysis of SALL4 expression in SNU-398 and HuH-7 cells four days post-
transduction. (B) MTS analysis of HCC cell viability upon SALL4 gene knockdown by scrambled 
control shRNAs (Scr shRNA) or SALL4-specific shRNAs (shSALL4) in SNU-398 (left), HuH-7 
(middle) and SNU-387 (right) cells. Error bars indicate standard error of three replicates. * P < 
0.05; *** P < 0.0001. (C) Growth curve of SNU-398. ** P < 0.01. (D) Caspase 3/7 assay shows an 
increase in apoptosis in SALL4-knockdown SNU-398 cells at day 4 post-transduction. ** P < 0.01; 
*** P < 0.0001. (E) Western blot shows the expression of total caspase 3 and cleaved caspase 3 in 
SNU-398 cells four days post-transduction. (F) Effects of SALL4 gene knockdown on 
tumorigenicity of HCC cells. Left panel: representative images show immunocompromised mice 
transplanted with scrambled shRNA 1- or shSALL4 1-treated HuH-7 cells. Arrow shows 
subcutaneous tumor on the right flank of the mouse. Middle panel: tumor volumes of the 
subcutaneous tumors. Statistical significance of the final time point could not be determined 
because there was only one mouse left in the scrambled control group. * P < 0.05. Right panel: 
Kaplan-Meier plot shows poorer survival advantage for mice harboring SNU-398 or HuH-7 cells 
infected with scrambled control shRNA 1 as compared to mice harboring cells infected with 
shSALL4 1. N = 12; P = 0.04.  
 




Figure S2. SALL4 is a novel oncofetal protein in HCC. In healthy humans, SALL4 is expressed 
in fetal liver but silenced in mature adult liver. In a subgroup of HCC livers, SALL4 is re-activated 
and plays a functional role in hepatocarcinogenesis by silencing the tumor suppressor PTEN 
through the recruitment of the NuRD complex. A therapeutic peptide can be used to block the 
interaction between SALL4 and the NuRD complex, thereby activating PTEN transcription. 
Upregulation of PTEN expression leads to downregulation of pAKT level and silencing of the 
PI3K/AKT survival signaling, resulting in decreased HCC cell viability and tumorigenicity. We 
propose SALL4 to be a novel oncofetal protein that can be specifically targeted for treatment of a 












Table S1. Demographic and Clinicopathological Characteristics of the Patients (Singapore Cohort) 






SALL4neg SALL4pos P value 
Age, years      
< mean (56.2) 38 (48.1) 16 22 1.00 
≥ mean  41 (51.9) 18 23   
Gender      
Female 15 (19) 6 9 1.00 
Male 64 (81) 28 36   
Ethnicity      
Chinese 62 (78.5) 28 34 0.58 
Non-Chinese 17 (21.5) 6 11   
Tumor grade      
I & II 69 (87.3) 48 21 1.00 
III & IV 10 (12.7) 7 3  
TNM stage      
I & II 64 (81) 28 36 0.75 
III 15 (19) 6 9   
Child-Pugh class      
A and B 68 (86.1) 30 38 0.75 
C 11 (13.9) 4 7   
     








SALL4neg SALL4pos P value 
BCLC stage      
A 57 (72.2) 22 35 0.22 
B 22 (27.8) 12 10   
HBsAg (n=76)      
Negative 24 (31.6) 10 14 0.81 
Positive 52 (68.4) 24 28   
HCV (n=78)      
Negative 74 (94.9) 34 40 0.13 
Positive 4 (5.1) 0 4   
Serum AFP, ng/dl (n=70)      
< 10.0 21 (30) 11 10 0.31 
≥ 10.0 49 (70) 19 30   
Tumor size, cm (n=78)      
< mean (6.2)  49 (62.8) 18 31 0.24 
≥ mean 29 (37.2) 15 14   
Multinodularity      
No 56 (70.9) 22 34 0.33 




    
No  47 (88.7) 19 28 1.00 
Yes 6 (11.3) 2 4   
 








SALL4neg SALL4pos P value 
Satellitosis      
No  67 (84.8) 27 40 0.34 
Yes 12 (15.2) 7 5   
Portal hypertension      
No 66 (83.5) 28 38 1.00 
Yes 13 (16.5) 6 7   
Pre-Op Treatment      
No 55 (69.6) 25 30 0.63 
Yes 24 (30.4) 9 15   
Recurrence (n=37)      
Early (<2 years) 9 (24.3) 5 4 0.46 
Late (≥2 years) 28 (75.7) 11 17   
HCC, hepatocellular carcinoma; MMPM, morpho-molecular prognostic model; SD, standard 
deviation; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis 
SALL4neg: IHC score 0; SALL4pos: IHC score +1 to +4  
aN=79 (unless otherwise noted in brackets). 
bFisher’s exact test 
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Table S2. SALL4 expression status of primary HCC tissues from the Singapore cohort 
IHC scorea Frequency, n Percentage (%) 
0 76 44.4 
1 75 43.9 
2 12 7.02 
3 4 2.34 
4 4 2.34 
Total 171 100 
aSALL4 expression was scored according to published scoring criteria used for germ cell tumors8-
10, with some modifications. We scored SALL4 expression according to the percentage of tumor 
cells stained positive for SALL4, 0: no tumor cells stained positive, 1: 1 – 30% of tumor cells 
stained positive, 2: 31 – 50% of tumor cells stained positive, 3: 51 – 80% of tumor cells stained 
positive, 4: >80% of tumor cells stained positive.  
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Table S3. Demographic and Clinicopathological Characteristics of the Patients (HK Cohort) and 
Association between SALL4 Expression with Clinicopathological Parameters.a,b 
Clinicopathological Parameters Frequency (%) SALL4 mRNA expression 
 median  median P values 
Sex      
Male 179 (78.5) 95 84 0.08 
Female 49 (21.5) 19 30   
Age      
  105 (46.1) 44 61 0.02 
  123 (53.9) 70 53   
Alcohol (n=217)      
                 No 133 (61.3) 65 68 0.52 
                 Moderate/Heavy 84 (38.7) 45 39   
Tumor size, cm (n=217)      
  77 (33.8) 37 40 0.67 
  151 (66.2) 77 74   
Alpha fetoprotein, ng/mL      
  116 (50.9) 78 38 >0.001 
  112 (49.1) 36 76   
HBsAg      
Negative 31 (13.6) 22 9 0.01 
Positive 197 (86.4) 92 105   
Histological differentiation (n=191)      
Well 37 (19.4) 24 13 0.04 
Moderate/Poor 154 (80.6) 77 77   
BCLC stage (n=94)      
0 & A 67 (71.3) 39 28 0.38 
B & C 27 (28.7) 13 14   
TNM stage      
Early (I, II) 103 (45.2) 56 47 0.27 
Late (III, IV) 125 (54.8) 58 67   
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Clinicopathological Parameters Frequency (%) SALL4 mRNA expression 
 median  median P values 
Early Recurrence (n=139)      
Absent 40 (28.8) 23 17 0.05 
Present 99 (71.2) 39 60   
Late Recurrence (n=89)      
Absent 68 (76.4) 39 29 0.71 
Present 21 (23.6) 13 8   
Venous infiltration (n=227)      
Absent 114 (50.2) 64 50 0.10 
Present 113 (49.8) 49 64   
aN=228 (unless otherwise noted in brackets). 
bChi-square test 
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Table S4. Univariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for clinicopathological 
features and SALL4 expression (SG cohort).a 
 Overall Survival Early Recurrence Late Recurrence 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Clinicopathological parameters 



















Gender (female vs male) 0.65 0.3-1.42 0.28 - - - 0.19 0.05-0.67 0.01 
Ethnicity  
(chinese vs non-Chinese) 
1.45 0.49-4.32 0.22 1.30 0.12-14.51 0.83 3.39 0.39-29.33 0.27 
Tumour Grade (I&II vs III&V) 0.87 0.26-2.88 0.82 - - - 1.16 0.34-3.92 0.81 
TNM (I&II vs III&IV) 1.51 0.56-0.41 0.42 - - - 1.22 0.32-4.63 0.77 
Child-Pugh (A&B vs C) 2.22 0.82-6.0 0.12 - - - 1.47 0.31-6.85 0.63 
BCLC stage (A vs B) 2.08 0.9-4.83 0.09 - - - 1.32 0.38-4.53 0.66 
HBsAG (negative vs positive) 1.27 0.49-3.28 0.62 0.45 0.03-7.37 0.57 0.36 0.09-1.45 0.15 
HCV (negative vs positive) 0.79 0.11-5.87 0.81 - - - 1.48 0.19-11.72 0.71 
Serum AFP, ng/dl (<20.0 vs ≥20.0) 2.22 0.89-5.45 0.08 - - - 5.76 0.71-46.47 1.00 
Tumor size, cm (<6.2 vs ≥6.2) 0.78 0.33-1.83 0.57 - - - 0.8 0.23-2.78 0.73 
Multinodularity (no vs yes) 1.67 0.73-3.84 0.22 - - - 1.32 0.39-4.53 0.66 
Lymphovascular invasion  
(no vs yes) 
1.32 0.17-10.46 0.79 - - - - - - 
Satellitosis (no vs yes) 0.97 0.33-2.86 0.96 0.75 0.07-7.94 0.81 0.79 0.17-3.67 0.77 
Portal hypertension  
(no vs yes) 
0.99 0.34-2.91 0.98 - - - 0.76 0.09-5.98 0.79 
Pre-op treatment (no vs yes) 
 
1.74 0.77-3.91 0.18 - - - 1.73 0.51-5.9 0.38 
Protein expression          
 SALL4 (positive vs negative) 2.92 1.15-7.39 0.02 0.39 0.04-3.78 0.42 5.35 1.14-25.06 0.03 
aUnivariate analysis, Cox proportional hazards regression model.  
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Bold values denoted statistical significance at α=0.05; Dashes indicate no modeling as coefficients did not converge.  
SALL4 negative: IHC score 0; SALL4 positive: IHC score +1 to +4.  
HR, hazard risk ratio; CI, confidence interval; TNM, tumor-node-metastasis.
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Table S5. Univariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for clinicopathological 
features and SALL4 expression (HK cohort).a 
  Overall survival Early recurrence Late recurrence 
P value P value P value 
Clinicopathological parameters     
AFP, ng/mL (< 100 vs ≥ 100) 0.01 <0.01 0.06 
No. of tumor nodule (< 3 vs ≥ 3) 0.01 < 0.001 0.83 
Venous infiltration (Y vs N) < 0.001 < 0.001 0.26 
































Gene expression     
SALL4 (< median vs ≥ median) <0.01 0.02 0.56 
aUnivariate analysis, Kaplan-Meier analysis.  
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Table S6. Multivariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for the 
clinicopathological features and SALL4 expression (SG cohort).a 
 Overall Survival Early Recurrence Late Recurrence 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Clinicopathological parameters          
Serum AFP, ng/dl (<20.0 vs  ≥20.0) 2.08 0.83-5.22 0.12 - - - 3.2 0.25-40.48 0.37 
BCLC stage (A vs B) 1.84 0.75-4.52 0.18 - - - 0.74 0.16-3.27 0.69 
            
Protein expression          
 SALL4 (positive vs negative) 2.87 1.09-7.52 0.03 0.62 0.05-6.99 0.69 2.7 0.41-18.72 0.29 
aMultivariate analysis, Cox proportional hazard regression model. Variables were adopted for their prognostic significance (p<0.1) 
by univariate analysis. Dashes indicate no modelling as coefficients did not converge. 
SALL4 negative: IHC score 0; SALL4 positive: IHC score +1 to +4. 
HR, hazard ratio; CI, confidence interval 
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Table S7. Multivariate overall survival, early recurrence (< 2 years) and late recurrence (≥ 2 years) analysis for the clinicopathological 
features and SALL4 expression (HK cohort).a 
  Overall survival Early recurrence Late recurrence 
  HR 95% CI P value HR 95%CI P value HR 95%CI P value 
Clinicopathological           
Serum AFP, ng/mL  
(<100 vs ≥ 100) 
- - - - - - 0.31 0.11 – 0.86 0.03 
No. of tumor nodules  
(< 3 vs ≥ 3) 
- - - 2.33 1.45 – 3.76 < 0.001 - - - 
Tumor size, cm (<5 vs ≥5) 1.71 1.05 – 2.76 0.03 - - - - - - 
TNM stage (I&II vs III&IV) - - - - - - 0.34 0.14 – 0.83 0.02 
Venous infiltration (Y vs N) 0.28 0.17 – 0.44 < 0.001 0.42 0.27 – 0.66 < 0.001 - - - 
            
Gene expression           
SALL4  
(< median vs ≥ median) 
1.52 1.00 – 2.32 0.05 1.67 1.11 – 2.51 0.01 - - - 
aMultivariate analysis, Cox proportional hazard regression model. Dashes indicate no modeling as coefficients did not converge. 
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